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1 Summary 
Several neurodegenerative diseases, including Huntington’s disease 
(HD) and spinal and bulbar muscular atrophy (SBMA), are associated with 
aberrant folding and aggregation of polyglutamine-expansion proteins. In the 
first part of this work the zebrafish, Danio rerio, was established as a vertebrate 
HD model permitting the screening for chemical suppressors of polyglutamine 
aggregation and toxicity. Upon expression in zebrafish embryos, polyglutamine-
expanded fragments of huntingtin (htt) accumulated in large SDS-insoluble 
inclusions, reproducing a key feature of HD pathology. Real-time monitoring of 
inclusion formation in the living zebrafish indicated that inclusions grow by 
rapid incorporation of soluble htt species. Expression of mutant htt increased the 
frequency of embryos with abnormal morphology and the occurrence of 
apoptosis. Strikingly, apoptotic cells were largely devoid of visible aggregates, 
suggesting that soluble oligomeric precursors may instead be responsible for 
toxicity. As in non-vertebrate polyglutamine disease models, the molecular 
chaperones, Hsp40 and Hsp70, suppressed both polyglutamine aggregation and 
toxicity. Using the newly established zebrafish model, two compounds of the N’-
benzylidene-benzohydrazide class directed against mammalian prion proved to 
be potent inhibitors of polyglutamine aggregation, suggesting common 
structural mechanisms of aggregation for prion and polyglutamine disease 
proteins.  
In the second part, a novel yeast model of SBMA was set up, which 
was used to investigate the molecular mechanism behind SBMA and its 
associated androgen insensitivity syndrome (AIS). SBMA is caused by a 
polyglutamine-expansion in androgen receptor (AR), a key player in male sexual 
differentiation. Interestingly, more than 80% of SBMA patients show signs of 
mild-to-moderate AIS. Upon expression in yeast, polyglutamine-expanded N-
terminal fragments of AR aggregate and cause toxicity, reproducing key features 
of SBMA pathology. Pronounced toxicity was associated with nuclearly-localized 
AR fragments with 102 Q, which primarily accumulated as soluble oligomers in 
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the 200 – 500 kDa size range. Analysis using a luciferase reporter system revealed 
that full-length polyglutamine-expanded AR is fully functional in transactivation, 
but becomes inactivated in the additional presence of aggregating N-terminal 
fragments. Furthermore, greatest impairment of full-length AR activity 
correlated with its interaction with soluble oligomers of AR fragments. Taken 
together, the polyglutamine-expansion mutation in AR promotes a gain-of-
function mechanism that results in the formation of toxic oligomers, which in 
turn cause loss-of-function through direct interaction with full-length AR 
perhaps by inducing its misfolding. These results provide new mechanistic 
insight into the loss-of-function mechanism behind AIS in SBMA.  
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2 Introduction 
In 1854 the German physician scientist Rudolph Virchow introduced 
the term ‘amyloid’, derived from the Latin and Greek terms for starch (amylum 
and amylon, respectively), to describe a substance in the cerebral corpora 
amylacea that caused an abnormal macroscopic appearance of the latter. He was 
misled by the observation that the substance stained positive at a iodine staining 
reaction, a common test to identify cellulose or starch. Later, it was shown that 
not carbohydrates but proteins with a propensity to undergo changes in 
conformation form amyloidogenic fibrils (Sipe and Cohen, 2000). Nowadays, the 
term amyloid is associated with a growing number of human diseases, for 
example Alzheimer’s, Parkinson’s and Polyglutamine diseases but also 
Spongiform encephalopathies, that are associated with misfolded proteins that 
form such amyloidogenic fibrils. Why do proteins ‘misfold’ and how is this 
process linked to disease? 
 
2.1 Protein folding 
Proteins (‘prota’, greek, meaning ‘of primary importance’) are, like 
other biological macromolecules such as polysaccharides and nucleic acids, 
essential parts of all living organisms. They participate in every process within 
the cell and are involved in biochemical reactions, have structural or mechanical 
functions and are also important in cell signaling, immune responses, cell 
adhesion, and the cell cycle.  
Proteins are composed of amino acids, which consist of an amino 
group, a carboxyl group, a hydrogen atom and a variable side chain bound to a 
carbon atom. Twenty standard amino acids exist that differ in the side chain and 
as a result thereof, contribute unique properties. The amino acids are arranged in 
a linear chain and joined together by peptide bonds between the α-carboxyl 
group of one amino acid and the α-amino group of another. However, to become 
functionally active the amino acid sequence has to adopt a unique three-
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dimensional structure, which is achieved via sterical limits and complex 
interactions between the amino acids. This condition is regarded as native state 
or physiologically folded providing the energetically most stable structure.  
 
2.1.1 General aspects of protein folding 
One of the most fundamental phenomena in nature is the ability of 
proteins to fold de novo to their functional i.e. native states in a physiologically-
relevant time (Jahn and Radford, 2005). Anfinsen demonstrated that the 
information required to reach the native state is encoded in the primary structure 
of a protein (Anfinsen, 1973). Theoretically, a small polypeptide would require at 
least a period of time equivalent to the age of the universe to arrive at its correct 
native conformation if it is to attain its correctly folded configuration by 
sequentially sampling all the possible conformations (Levinthal, 1969). In reality 
however, an average-sized protein folds usually in less than one second (Karplus, 
1997). Thus, it seems likely that proteins do not fold randomly but rather 
according to specific, defined pathways.  
It is easy to imagine that there may not be just a single route to the 
native state. Towards the native structure, random fluctuations occur, and 
different native as well as non-native contacts form. Native interactions between 
residues are assumed to be more stable than non-native contacts, and as such 
contacts form, the number of available conformations is reduced. As a 
consequence thereof, the folding of the polypeptide chains is driven towards the 
native state (Jahn and Radford, 2005).  
Energy landscapes are used to describe the search of the unfolded 
polypeptide down a funnel-like energy profile towards the native structure 
(Figure 1). Each polypeptide sequence follows its own energy landscape that is 
unique like a fingerprint. Partially folded states on this landscape can be 
intrinsically prone to aggregation, and favorable intermolecular contacts may 
lead to their association and ultimately to protein-misfolding diseases. Since the 
number of possible interactions increases with the size of the polypeptide chain, 
small single domain proteins, usually less than 100 amino acids in length fold 
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relatively fast (sub-second timescale). The folding landscape of these proteins is 
usually relatively smooth, with only a small number of possible kinetic traps 
(Daggett and Fersht, 2003; Fersht, 2000). However, the larger the proteins are 
(more than 100 residues), the more they face a much rougher landscape in which 
states of folding intermediates are commonly populated on the way to the native 
protein. A possible explanation for this is that larger chains have a higher 
tendency to collapse in aqueous solution forming more compact states. These 
compact states include both, native and non-native interactions and the 
reorganization of the interresidual contacts may include high free-energy 
barriers. As a result thereof, partially folded or ‘intermediate’ states accumulate. 
This can be beneficial, if the intermediate is productive for folding, so-called ‘on-
pathway,’ or unprofitable if the native state cannot be reached without 
substantial re-organizational events (off-pathway). Parallel folding of different 
regions also exists, as it is the case in large multidomain proteins, where a final 
folding step establishes all native intra- and interdomain contacts resulting in the 
final functional form (Radford et al., 1992).   
 
Figure 1: Schematic energy landscape of protein folding and aggregation. 
Rugged surface that shows kinetic traps and energy barriers leading to a multitude of 
conformations towards the native state by intramolecular contact formation, or, upon 
intermolecular contacts towards the formation of amyloid fibrils (adapted from Jahn and 
Radford, 2005).  
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2.1.2 Protein folding in vivo 
In a living cell, the folding of a polypeptide into its native 
conformation is not an issue that is left to chance. The in vivo situation is much 
more complex than the in vitro situation. For instance, the interior of a cell is a 
crowded and dynamic environment. The protein concentration in a cell has been 
estimated to be as high as 300 mg/ml, which equals approximately 20 - 30% of 
the total cellular volume (Zimmerman and Trach, 1991). As a consequence 
thereof, the mutual impenetrability of all solute molecules implicates a non-
specific steric repulsion. This phenomenon has been described as ‘molecular 
crowding’ or ‘excluded volume’ effect (Ellis, 2001; Minton, 2001). Steric exclusion 
results in an increase in the effective concentration of each macromolecular 
species and since aggregation is highly concentration dependent, molecular 
crowding promotes the aggregation of partially folded and misfolded 
polypeptides. Molecular crowding favors association of macromolecules in 
biochemical equilibrium as the available volume increases upon association of 
macromolecules (Zimmerman and Trach, 1991). Concomitantly, small structures 
are favored over large. Applied to macromolecules, the collapse of nascent 
polypeptide chains into compact functional proteins or the aggregation of 
unfolded polypeptides into ordered structures is the logical consequence.  
Another obstacle that has to be overcome in vivo i.e. in the cell is the 
vectorial synthesis of the polypeptides. In eukaryotes, translation occurs on a 
timescale up to several minutes. Since stable folding of a domain (100 – 300 
amino acids) can only occur after its complete synthesis, parts of nascent 
polypeptides chains permanently face misfolding and aggregation because 
hydrophobic stretches cannot immediately be buried upon folding (Creighton, 
1990; Jaenicke, 1991). The close proximity to other nascent chains (of the same 
type as it is the case in polyribosomes) additionally increases the tendency to 
aggregate (Hartl and Hayer-Hartl, 2002).  
Because of the challenges posed by the in vivo folding environment, a 
large network of proteins, including molecular chaperones and proteases, has 
evolved as a quality control system to promote the correct folding of proteins on 
one hand and the rapid degradation of mutated or misfolded polypeptides on 
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the other. Protein homeostasis is therefore maintained by continuously subjecting 
the entirety of proteins in the cell to this quality-control system (Kleizen and 
Braakman, 2004; Young et al., 2004).  
 
2.1.2.1 Molecular chaperones 
The folding of newly synthesized proteins is assisted by molecular 
chaperones. They guide the polypeptides through the landscape of folding to 
their native state by multiple, sequential interactions thereby preventing 
aggregation (Maier et al., 2005; Young et al., 2004). Importantly, they do not 
contribute conformational information to the folding process (Hartl and Hayer-
Hartl, 2002).  
The cytosol provides a well-developed network of chaperones which 
cooperate in a topologically and timely ordered manner (Figure 2; Ellis and 
Hartl, 1996; Frydman and Hartl, 1996; Hartl and Hayer-Hartl, 2002; Young et al., 
2004). In eukaryotes, the emerging nascent chain is received by NAC (nascent 
chain-associated complex), a ribosome-associated heterodimeric complex. 
Although not yet fully elucidated NAC probably binds to and therefore protects 
hydrophobic peptide stretches (Young et al., 2004).  
The cytosolic Hsp70s (heat shock protein 70) i.e. nonribosome-binding, 
form part of the so-called Hsp70 system that is highly conserved in prokaryotes 
as well as in eukaryotes. With cochaperones of the Hsp40 family, the Hsp70s 
function by binding and releasing extended polypeptides segments of proteins 
that are in a non-native state (Hartl and Hayer-Hartl, 2002). Thereby, the 
carboxy-terminal domain of Hsp40s shows a high affinity for hydrophobic 
peptides and can thus recruit Hsp70s to nascent chains (Langer et al., 1992; 
Rudiger et al., 2001; Sha et al., 2000). The interaction of the unfolded protein and 
Hsp70 is not restricted to a single event and unfolded polypeptides can undergo 
multiple rounds of binding and release. In particular, nascent chains expose 
multiple hydrophobic stretches requesting the binding of several Hsp70 
chaperone to the same polypeptide.  
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Figure 2: Schematic representation of the chaperone network of the eukaryotic 
cytosol. 
(A) In mammals, Hsc70 and Hsp40 interact with the nascent polypeptide chain emerging 
from the ribosome. (B) In Saccharomyces cerevisiae, RAC recruits Ssb to bind nascent 
chains. (C) The folding to the native states of actin and tubulin nascent chains is assisted 
by GimC/prefoldin and TRiC. In addition, Hsc70 and Ssb also cooperate with TRiC in the 
folding. Other nascent chains can fold spontaneously, are assisted by Hsc70 or are 
passed to Hsp90 via the co-chaperone HOP that mediates the transfer from Hsc70 to 
Hsp90 (adapted from Young et al., 2004). 
 
Additional complexes that recognize hydrophobic stretches and are 
involved in nascent polypeptide binding, particularly of actin and tubulin, are 
GimC in S. cerevisiae and prefoldin in mammals, respectively (Geissler et al., 1998; 
Vainberg et al., 1998). In an ATP-independent manner, hydrophobic extensions 
enable recognition of substrates and probably mediate the transfer of 
polypeptides to chaperonin TRiC (Martin-Benito et al., 2002). The chaperonins 
differ from the other cytosolic chaperones with regard to the folding mechanism. 
Chaperonins are relatively large, cylindrical complexes that provide a physically 
defined compartment inside. Unfolded polypeptides get captured through 
hydrophobic interactions with multiple chaperonin subunits and are 
subsequently relocated into the central ring cavity. The latter enables complete 
proteins or domains to fold while being sequestered from the cytosol. This way, 
the chaperonins prevent non-productive interactions with other unfolded 
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polypeptides (Hartl and Hayer-Hartl, 2002; Meyer et al., 2003). The activity of all 
chaperonins is ATP-dependent and folding cycles are repeated until the protein 
reaches its native state. 
Another ATP-regulated chaperone in the eukaryotic cytosol is the 
highly abundant and essential chaperone Hsp90. (Richter and Buchner, 2001; 
Young and Hartl, 2000; Young et al., 2001). The homodimeric Hsp90 is involved 
in the folding of a diverse set of proteins, including transcription factors e.g. 
steroid hormone receptors, regulatory kinases and other proteins, often in 
cooperation with Hsc70 (Young et al., 2004).  
Lastly, chaperones of the Hsp100 family unfold proteins or disrupt 
protein aggregates in an ATP-dependent manner (Ben-Zvi and Goloubinoff, 
2001). That was shown for e.g. Hsp104 which upon co-expression reduced the 
formation of polyglutamine aggregates in yeast and Caenorhabditis elegans 
(Krobitsch and Lindquist, 2000; Satyal et al., 2000). 
 
2.1.2.2 Cellular quality control  
Proteins that become useless, as is the case for regulatory proteins as 
well as misfolded proteins, undergo a sophisticated system for protein 
degradation. This is particularly important for misfolded proteins since they 
might exert harmful properties. Whenever chaperones fail to refold misfolded 
proteins, another system has to become responsible for their disposal. 
The ubiquitin-proteasome system (UPS) is probably the most 
prominent mechanism for disposing of faulty proteins. In this system, multimers 
of the ubiquitin polypeptide (Ub) are covalently attached to proteins and are 
thereby labelled for targeting to and degradation by the 26S proteasome 
(Hershko and Ciechanover, 1998). The 26S proteasome is a multi-subunit, self-
compartmentalized protease composed of a 20S core complex bearing rather non-
specific proteolytic sites within its cavity and two axial 19S regulatory caps 
(Pickart and Cohen, 2004). Subsequent to deubiquitylation and unfolding, the 
substrates are translocated into the 20S catalytic chamber where they are digested 
to peptides that are 2-24 residues long (Goldberg, 2003; Kisselev et al., 1999). The 
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peptides released by the proteasome are digested by cellular endopeptidases and 
finally hydrolyzed to amino acids by aminopeptidases (Saric et al., 2004).  
 
 
 
Figure 3: Cellular mechanism of protein degradation 
(A) Schematic overview of proteasomal degradation. BAG-1, CHIP and ubiquitin-
conjugating enzymes of the Ubc4/5 family associate with substrate-bound Hsc70. 
Thereby, BAG-1 binds to the adenosine triphosphatase domain of peptide-bound Hsc70, 
Ubc4/5 is thought to bind to the carboxyl terminal U-box (u) of CHIP which associates 
with the carboxyl terminal domain of Hsc70 (c). The ubiquitin-like domain of BAG-1 (ubl) 
remains exposed in the formed complex and serves as a proteasomal sorting signal for 
the ubiquitinated substrate which finally gets degraded by the proteasome. (B) Schematic 
overview of macroautophagy. The initial phagophore that is formed by a membrane of 
unknown origin expands to sequester cytoplasm and closes to form the double-
membrane autophagosome. The latter fuses with a lysosome to form the 
autophagolysosome and the acid hydrolases therein (AH) degrade its content. The 
resulting macromolecules are released back into the cytosol (Alberti et al., 2003; 
Rubinsztein et al., 2007). 
Since a large number of proteins (approx. 25% of total proteome) are 
destined to enter secretory pathways and herein, the endoplasmic reticulum (ER) 
is responsible for their structural maturation, the ER harbors two distinct 
mechanisms to handle misfolded proteins. The first one, the unfolded protein 
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response (UPR), increases the folding capacity of the ER in response to ER-
directed stress (Schroder and Kaufman, 2005; van Anken and Braakman, 2005a; 
van Anken and Braakman, 2005b). The second one, termed ER-associated 
degradation (ERAD), recognizes and targets terminally misfolded proteins across 
the ER membrane into the cytosol. There they meet the fate of all cytosolic 
misfolded proteins, degradation by the UPS (Romisch, 2005). 
Aggregates however, seem to undergo another way of clearance. 
Although it was shown that aggregates are to a large extent reactive with anti-
ubiquitin antibodies, as they are recognized by the ubiquitin conjugation system 
as misfolded species, they seem to be an insurmountable obstacle for the 
proteasome. They may even inhibit proteasomal function, possibly by “choking” 
the proteasome chamber (Bence et al., 2001; Bennett et al., 2005; Venkatraman et 
al., 2004). More complex substrates including protein complexes and organelles 
are degraded via autophagy (Figure 3). This process is characterized by the 
recognition and engulfment of targeted proteins or organelles into 
autophagosome vesicles, double membrane structures, that become fused with 
lysosomes. As a consequence thereof, the vesicles including their contents are 
broken down by the lysosomal hydrolases (Levine and Klionsky, 2004). 
Autophagy was also shown to degrade large aggregates composed of a 
polyglutamine-expanded huntingtin fragment (Ravikumar et al., 2002; 
Ravikumar et al., 2004; Yamamoto et al., 2000) and also the clearance of mutated 
forms of α-synuclein that cause Parkinson’s disease, seems to be highly 
dependent on autophagy (Webb et al., 2003). Thus peptides may become 
inaccessible to the proteasome when they oligomerise.   
 
2.2 Protein misfolding and conformational diseases 
Since the native conformation of proteins is not rigid, random 
conformational fluctuations can lead to the transient formation of aggregation-
prone intermediate states that can initiate aggregation (Jahn and Radford, 2005). 
It is easy to imagine that the function of the cellular quality-control system is 
essential and hence, small irregularities have detrimental consequences. Large 
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quantities of partially folded proteins can accumulate, the capacity of the quality-
control system gets overwhelmed and intracellular aggregates can form before 
refolding or degradation is possible (Barral et al., 2004). 
 
2.2.1 Factors that influence the aggregation of proteins 
Although it was shown that many proteins not known to be involved 
in misfolding diseases can aggregate in vitro, the propensity to undergo 
aggregation varies between molecules (Guijarro et al., 1998). It is mostly 
dependent on the physicochemical features of the molecules such as charge, 
secondary-structure propensities and hydrophobicity (Chiti et al., 2003). In 
addition, external factors that promote exposure of hydrophobic side chains for 
example, low pH or fragmentation can facilitate aggregation (Dobson, 2003).  
 
2.2.2 Amyloidosis 
Incorrectly folded better known as misfolded proteins are 
polypeptides that are trapped somewhere in the folding pathway and did not 
achieve native conformation. These misfolded proteins stress the cell not only 
due to the reduction in the quantity of functional protein but also they often gain 
characteristics that cause toxicity. This is reflected in grave human disorders that 
are caused by such proteins that failed to adopt, or remain in, their native 
functional conformational state (Chiti and Dobson, 2006). A very prominent class 
among those are the so-called ‘amyloidosis’ (Stefani, 2004). 
 
2.2.2.1 Common aspects 
The name amyloidosis derives from the characteristic fibrils these 
aggregated proteins form, ‘amyloid fibrils’ in vitro and ‘intracellular inclusions’ in 
vivo, respectively (Westermark et al., 2005), that can be stained with the dye 
Congo red in a manner similar to starch (amylose) (Sipe and Cohen, 2000). 
Remarkably, although the precursor proteins that comprise the fibrils are 
structurally very diverse, they do not share any obvious sequence identity nor a 
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similar secondary structure composition, the associated fibrils however, are very 
similar in their overall properties and appearance (Sunde and Blake, 1997; Tycko, 
2004). 
In addition to non-neuropathic systemic amyloidoses, the so-called 
neuropathic amyloidoses exist in which aggregation occurs in the brain (Table 
1:). Well known examples are Alzheimer’s, Parkinson’s and polyglutamine 
disease but also Spongiform encephalopathies (Chiti and Dobson, 2006; 
Westermark et al., 2005). A pathological hallmark all these diseases have in 
common are the proteinaceous deposits found in patients. These deposits are 
made of a major protein component that forms the core and then additional 
associated species, including metal ions, glycosaminoglycans, collagen and many 
others (Alexandrescu, 2005; Hirschfield and Hawkins, 2003). Interestingly, the 
toxicity is most likely independent of the function of the normal protein, but 
instead dependent on aggregates or their precursors in the aggregation pathway, 
thus toxicity is, at least in part, the result of a ‘gain of function’ mechanism.  
 
Table 1: A summary of the main neuropathic amyloidoses and the proteins or 
peptides involved.  
Clinical syndrome Fibril component 
Alzheimer's disease Aβ peptides (1–40, 1–41, 1–42, 1–43); Tau 
Spongiform encephalopathies Prion protein (full-length or fragments) 
Parkinson's disease α-synuclein (wild type or mutant) 
Fronto-temporal dementias Tau (wild type or mutant) 
Familial Danish dementia ADan peptide 
Familial British dementia ABri peptide 
Hereditary cerebral haemorrhage with 
amyloidoses 
Cystatin C (minus a 10-residue fragment); Aβ 
peptides 
Amyotrophic lateral sclerosis Superoxide dismutase (wild type or mutant) 
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Clinical syndrome Fibril component 
Dentatorubro-pallido-Luysian atrophy Atrophin 1 (polyglutamine expansion) 
Huntington’s disease Huntingtin (polyglutamine expansion) 
Cerebellar ataxias Ataxins (polyglutamine expansion) 
Kennedy’s disease Androgen receptor (polyglutamine expansion) 
Spino cerebellar ataxia 17 TATA box-binding protein (polyglutamine 
expansion) 
 
2.2.2.2 Structure and formation of amyloid fibrils 
Much effort was spent to elucidate the aggregation pathway towards 
the final amyloid fibril (Figure 4). Transmission electron microscopy (TEM) and 
atomic force microscopy revealed, that the fibrils, composed of proteins of very 
different size and native structure, usually consist of a number (typically 2-6) of 
protofilaments, each about 2-5 nm in diameter (Serpell et al., 2000). These 
protofilaments twist together to form rope-like fibrils that are typically 7-13 nm 
wide (Serpell et al., 2000; Sunde and Blake, 1997) or associate laterally to form 
long ribbons that are up to 30 nm wide and 2-5 nm thick (Bauer et al., 1995; 
Pedersen et al., 2006; Saiki et al., 2005). In each protofilament the protein or 
peptide molecules are arranged so that the polypeptide chain forms β-strands 
that run perpendicular to the long axis of the fibril structure (Sunde and Blake, 
1997), a feature that confers outstanding stability and insolubility. Thereby, the 
fraction of the residues that are incorporated in the core structure can vary 
substantially and the influence of the side chains results in significant differences 
in detail (Fandrich and Dobson, 2002).  
Since it was shown that many proteins not known to be involved in 
amyloid disease can aggregate in vitro into amyloid-like structures, it seems that 
the formation of the cross-β fold is an inherent property of the polypeptide chain 
(Guijarro et al., 1998). Interestingly, the major driving forces for aggregation and 
correct folding are the same, namely the formation of hydrogen bonds and the 
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burial of hydrophobic surface area. The key residues however, that drive either 
aggregation or correct folding are different (Chiti et al., 2002b).  
Amyloid fibril formation has many characteristics of a nucleated 
growth mechanism, which means, that a lag phase is followed by a rapid 
exponential growth phase. In this process, the lag phase is the time required for 
nuclei formation, which is followed rapidly by further association of either 
monomers or oligomers with the nucleus.  (Naiki et al., 1997; Pedersen et al., 2004; 
Serio et al., 2000; Uversky et al., 2002).  
The formation of the amyloid fibrils is preceded by the formation of a 
series of metastable, nonfibrillar species which have been termed protofibrils 
(Harper et al., 1997a; Harper et al., 1997b; Walsh et al., 1999; Walsh et al., 1997). 
The latter differ in their appearance and can adopt a spherical bead structure or 
beaded chains that again can form annular structures upon circularization. All of 
these structures which have been observed amongst others for Aβ peptide, α-
synuclein or polyglutamine-containing proteins, have the bead-like units of 2-5 
nm in diameter in common (Conway et al., 2000; Harper et al., 1997a; Harper et 
al., 1997b; Kayed et al., 2004; Walsh et al., 1999; Walsh et al., 1997). These species 
are characterized by extensive β-structure as well as the ability to bind Congo red 
and interestingly, a specific antibody can bind to protofibrillar species from 
different sources but not to their corresponding monomeric or fibrillar states. 
This suggests, that similar to the amyloid fibrils, already these soluble amyloid 
oligomers have important common structural elements independent of the 
primary structure (Kayed et al., 2003). Since the β-strands within in the sheets of 
the protofibrils are initially misaligned they have to undergo several detachment 
and re-annealing events or internal structural reorganization within the sheets is 
necessary towards the formation of the final amyloid fibrils (Petty et al., 2005). 
Not many details are known about the formation of the protofibrils but it was 
suggested that structured protofibrillar species can form from the assembly of 
small and relatively disorganized oligomers (Nguyen and Hall, 2004). Hence, 
large, globular proteins need to (partially) unfold to aggregate into amyloid 
fibrils (Dobson, 1999; Kelly, 1998; Uversky and Fink, 2004). Thus, it is not 
surprising that among the familial forms of disease often mutations can be found, 
Introduction 16                                  
 
that destabilize the native structure and as a consequence thereof, increase the 
population of nonnative states (Canet et al., 2002; Ferrao-Gonzales et al., 2000; 
Raffen et al., 1999). Also fragments of globular proteins generated by proteolysis, 
as it is the case e.g. in several polyglutamine diseases, tend to aggregate most 
likely because of their inability to fold in the absence of the remainder of the 
polypeptide chain (Chiti and Dobson, 2006).  
The polyglutamine fibrils are of particular interest because of the 
possibility that the additional array of hydrogen-bonding interactions involving 
the side chains results in a structure significantly different from that of the 
classical amyloid fibrils (Chiti and Dobson, 2006).  
 
Figure 4: Schematic representation of the general mechanism of amyloid fibril 
formation 
(A) Aggregation-prone folding intermediates, often rich in β-sheet structure, associate 
with each other to form soluble oligomers, (B) which assemble into amorphous or ring-
shaped structures. (C) These undergo further assembly into protofibrils or protofilaments 
and finally (D), mature amyloid fibrils which often accumulate in plaques or inclusion 
bodies (E) (adapted from Chiti and Dobson, 2006; Dobson, 2003).   
 
For the sake of completeness, it should be mentioned that aggregation 
of globular proteins is not restricted to partial unfolding. Thermodynamic studies 
revealed that for some proteins e.g. the pathogenic variant of ataxin-3, 
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aggregation occurs via the formation of native-like oligomers, that undergo 
structural reorganization to form amyloid protofibrils that have extensive β-
structure (Chow et al., 2004; Plakoutsi et al., 2005). In terms of determinants that 
favour the aggregation of an unfolded polypeptide, hydrophobicity of the side 
chains, low net charge and a high propensity to form β-sheets must be noted 
(Broome and Hecht, 2000; Chiti et al., 2002a; Chiti et al., 2002b; Otzen et al., 2000; 
Schmittschmitt and Scholtz, 2003; Wurth et al., 2002).  
 
2.2.2.3 Aggregation mediated toxicity 
Recent findings suggest that not the intracellular inclusions but more 
likely precursors to amyloid fibrils, such as low-molecular-weight oligomers 
and/or structured protofibrils are the pathogenic species (Arrasate et al., 2004; 
Behrends et al., 2006). This would explain the observed onset of toxic 
manifestations before intracellular deposits of the respective protein were 
detectable in either Alzheimer’s disease, Parkinson’s disease or Huntington’s 
disease (Bennett et al., 2005; Kitada et al., 1998; Larson et al., 1999; Moechars et al., 
1999). Concomitantly, prefibrillar forms of non-disease-related proteins turned 
out to be highly toxic to cultured fibroblasts and neurons, whereas the 
monomeric native states and the amyloid-like fibrils displayed little toxicity 
(Bucciantini et al., 2002; Malisauskas et al., 2005; Sirangelo et al., 2004). Why do 
these prefibrillar forms cause toxicity? Unfortunately, only little is known about 
how these prefibrillar forms mediate toxic effects. Most likely, toxicity results 
from the exposure of an array of groups on their surface that are normally buried 
in globular proteins or dispersed in highly unfolded peptides. This probably 
results in a set of inappropriate interactions with cellular components, such as 
membranes or proteins what leads to the malfunctioning of crucial aspects of the 
cellular machinery and ultimately to cell death (Chiti and Dobson, 2006). The fact 
that small aggregates have a higher proportion of residues on their surface in 
comparison to larger aggregates, such as amyloid fibrils, could explain the 
increased toxicity of the former.  
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2.3 Polyglutamine diseases 
The polyglutamine disorders represent the most common form of 
inherited neurodegenerative disease (Riley and Orr, 2006). They are caused by 
expansion of a translated CAG repeat that results in an extended stretch of 
glutamine residues in the disease protein. Actually, nine neurodegenerative 
disorders are known to be caused by expansion of an translated CAG repeat 
Huntington’s disease (HD), Dentatorubral-pallidoluysian atrophy (DRPLA), 
Spinocerebellar ataxias SCA1, SCA2, SCA3/MJD, SCA6, SCA7 and SCA17 and 
Spinal bulbar muscular atrophy (SBMA, or Kennedy’s disease). Apart from the 
polyglutamine stretch, the proteins involved are structurally unrelated but are 
thought to share common pathogenic mechanisms (Orr and Zoghbi, 2001). 
Interestingly, the polyglutamine stretch seems to be unique to the 
human genome although genes were identified that are highly homologous to 
the polyglutamine ones. The fact that the polyglutamine stretch itself however is 
not conserved within these genes suggests that it is not necessary for normal 
function (Hardy and Orr, 2006). The length of a non-expanded polyglutamine 
tract is polymorphic and usually ranges from 10 to 35 glutamines in normal 
individuals. Independent of the protein involved in polyglutamine disease, an 
extension beyond this threshold causes the respective disease. This seems to be a 
result of a conformational change in the protein, which promotes aggregation of 
the latter (Scherzinger et al., 1997). The CAG sequence is an unstable repetitive 
element and since mutant CAG repeats show both somatic and germline 
instability the repeat grows upon passage from generation to generation. As a 
consequence thereof affected members in successive generations have an earlier 
age of onset and a more rapidly progressing form of the disease, a phenomenon 
that is known as genetic anticipation (Gatchel and Zoghbi, 2005).  
 
2.3.1 Polyglutamine mediated pathogenesis 
The group of polyglutamine diseases which are with the exception of 
the X-linked androgen receptor inherited autosomal dominantly share many 
features with other families of neurodegenerative diseases (Zoghbi and Orr, 
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2000). All of these disorders are progressive, typically strike at midlife and have a 
course that consists of an extended period of neuronal dysfunction followed by 
neuronal loss and eventually death 10–20 years after onset (Hardy and Orr, 
2006). The age of onset and the severity of the disease is inversely related to the 
length of the polyglutamine tract, a characteristic of this group of 
neurodegenerative disorders. The propensity to aggregate however, increases 
with the number of glutamines. Thus, a hallmark of the diseases is the 
accumulation of insoluble material within neurons but also peripheral tissue.  
In the beginning it was thought that the genetic similarities among 
these polyglutamine mediated neurological disorders share a common 
mechanism of pathogenesis entirely dependent on the toxic properties of the 
polyglutamine tract. This was associated with the enhanced ability of 
polyglutamine peptides to form extra- and intranuclear aggregates. The concept 
of large inclusions of mutant polyglutamine being closely associated with 
neurodegenerative disease, has become suspect. Increasing evidence suggests 
that IBs, and the fibrillar aggregates therein, may not represent the primary 
neurotoxic agent (Arrasate et al., 2004; Behrends et al., 2006; Cleary et al., 2005; 
Ross and Poirier, 2005; Walsh et al., 2002). Instead, soluble intermediates in the 
aggregation pathway are likely to be the key toxic species, giving rise to 
neurodegeneration through various mechanisms. (Bennett et al., 2005; Schaffar et 
al., 2004). 
Another fact that suggests more complicated pathologic mechanism is 
that although the disease-causing proteins are widely expressed in the central 
nervous system and also in peripheral tissues, nevertheless specific collections of 
neurons degenerate in each disease. This in turn results in characteristic patterns 
of pathology and clinical symptoms. For instance, the region mainly affected in 
SBMA includes the spinal and bulbar motor neurons whereas in HD it is the 
caudate nucleus, putamen and the cerebral cortex (Table 2:). This might be due to 
very specific interactions of polyglutamine-expanded proteins with other cellular 
constituents during the aggregation process which can even result in recruitment 
of the latter into the aggregates (McCampbell et al., 2000; Nucifora et al., 2001; 
Preisinger et al., 1999). Presumably, exposed β-sheets in intracellular 
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polyglutamine monomers or oligomers interact unfavorably with the surface of 
other proteins thereby disturbing various cellular functions (Sakahira et al., 
2002b). But also the protein context of the expanded polyglutamine is 
hypothesized to have key roles in disease-specific processes since it was shown 
that the flanking regions affect the toxicity of the polyglutamine stretch (Dehay 
and Bertolotti, 2006; Duennwald et al., 2006a). Interestingly, cell specificity 
declines with the progression and severity of disease for instance juvenile-onset 
or large polyglutamine expansions, respectively (Zoghbi and Orr, 2000). 
Several non-exclusive hypotheses were proposed to explain 
polyglutamine mediated neurodegeneration. Thereby, the most prominent 
include the inactivation of essential transcription factors and inhibition of the 
ubiquitin proteasome system. It was shown that glutamine-rich regions trigger 
the transient association of transcriptional regulators into their transcriptional 
complexes (Gerber et al., 1994). Being presumably flexible and unstructured they 
probably recruit additional factors or bridge large distances, as it is required in 
transcription (Faux et al., 2005). Thus it seems possible that polyglutamine 
expanded species, monomers but also oligomers, interact with such glutamine-
rich regions of transcriptional regulators and as a consequence thereof the 
activity of the latter is disturbed (Cha, 2000; Sakahira et al., 2002b; Schaffar et al., 
2004).  
Inhibition of the ubiquitin proteasome system is considered as the 
second major explanation for polyglutamine mediated toxicity due to the fact 
that polyglutamine containing fragments accumulate and form inclusions which 
were shown to be relatively stable. It was observed that these inclusions contain 
not only molecular chaperones but also components of the ubiquitin proteasome 
system (Ciechanover and Brundin, 2003; Sakahira et al., 2002b). Since they were 
also tested ubiquitin-positive it seems that these polyglutamine expanded 
proteins are recognized as misfolded species that have to be degraded by the 
ubiquitin proteasome system (Li et al., 1998a). If impairment of the ubiquitin 
proteasome system contributes to the polyglutamine diseases is still under 
discussion but recent studies support this hypothesis (Bennett et al., 2007; Pandey 
et al., 2007).  
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Table 2: Molecular characteristics of polyglutamine neurodegenerative diseases 
Disease Gene 
product 
Normal 
CAG(n) 
Expanded 
CAG(n) 
Protein 
localization 
Brain regions most 
affected 
SBMA Androgen 
receptor 
9–36 38–62 Nuclear and 
cytoplasmic 
Anterior horn and 
bulbar neurons, dorsal 
root ganglia 
HD Huntingtin 6–34 36–121 Cytoplasmic Striatum, cerebral 
cortex 
SCA1 Ataxin-1 6–44 39–82 Nuclear in 
neurons 
Cerebellar Purkinje 
cells, dentate nucleus; 
brainstem 
SCA2 Ataxin-2 15–31 36–63 Cytoplasmic Cerebellar Purkinje 
cells, brain stem, 
fronto-temporal lobes 
SCA3 Ataxin-3 12–41 62–84 Cytoplasmic Cerebellar dentate 
neurons, basal ganglia, 
brain stem, spinal cord 
SCA6 CACNA1A 4–18 21–33 Cell 
membrane 
Cerebellar Purkinje 
cells, dentate nucleus, 
inferior olive 
SCA7 Ataxin-7 4–35 37–306 Nuclear Cerebellum, brain 
stem, macula, visual 
cortex 
SCA17 TATA-BP 29-42 47-55 Nuclear Cerebellum, cerebral 
cortex 
DRPLA Atrophin-1 6–36 49–84 Cytoplasmic Cerebellum, cerebral 
cortex, basal ganglia, 
Luys body 
 
However, other hypotheses came up in order to explain the toxicity of 
the polyglutamine expanded proteins. In concordance with the inactivation of 
nuclear transcription factors the functions of many additional cytoplasmic and 
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nuclear proteins that were found in aggregates are altered (Harjes and Wanker, 
2003; Li and Li, 2004). It was also suggested that polyglutamine expanded 
proteins may damage cells via a channel mechanism since they were shown to 
form ion channels in planar lipid bilayers. This mechanism could cause damage 
to the plasma membrane by running down ionic gradients, discharging 
membrane potential; or allowing influx of toxic ions such as Ca2+ (Hirakura et al., 
2000; Monoi et al., 2000; Trushina and McMurray, 2007). Other groups postulated 
mitochondrial dysfunction that again causes oxidative stress due to ATP deficits, 
Ca2+ release, loss of antioxidants and overproduction of reactive oxygen species 
(reviewed in Trushina and McMurray, 2007). There is also evidence that axonal 
and dendritic trafficking is impaired as it was observed that polyglutamine 
aggregates are able to physically block and as a consequence thereof alter neurite 
transport and thus deprive neuronal processes of factors or components that are 
important for axonal and dendritic functions. The soma may then be affected, 
leading to neuronal dysfunctions and possibly to cell death (Lee et al., 2004; 
Piccioni et al., 2002). Although it is unknown what process is responsible for the 
pathological cascade in the polyglutamine diseases, it seems likely that all 
contribute to some extent to the pathophysiology.  
 
2.3.1.1 Toxic species 
As already mentioned, a hallmark of polyglutamine diseases is the 
formation of inclusion bodies. Since the size of the polyglutamine stretch was 
shown to correlate with an enhanced ability of polyglutamine peptides to form 
extra- and intranuclear aggregates as well as with an earlier onset of disease the 
aggregates were suspected of mediating toxicity. There is indeed evidence 
supporting this hypothesis as it was shown that inhibition of aggregate formation 
by peptides, chemical compounds, intrabodies against huntingtin or molecular 
chaperones leads to suppression of both, inclusion body formation and 
cytotoxicity of polyglutamine peptides in vivo (Colby et al., 2004; Cummings et al., 
1998; Muchowski et al., 2000; Nagai et al., 2003; Sanchez et al., 2003; Warrick et al., 
1999). Nevertheless, the concept of large inclusions of mutant polyglutamine 
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being the toxic species, has become suspect and the idea came up that they might 
be even beneficial and neuroprotective (Arrasate et al., 2004; Bates, 2003; Sakahira 
et al., 2002a). This hypothesis is based on the observation that the regions in the 
brain that show the highest density of inclusions do not overlap with those 
undergoing massive degeneration (Gutekunst et al., 1995; Kuemmerle et al., 1999). 
Studies on transgenic mouse models as well as cell culture models revealed no or 
only little correlation between inclusion bodies and neurodegeneration or 
dysfunction (Arrasate et al., 2004; Saudou et al., 1998; Slow et al., 2005). Enhancing 
inclusion body formation even resulted in suppression of toxicity (Bodner et al., 
2006). Consequently, it was suggested that inclusion body formation is an active 
cellular regulation mechanism for handling misfolded or aggregated proteins 
promoting neuronal survival (Kopito, 2000). As the level of diffuse 
polyglutamine peptide was recently shown to correlate with toxicity, the 
expanded polyglutamine peptides probably gain cytotoxicity during the 
aggregation process, before inclusion body formation (Arrasate et al., 2004). 
Extensive study on this topic was carried out but the difficult handling of the in 
aqueous solution highly insoluble polyglutamine peptides impedes with clear 
results. So far amorphous oligomers were suspected of gaining characteristics 
that mediate toxicity and a recent study demonstrated that already a 
polyglutamine expanded peptide monomer exerts toxic effects upon a β-sheet 
conformational transition (Bennett et al., 2005; DiFiglia et al., 1997; Li et al., 2007; 
Nagai et al., 2007; Schaffar et al., 2004).  
Notably, in addition to the polyglutamine expanded proteins also 
polyglutamine containing fragments of the respective full-length proteins were 
found in the inclusion bodies (Becher et al., 1998; Butler et al., 1998; DiFiglia et al., 
1997; Li et al., 1998b). Studies on these fragments revealed that they are more 
prone to aggregate and are substantially more toxic, in most cell culture and 
mouse models, than their full-length counterparts (de Almeida et al., 2002; Peters 
et al., 1999; Saudou et al., 1998). Probably, they are even crucial for aggregation 
and cytotoxicity as it was recently suggested (Graham et al., 2006). Caspases are 
thought to be responsible for the cleavage of polyglutamine containing proteins 
since masking of the predicted cleavage sites suppressed both aggregation as 
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well as toxicity and the rate of cleavage  was shown to be polyglutamine length 
dependent (Ellerby et al., 1999; Graham et al., 2006; Kobayashi et al., 1998; 
Wellington et al., 1998). The activity of the caspases necessary for the initial 
cleavage of the polyglutamine peptide may reside in the inherent low-level 
activity of the zymogen. Accumulation and aggregation of toxic fragments may 
trigger additional caspase activity (such as caspase-8) that may activate 
additional effector caspase activity and contribute to cell death (Wellington and 
Hayden, 2000; Wellington et al., 2000). This could also explain the late onset of the 
disease as the quality control system of the cell might cope with the formation of 
fragments under normal conditions. But as the quality control system becomes 
compromised as it is likely the case in aging cells, toxic fragments accumulate to 
toxic levels.  
 
2.3.1.2 Gain of function versus loss of function 
It is widely accepted that neuronal dysfunction and death in all 
polyglutamine diseases is due to a toxic gain-of-function mechanism associated 
with an expanded polyglutamine repeat in the respective protein. This is 
supported by the dominant inheritance pattern of all polyglutamine diseases, 
together with an extensive studies on cell culture and animal models of these 
diseases (Piccioni et al., 2001; Zoghbi and Orr, 2000).  
The proposed toxic gain-of-function mechanism becomes particularly 
apparent in SBMA. Unlike most other polyglutamine repeat diseases, the 
function of the protein mutated in SBMA, the androgen receptor, is well 
established. Patients with androgen resistance syndromes, e.g. due to mutations 
in the androgen receptor, do not develop signs of neurodegeneration. Thus, it is 
likely that the SBMA neurological phenotype is due to a newly-gained toxic 
effect of the expanded polyglutamine repeat, rather than to a loss of androgen 
receptor function (Brooks and Fischbeck, 1995; Piccioni et al., 2001).  
Although polyglutamine expansion mutations produce a dominant 
gain-of-function toxicity, it seems obvious that the overall activity of the disease 
causing protein is altered either due to intrinsic properties of the elongated 
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polyglutamine stretch or to a reduction in the total amount of the respective 
protein due to aggregation. This might contribute to disease pathogenesis and 
explain differences in pathology among the polyglutamine diseases. As most 
polyglutamine disease proteins are widely expressed throughout the neuraxis 
but only cause degeneration in select regions of the central nervous system, 
partial loss of disease protein function could render particular neurons 
exquisitely sensitive to the toxic gain-of-function effects that a polyglutamine 
expansion imparts to the disease protein (Thomas et al., 2006). Although a 
mechanistic explanation for how loss-of-function of a polyglutamine protein 
contributes to polyglutamine disease pathogenesis is lacking, studies on HD but 
also on SBMA revealed considerable evidence for a pathogenic role of diminished 
normal function of disease proteins containing polyglutamine repeat expansions 
(Dragatsis et al., 2000; Leavitt et al., 2001; Leavitt et al., 2006b; Thomas et al., 2006).  
 
2.3.1.3 Advances towards medical treatment 
Up to now, there is no known cure for polyglutamine diseases and 
existing pharmacological therapies are targeted at managing, rather than 
preventing, symptoms. Currently, a wide variety of research towards 
establishing therapies targeting each step in the pathogenesis of the 
polyglutamine diseases is in progress, which includes suppressing mutant gene 
expression by RNAi (Boado et al., 2000; Gonzalez-Alegre, 2007; Haque and 
Isacson, 1997; Haque et al., 1997; Hasholt et al., 2003; Nellemann et al., 2000; Yen et 
al., 1999), inhibiting protein misfolding/aggregation (Cummings et al., 1998; 
Kobayashi et al., 2000; Muchowski and Wacker, 2005; Warrick et al., 1999; 
Wyttenbach, 2004; Wyttenbach et al., 2000), promoting protein degradation 
(Adachi et al., 2007; Janknecht, 2002; Jia et al., 2007; Seo et al., 2007; Waza et al., 
2005; Yang et al., 2007), activating transcription (Janknecht, 2002; Shimohata et al., 
2005), restore mitochondrial deficits (Kim et al., 1999; Oliveira et al., 2006; Oliveira 
et al., 2007), inhibiting neuronal cell death (Kim et al., 1999), and neuroprotection 
by neurotrophic factors (Anderson et al., 1996; Perez-Navarro et al., 2000; Petersen 
and Brundin, 1999; Saudou et al., 1998; Ventimiglia et al., 1995). Certainly, the 
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most powerful approach would be the prevention of the toxic species since it 
appears that independent of the protein context the toxic mechanism is shared by 
all polyglutamine diseases. However, the lack of knowledge with regard to the 
toxic species impedes with the identification of powerful drugs. Nevertheless, 
several compounds or antibodies with anti-aggregation activity have been 
identified, such as small molecules, but their benefits remain questionable 
(Bonelli and Hofmann, 2007; Heiser et al., 2002; Hockly et al., 2006; Sanchez et al., 
2003; Wang et al., 2005; Wolfgang et al., 2005; Wood et al., 2007). Similarly, the 
idea to promote aggregation revealed promising results, however, an approved 
drug is still missing (Bodner et al., 2006). 
 
2.3.2 Huntington’s disease 
Huntington’s disease is the most prevalent of the nine polyglutamine 
diseases. In Europe and North America the risk to develop Huntington’s disease 
is approximately 1:10,000. Thereby, both sexes are affected with the same 
frequency. Huntington’s disease is inherited in an autosomal dominant manner 
and is characterized by irrepressible motor dysfunction, cognitive decline and 
psychiatric disturbance, which lead to progressive dementia and death 
approximately 15-20 years after disease onset (Bates, 2000; Martin and Gusella, 
1986). To date there is no effective treatment to prevent or delay disease 
progression (Borrell-Pages et al., 2006). 
2.3.2.1 Huntingtin  
Huntingtin is an essential ~350-kDa protein that contains a 
polymorphic glutamine/proline-rich domain at its amino terminus (Figure 5). 
Although the gene was discovered more than a decade ago, its role has not been 
fully elucidated yet. Apart from the polyglutamine stretch it shares no sequence 
homology to other known human proteins. Huntingtin is ubiquitously expressed 
but the highest levels are found in the testis and brain (Difiglia et al., 1995; 
Gutekunst et al., 1995; Trottier et al., 1995). Within the brain, the neocortex, the 
cerebellar cortex, the striatum and the hippocampus were identified as main 
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expression sites, a pattern that only partially overlaps with the regions most 
affected in Huntington’s disease (Figure 6; Fusco et al., 1999). The cellular 
distribution is as diverse. It is mainly found in the cytoplasm, but is also located 
in the nucleus, within neurites and at synapses. But it was also shown to 
associate with organelles and structures, such as clathrin coated vesicles, 
endosomal and endoplasmic compartments, mitochondrial, microtubules as well 
as plasma membrane (Difiglia et al., 1995; Gutekunst et al., 1995; Hoogeveen et al., 
1993; Kegel et al., 2002; Kegel et al., 2005; Trottier et al., 1995).  
 
 
Figure 5:  Major interaction domains of the huntingtin protein (Truant et al., 
2007).  
 
Huntingtin was shown to interact with a variety of proteins involved in gene 
expression, intracellular transport, intracellular signalling and metabolism 
(Borrell-Pages et al., 2006; Harjes and Wanker, 2003; Li and Li, 2004). It appears 
that huntingtin regulates transcription by shuttling transcription factors between 
the nucleus and the cytoplasm (Cattaneo, 2003; Charrin et al., 2005; Sugars and 
Rubinsztein, 2003; Zuccato et al., 2003). Huntingtin is suggested to be involved in 
trafficking since it interacts with many proteins that regulate intracellular 
transport or endocytosis. (Gauthier et al., 2004; Kalchman et al., 1997; Li et al., 
1995; Modregger et al., 2002; Singaraja et al., 2002; Wanker et al., 1997). 
Interestingly, it confers anti-apoptotic properties and protects against 
polyglutamine expanded huntingtin-induced cell death (Cattaneo et al., 2001; 
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Gervais et al., 2002; Hackam et al., 2000; Ho et al., 2001; Leavitt et al., 2001; Leavitt 
et al., 2006a; Rigamonti et al., 2000; Zhang et al., 2003). 
 
Figure 6: Coronal and mid-sagittal section through the human cerebrum 
(adapted from www.CNSforum.com). 
 
2.3.2.2 Characteristics, affected region, phenotype 
The first symptoms of Huntington’s disease usually appear in middle 
age. Most of the patients show involuntary movements of the face, fingers, feet or 
thorax in the beginning which at the same time act as an indicator for 
Huntington’s disease (Folstein et al., 1986). In addition to the physical symptoms 
patients also develop psychiatric disturbances, for instance depression, anxiety, 
apathy and irritability which usually occur 10-20 years before onset of the 
choreiform movements (Craufurd et al., 2001). At a later stage, the patients suffer 
from choreiform movements of the head, neck, arms and legs as well as cognitive 
deficits such as impairments of memory and language comprehension (Bachoud-
Levi et al., 2001). Males in addition, become frequently sexually dysfunctional 
and have testicular abnormalities (Fedoroff et al., 1994; Van Raamsdonk et al., 
2007). At the final stage of the disease, patients become severely rigid and 
akinetic and present severe dementia. 15-20 years after the first symptoms appear 
the patient usually dies.  
At the cellular level, Huntington’s disease causes the selective 
dysfunction and death of specific neuronal subpopulations within the central 
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nervous system. The gamma-aminobutyric acid-releasing spiny-projecting 
neurons of the striatum and the subcortical brain structure that controls body 
movement are mainly affected and to a lesser extent, neurons within the cerebral 
cortex (Vonsattel et al., 1985). With the progression of the disease, a general 
neuronal loss in several brain regions such as the globus pallidus, the 
subthalamic nuclei, the substantia nigra, the cerebellum and the thalamus is 
observed.   
 
2.3.3 SBMA 
Spinal and bulbar muscular atrophy (SBMA; Kennedy’s disease) is an 
X-linked dominant neurodegenerative disorder that results from expanded 
glutamine repeats in the amino terminus of the androgen receptor (AR) protein 
(La Spada et al., 1991). In Europe the risk of being affected by SBMA is about 
1:10,000 to 1:50,000. The onset of the disease is usually between 30 and 60 years 
and is characterized by progressive lower motor neuron degeneration in the 
spinal cord and bulbar nuclei of the brain stem (Katsuno et al., 2006; Kennedy et 
al., 1968; Li et al., 1998a). It mainly affects males and SBMA is frequently 
associated with gynaecomastia, testicular failure and other feminized signs. 
Female carriers of SBMA, even homozygous, usually do not show disease 
phenotypes (Abou-Sleymane et al., 2006; Schmidt et al., 2002; Sobue et al., 1993). 
Presumably, this is due to low concentrations of testosterone, a ligand of the AR 
protein which is a steroid hormone transcription factor.  
 
2.3.3.1 AR 
Of all proteins associated with polyglutamine disease the AR protein is 
probably the best investigated. The AR is a member of the steroid and nuclear 
receptor superfamily and is regulated by the binding of androgens. The AR gene 
consists of eight exons and encodes a protein with 919 amino acid residues. Exon 
1 of the gene consists of two polymorphic repeat motifs (CAG and GGN), 
encoding variable lengths of polyglutamine and polyglycine stretches, 
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respectively, which are separated by 248 amino acids of non-polymorphic 
sequence (Faber et al., 1989; Lubahn et al., 1988). The AR protein consists of an N-
terminal transactivation domain (TAD), a central DNA-binding domain (DBD), a 
C-terminal ligand-binding domain (LBD), and a hinge region connecting the LBD 
and the DBD (Figure 7). The LBD is in addition to ligand binding also involved 
in dimerization of the receptors and contains a ligand-dependent activation 
function (AF2) (Brinkmann et al., 1989; Gelmann, 2002). In contrast to other 
nuclear receptors, the NTD of AR harbors one or more transcriptional activation 
function (AF1) and is known to strongly interact with the LBD in a hormone 
dependent manner (Brinkmann, 2001; Singh et al., 2006). But also a number of co-
regulators modulate the actions of AR (Chamberlain et al., 1994; Faber et al., 1989; 
Kazemi-Esfarjani et al., 1995).  
The AR is a key player in male sexual differentiation since AR 
transcription mediates muscle and bone growth, spermatogenesis and the 
development of secondary sexual characteristics (Mooradian et al., 1987). Since 
AR is present in the brain in areas critical for learning and memory such as the 
thalamus and hippocampus, it is also thought to be important for cognitive 
function but similar to Huntington’s disease a lack of correlation between the AR 
protein expression levels and pathological involvement in SBMA is seen (Li et al., 
1998a; Li et al., 1998b; Yaffe et al., 2003). In non-neural tissues AR protein is 
mainly expressed in the testis, skin, and muscle, whereas it is low in the kidney, 
spleen, and liver (Li et al., 1998a; Li et al., 1998b).  
At the cellular level, AR is predominantly cytoplasmic and rapidly 
translocates into the nucleus upon binding of the ligand (Simental et al., 1991). 
This is mediated by a large dynamic heterocomplex composed of heat shock 
proteins, co-chaperones, and tetratricopeptide repeat (TRP)-containing proteins 
(Pratt and Toft, 1997). Unbound to ligand, the AR is maintained in a partially 
unfolded, inactive conformation that allows efficient ligand binding (Pratt et al., 
2004). Involved in folding of the nascent peptide and assembly of the final 
chaperone complex are Hsp70, Ydj1, Hip (hsc70 interacting protein) and Hop 
(Hsp organizer protein). The chaperone-complex that finally ensures a high 
affinity for ligand binding consists of Hsp90, p23 and TPR-containing 
Introduction 31                                  
 
immunophilin (Davies et al., 2002; Fan et al., 2005; Freeman et al., 2000; Frydman 
and Hohfeld, 1997; Georget et al., 2002; Hohfeld et al., 1995). Since the interactions 
between steroid hormone receptors and molecular chaperones are transient there 
is an ongoing dynamic folding/refolding cycle (Jakob and Buchner, 1994; Pratt et 
al., 2004; Smith, 1993). Upon addition of androgens, the TPR-containing 
immunophilin gets substituted for another, which is thought to guide the 
receptor in a retrograde direction along microtubules (Davies et al., 2002). Hsp70 
and Ydj1 presumably assist AR in crossing the nuclear membrane (Caplan and 
Douglas, 1991; Rassow et al., 1995; Smith and Toft, 1993). Inside the nucleus, Bag-
1L is believed to facilitate transactivation mediating the recruitment of AR and 
Hsp70 to its promoter (Froesch et al., 1998; Shatkina et al., 2003). Once bound to 
specific elements on the DNA, the so-called androgen response elements (AREs), 
transcription of the respective target genes leads to an androgen response that 
physiologically involves genes responsible for male sexual differentiation in 
utero and for male pubertal changes. In adult males, androgen is mainly 
responsible for maintaining libido, spermatogenesis, muscle mass and strength, 
bone mineral density, and erythropoisis (Johansen, 2004). As long as androgens 
are present, there is a molecular chaperone-mediated continuous 
disassembly/reassembly of the complex and transcriptional activation continues 
(Freeman and Yamamoto, 2001; Pratt et al., 2004). The degradation of AR occurs 
via the ubiquitin-proteasome pathway (Pratt et al., 2004). This process is 
mediated by CHIP (carboxyl terminus of Hsc70-interacting protein), which 
interacts with ARs that are unable to successfully transition into the high-affinity 
ligand-binding conformation (He et al., 2004). 
AR dysfunction is not only associated with SBMA. Since androgen 
pathways are integrated with several other pathways regulating metabolic 
processes in the human body alterations in AR transactivation capacity may lead 
to disturbances in the secondary sexual differentiation as well as in the 
physiology of numerous other organs. Extensive research revealed that AR 
dysfunction is implicated in reproductive disorders, in neurological disorders, in 
disorders of aero-digestive tract and digestive system as well as in disorders 
related to general body health and fitness (reviewed in Rajender et al., 2007).  
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Figure 7: Genetic organization of the AR gene on the X-chromosome and major 
functional domains of the encoded protein (Rajender et al., 2007). 
 
2.3.3.2 Characteristics, affected region, phenotype 
The major symptoms of SBMA are weakness, atrophy, and 
fasciculations of bulbar, facial and limb muscles (Katsuno et al., 2004). First 
symptoms are often postural tremor such as tremor of the outstretched hands, 
muscle cramps, and in the early stage of the disease contraction fasciculations are 
noticeable in the face, neck, and tongue. Eventually, individuals develop limb 
weakness which usually begins in the pelvic or shoulder regions. Later, 
weakness of the facial and tongue muscles may occur and often leads to 
dysphagia (difficulty in swallowing), dysarthria (slurring of speech), and 
recurrent aspiration pneumonia. Although symptoms usually show up in the 
30’s patients reach a near-normal lifespan.  
At the cellular level, SBMA patients show degeneration of anterior 
horn cells, bulbar neurons, and dorsal root ganglion cells, hence, motor nerves 
that control breathing, swallowing, talking and moving (Sobue et al., 1989).  
The majority of patients show also signs of androgen insensitivity such 
as gynaecomastia, impaired spermatogenesis, testicular atrophy, impotence and 
decreased fertility, some of which are detected before the onset of motor 
symptoms (Dejager et al., 2002). This observation suggests that the polyglutamine 
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expansion mutation in SBMA imparts a partial loss-of-function in tissues 
important for the expression of male secondary sexual characteristics.  
 
2.3.3.3 AIS 
Impaired AR function causes the androgen insensitivity syndrome 
(AIS) which is most severe in the absence of functional AR, known as testicular 
feminization. Patients of the latter, fail to develop male external genitalia, have a 
female appearance and are infertile whereas patients with reduced AR activity 
often express phenotypic signs of gynaecomastia, testicular atrophy and reduced 
fertility (Brinkmann, 2001; Lyon and Hawkes, 1970; Pinsky et al., 1992). AIS 
patients usually suffer from various types of mutations in the AR gene that 
devastate the functionality of AR protein (Brinkmann, 2001). Interestingly, more 
than 80% of SBMA patients show in addition to neurodegeneration also signs of 
mild-to-moderate AIS, for instance varying degrees of testicular atrophy, 
impaired fertility and gynecomastia (Dejager et al., 2002). But unlike other AIS 
patients, the AIS in SBMA is not a fixed feature of the disease; sex differentiation 
proceeds normally and characteristics of AIS develop slowly progressive, similar 
to the neurological symptoms that appear later in life (Brinkmann, 2001; Dejager 
et al., 2002).  
To elucidate the molecular mechanism of this non-classic form of mild, 
late-onset AIS in SBMA, several studies were carried out with contradicting 
results. Some groups propose decreased levels of AR protein expression to be the 
cause of the loss of AR function in SBMA (Brooks et al., 1997; Choong et al., 1996) 
but this was not observed by others (Ellerby et al., 1999; LaFevre-Bernt and 
Ellerby, 2003; Sopher et al., 2004; Stenoien et al., 1999). A decrease in AR apparent 
ligand binding affinity in subjects with SBMA was reported (Danek et al., 1994; 
MacLean et al., 1995; Warner et al., 1992) but cell line studies could not confirm 
this result (Brooks et al., 1997; Chamberlain et al., 1994; Kazemi-Esfarjani et al., 
1995). The majority of researchers favors a linear decrease of transactivation 
function with progressive expansion of the polyglutamine repeat (Chamberlain et 
al., 1994; Dejager et al., 2002; Kazemi-Esfarjani et al., 1995; Thomas et al., 2006; Tut 
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et al., 1997), whereas Brooks et al. observed no differences in transactivation 
capacity comparing AR proteins with either 24Q or 65Q in a stably transfected 
motor neuron hybrid cell line (Brooks et al., 1997). Two studies suggest impaired 
interaction of polyglutamine expanded AR protein with AR co-activators (Hsiao 
et al., 1999; Irvine et al., 2000). Regardless of the high grade of contradictive 
observations these hypotheses are based on, they seem to be inappropriate to 
explain the slowly progressive, late-onset AIS in SBMA, since, for instance, 
altered ligand binding affinity or decreased transactivation function of 
polyglutamine expanded AR are intrinsic properties and do not develop over the 
years.  
An alternative attempt to explain the loss of AR function in SBMA, 
that takes into consideration the progressive development of AIS which 
resembles the appearance of neurological symptoms in SBMA (Dejager et al., 
2002), was given by Butler et al. and Stenoien et al. (Butler et al., 1998; Stenoien et 
al., 1999). They hypothesize that the reduction in transcriptional activity of AR 
protein in SBMA is due to aggregated and sequestered polyglutamine AR 
protein. Hence, the amount of active AR protein would decrease and furthermore 
it is possible, that the aggregates sequester other transcriptional components 
(Stenoien et al., 1999). However other studies ruled out sequestration of AR 
protein into aggregates to be the cause of impaired AR transactivation (Piccioni et 
al., 2001; Thomas et al., 2006). Summarizing, the underlying mechanism of AIS in 
SBMA still remains far from clear. 
 
2.4 Models of polyglutamine disease 
In the last decade a variety of different models of polyglutamine 
disease came up with major contributions towards the understanding of 
molecular mechanisms that cause toxicity but also therapeutic strategies. These 
models encompass a variety of assays in which the mutant gene or some portion 
of it has been introduced into living organisms which experience a phenotypic 
response in some measure indicative of the respective human polyglutamine 
disease. Thereby, the key features which are thought to be requisite for any 
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model of polyglutamine disease are aggregation and toxicity of the 
polyglutamine-expanded species.  
For high-throughput screening cell culture models were established, in 
which the outcome measure is cytotoxicity or some structural or biochemical 
measure related to pathogenesis. Lower organisms such as yeast, Drosophila, or 
Caenorhabditis elegans, provide a more salient context for the genetic mutation and 
opportunity for genetic analyses. They enable suppressor screens to identify 
genes that alleviate or modify the disease, therefore a powerful approach to 
identifying pathways involved in polyglutamine disease pathology and possible 
protective strategies (Hersch and Ferrante, 2004; Rubinsztein, 2002). However, 
these organisms could have important differences in the pathways that regulate 
and are perturbed by the polyglutamine disease mutation in humans. In 
addition, these simpler models do not express the mutant protein in neuronal 
types that degenerate in human polyglutamine disease and as a consequence 
thereof, cell-specific effects could be overlooked. Thus, ultimately such 
candidates from lower model organisms or screening of high-throughput assays 
using libraries containing thousands to millions of small molecules will need 
confirmation in mammalian models since disease expression and response to 
potential therapies can be quite close to what occurs in humans. The proof of 
efficacy in mammalian models is considered a requisite before considering 
possible testing in humans (Hersch and Ferrante, 2004; Rubinsztein, 2002).  
 
2.4.1 Yeast 
Yeast, Saccharomyces cerevisiae, is probably the best understood 
eukaryotic organism at the molecular and cellular levels. It was the first 
eukaryotic model organism whose genome has been completely sequenced. Its 
experimental tractability, combined with the remarkable conservation of gene 
function throughout evolution, makes yeast the ideal model genetic organism. 
Since many core cellular processes and metabolic pathways are conserved 
between yeast and mammals, yeast can in many cases serve as a model of human 
disease, focusing on functional analyses of whole genomes (Ma, 2001). In terms 
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of handling and maintenance the short generation time and the ease of 
manipulating the genome allows biochemical studies from a single genetically 
defined cell (Drubin, 1989). The low genomic complexity in comparison to higher 
eukaryotic organism makes it less suitable for research on processes involved in 
differentiation and development, integration of tissues and organ systems, and 
activities of specialized cells and tissues (Drubin, 1989; Ma, 2001). 
Yeast has been also used to investigate the mechanisms of 
polyglutamine cytotoxicity and the formation and accumulation of 
polyglutamine aggregates. Thereby, investigations were focused on Huntington’s 
disease using yeast strains that express the first exon of the huntingtin gene with 
various numbers of glutamine codons. Studies in yeast cells unanimously 
confirmed the correlation between the size of the polyglutamine stretch and 
aggregation propensity (Krobitsch and Lindquist, 2000; Muchowski et al., 2000). 
The toxic effect of expanded polyglutamine fragments however, was shown to 
vary with the amino acid sequences flanking the polyglutamine tract and to be 
dependent on the [PIN+] prion determinant (Dehay and Bertolotti, 2006; 
Duennwald et al., 2006a; Meriin et al., 2002).  
 
2.4.2 Zebrafish 
The zebrafish, Danio rerio, is a common and useful model organism for 
studies of vertebrate development as well as gene function and it becomes more 
and more prominent for drug screening. It has several key advantages over other 
in vivo models of polyglutamine disease.  It is a vertebrate organism and contains 
homologues to many human genes, including the htt gene (Figure 8; Karlovich et 
al., 1998), making it a valuable tool to model human diseases such as HD. 
Additional important advantages include: the ease and cost efficiency with which 
in vivo drug tests can be performed; the robustness of the embryos that facilitates 
experimental manipulation; the transparency of zebrafish embryos allowing for 
visualization of morphological and physiological features in the live embryo; and 
the aqueous environment of the zebrafish, which facilitates drug administration 
(Zon and Peterson, 2005). Importantly, the zebrafish model system allows for the 
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evaluation of drug effectiveness in a whole organism, taking into account the 
stability and cellular targeting of the tested compound, as well as the assessment 
of potential side effects of the drug at active concentrations. Up to date, 
manipulation of the zebrafish genome pose a weak point of zebrafish as a model 
(van der Sar et al., 2004). With regard to neurodegenerative diseases, zebrafish 
have only recently been explored as a model (Miller et al., 2005; Rubinstein, 2003).  
 
 
Figure 8: Huntingtin but not the polyglutamine/polyproline stretch is conserved 
among zebrafish and human. 
An alignment of the human and zebrafish huntingtin protein showing the first ~500 amino 
acids. Exon 1 is framed with a dashed line, and identical amino acids are outlined in red. 
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2.5 Aim of thesis 
Though the polyglutamine stretch was shown to mediate toxicity in all 
of the polyglutamine diseases, neither the key toxic species along the aggregation 
pathway nor the exact molecular mechanisms leading to toxicity were 
uncovered.  
The overall goal of this study was to establish models of 
polyglutamine diseases to obtain new insights into the nature of the key toxic 
species and the molecular mechanisms of polyglutamine-mediated toxicity as 
well as to identify compounds that disrupt or alter the polyglutamine 
aggregation pathway as potential therapeutic agents.  
A first aim was to establish a zebrafish HD model capable of whole 
organism validation of candidate therapeutic compounds. It was expected that 
the  transparency of the zebrafish embryo would also allow for the determination 
of whether inclusion bodies of polyglutamine-expanded huntingtin directly 
contribute to toxicity. 
A second aim was to establish a yeast model of SBMA to characterize 
polyglutamine containing AR fragments in terms of gain-of-function toxic effects.  
To shed light on AIS in SBMA, it was hoped that this model would also allow for 
the monitoring of AR function under conditions mimicing pathogenesis.  
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3 Materials and Methods 
3.1 Material 
3.1.1 Instruments 
Abimed (Langenfeld, Germany): Gilson Pipetman (2, 10, 20, 100, 200, 1000 µl). 
Amersham Pharmacia Biotech (Freiburg, Germany): electrophoresis power supply EPS 
600, FPLC systems, prepacked chromatography column Superdex200. 
Beckman (München, Germany): DU 640 UV/VIS spectrophotometer;  
Avanti J-25, Avanti 30 and GS-6R centrifuge; Optima TLX ultracentrifuge. 
Biometra (Göttingen, Germany): T3 PCR-Thermocycler. 
Bio-Rad (München, Germany): electrophoresis chambers MiniProtean 2 and 3; 
electrophoresis power supply Power PAC 300, GelAirDryer. 
BioTek Instruments (Winooski, USA): Synergy HT Fluorescence Microplate Reader. 
Eppendorf (Hamburg, Germany): centrifuges 5415C and 5417R, Thermomixer Comfort, 
Microinjector FemtoJet. 
EG&G Berthold (Bad Wildbad, Germany): Lumat LB9507. 
Fisher Scientific (Schwerte, Germany): pH meter Accumet Basic. 
Fujifilm (Düsseldorf, Germany): Image Reader LAS 3000.   
Hoefer Scientific Instruments (San Francisco, USA): SemiPhore blotting transfer unit. 
Leitz (Wetzlar, Germany): Microscope Diavert 
Mettler Toledo (Gießen, Germany): balances AG285, PB602. 
Millipore (Eschborn, Germany): deionization system MilliQ plus PF, Millix-HA filters 
0.22 µm. 
NanoDrop Technologies Inc. (Wilmington, USA): NanoDrop-1000 Spectrophotometer 
New Brunswick Scientific (Nürtingen, Germany): orbital shaker and incubator Innova 
4430. 
Sartorius (Goettingen, Germany): vacuum filtration unit (0.2 µm). 
WTW (Weilheim, Germany): pH meter pH535. 
Zeiss (Jena, Germany): Microscope Axiovert 200M, inverted confocal microscope 
LSM510 META.  
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3.1.2 Chemicals 
All chemicals were of quality pro analysis and purchased from Sigma-
Aldrich (Deisenhofen, Germany) if not stated otherwise. Solutions were prepared 
with deionised, double distilled and sterile-filtered water. Concentration in 
percent of liquids are given as (v/v) and of solid chemicals as (w/v). 
Ambion (Austin, USA): MessageMachine Kit  
Amersham Pharmacia Biotech (Freiburg, Germany): LMW and HMW gel 
filtration calibration kits, protein G-Sepharose beads, ECL+ Detection Kit. 
BioMol (Hamburg, Germany): HEPES. 
BioRad (München, Germany): ethidiumbromide, Protein Assay Kit. 
BD Bioscience (Heidelberg Germany): doxycycline. 
Calbiochem (Bad Soden, Germany): TWEEN-20. 
Difco (Heidelberg, Germany): Bacto agar, Bacto yeast extract, Bacto peptone, Bacto 
tryptone, Yeast nitrogen base w/o amino acids. 
Fermentas (St. Leon-Rot, Germany): PageRuler™ Prestained Protein Ladder Plus, 
GeneRuler™ 100bp and 1 kb DNA Ladder. 
Fluka (Deisenhofen, Germany): DMSO. 
Invitrogen (Karlsruhe, Germany): LipofectamineTM-reagent. 
New England Biolabs (Frankfurt/Main, Germany), T4 DNA Ligase, DNA polymerase I 
(Klenow fragment), CIP, restriction endonucleases, prestained protein marker broad 
range. 
Merck (Darmstadt, Germany): Benzonase, EDTA, 2-Mercaptoethanol, paraformaldehyde. 
Molecular Probes (Karlsruhe, Germany): DAPI, TOPRO-3, Acridine Orange, ProLong®. 
Qiagen (Hilden, Germany): QIAprep spin miniprep Kit, QIAGEN Plasmid Midi Kit, 
QIAPrepEndoFree Plasmid Maxi kit, QIAquick PCR purification and gel extraction kits. 
Pierce (Bonn, Germany): Coomassie protein assay reagent. 
Promega (Mannheim, Germany): Wizard®PlusSV Minipreps, PureYield™ Plasmid 
Midiprep system, Wizard®SV gel and PCR clean-up system, Beetle Luciferin-potassium 
salt, Luciferase Assay System. 
Roche (Basel, Switzerland): ampicillin, Complete Protease inhibitor, DTT, 
ExpandTMLong Template PCR system. 
Schleicher & Schuell (Dassel, Germany): Protran™ nitrocellulose transfer membrane, 
nitrocellulose acetate membrane filter. 
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Seikagaku (Tokyo, Japan): Zymolyase-20T 
Serva (Heidelberg, Germany): Coomassie, Serva BlueR, PEG, PMSF, Acrylamide-Bis 
solution 30% (37:5:1), Citifluor. 
Stratagene (La Jolla, USA): PfuTurbo™ DNA Polymerase II, Yeast Carrier DNA. 
 
3.1.3 Buffers and growth media 
3.1.3.1 Buffers 
1 x TAE 1 mM EDTA 
 40 mM Tris/AcOH pH 8.0 
 
1 x SDS-PAGE  25 mM Tris 
running buffer 192 mM Glycine 
 1% SDS (Sodium-Dodecylsulfate) 
 
6 x SDS-PAGE  348 mM Tris-HCl, pH 6.8   
sample buffer  30% v/v glycerol  
10% w/v SDS  
60 mM DTT  
0.0012% w/v Bromophenol blue  
 
SDS-Gel staining 1.2 g/l Coomassie-Brilliant-BlueR-250 
solution 50% Ethanol 
 10% acetic acid 
 
SDS-Gel destaining 10% Ethanol 
solution 10% acetic acid 
 
Western blotting  25 mM Tris 
buffer 192 mM Glycine 
 15% Methanol 
 0.08% SDS 
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Stripping buffer 63 mM Tris/HCl pH 6.7 
 2% SDS 
 100 mM β-Mercaptoethanol 
 
1 x TBS 10 mM Tris/HCl pH 7.5 
 154 mM NaCl 
 
1 x TBSt 1 x TBS  
 0.1% Tween20 
 
Blocking buffer 1 x TBS 
 5% skimmed milk powder 
 
Antibody buffer 1 x TBSt 
 0.5% skimmed milk powder  
 
ECL solution 1 2.5 mM Luminol 
 400 µM Coomaric acid 
 100 mM Tris/HCl pH 8.5 
 
ECL solution 2 0.018% H2O2 
 100 mM Tris/HCl pH 8.5 
 
3.1.3.2 Buffers and growth media for bacterial work 
Luria-Bertani (LB)  1% tryptone (Difco) 
medium 0.5% yeast extract (Difco) 
 1% NaCl (Merck) 
 (+ 1.5% agar for solid medium) 
 
TYM medium 2% tryptone (Difco) 
 0.5% yeast extract (Difco) 
 0.1 M NaCl (Merck) 
 10 mM MgSO4 
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Ampicillin (antibiotic additive) was prepared as 1000 x stock solution (100 g/l) and filter 
sterilized before usage. 
 
3.1.3.3 Buffers and growth media for yeast 
YPD medium 2% peptone (Difco) 
 1% yeast extract (Difco) 
 2% glucose  
 (+ 3% agar for solid medium)   
 
SD-Drop-out-medium 0.67% yeast nitrogen base w/o amino acids (Difco) 
 4% 25 x Drop-out-mix stock solution  
 2% glucose  
 (+ 3% agar for solid medium)   
 
25 x Drop-out-mix  Adenine hemisulfate salt 400 mg 
 L-arginine (HCl) 200 mg 
 L-aspartic acid 1 g 
 L-glutamic acid (monosodium salt) 1 g 
 L-histidine 200 mg 
 L-leucine 600 mg 
 L-lysine 300 mg 
 L-methionine 200 mg 
 L-phenylalanine 500 mg 
 L-serine 3.75 g 
 L-threonine 2 g 
 L-tryptophan  400 mg 
 L-tyrosine 300 mg 
 L-valine 1.5 g 
 Uracil 200 mg 
 in 400 ml H2O  
 
To guarantee selective growth of certain yeast strains amino acids with regard to the 
respective selective marker were omitted.   
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SR-Drop-out-medium 0.67% yeast nitrogen base w/o amino acids (Difco) 
 4% 25 x Drop-out-mix stock solution  
 2% raffinose 
 (+ 3% agar for solid medium)   
 (+ 2% galactose for induction) 
 
3.1.3.4 Buffers and growth media for cell culture 
Growth Medium Dulbecco’s Modified Eagle’s Medium (Biochrom AG) 
 10% foetal calf serum 
 2 mM glutamine (Gibco) 
 100 U/ml Penicillin (Gibco) 
 100 µg/ml Streptomycin (Gibco) 
  
Growth Medium Dulbecco’s Modified Eagle’s Medium/F-12 (Gibco) 
 w/o steroids   
 10% Charcoal/Dextran treated fetal bovine serum (HyClone) 
 2 mM glutamine (Gibco) 
 100 U/ml Penicillin (Gibco) 
 100 µg/ml Streptomycin (Gibco)  
1 x PBS (Gibco) 
OptiMEM (Invitrogen) 
Trypsin-EDTA (Gibco) 
Trypsin-EDTA w/o phenol red (Gibco) 
 
3.1.3.5 Buffers and growth media for zebrafish 
E3 embryo medium 5 mM NaCl 
 0.17 mM KCl 
 0.33 mM CaCl2  
 0.33 mM MgSO4  
 0.1% Methylene Blue (fungicide) 
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3.1.4 Bacterial and yeast strains, cell and zebrafish lines 
3.1.4.1 Escherichia coli strains  
Strain Genotype Reference 
DH5αF’ F'/endA1 hsdR17(rK-mK+) supE44 thi-1 recA1 gyrA (Na1r) 
relA1 D(lacZYA-argF)U169(m80lacZDM15) 
Novagene 
SURE e14- (McrA-) D(mcrCB-hsdSMR-mrr)171 endA1 supE44 
thi-1 gyrA96 relA1 lac recB 
Novagene 
 
3.1.4.2 Saccharomyces cerevisiae strains 
Strain Genotype Reference 
YPH499 MATa ura3-52 lys2-801 ade2-101 trp1∆63  
his3∆200 leu2∆1 
(Sikorski and Hieter, 
1989) 
EJ250 MATa ade2-101 lys2-801 trp1∆1 his3∆200 
leu2∆1 ura3-52 URA3::ARE-ADE2 
(Ceraline et al., 2003) 
hsp104∆::LEU2 MATa ura3-52 lys2-801 ade2-101 trp1∆63  
his3∆200 leu2∆1 hsp104∆::LEU2 
Sarah Broadley 
 
3.1.4.3 Cell lines 
Strain Description Reference 
Neuro-2a 
(N2a) 
Murine neuroblastoma cells ATCC CCL-131 
SH-SY5Y Human neuroblastoma cells ATCC CCL-2 
 
3.1.4.4 Danio rerio  
The wild type line AB was used for all experiments. 
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3.1.5 Plasmids and Oligonucleotides 
3.1.5.1 Plasmids 
Plasmid rence Description Refe
pCS2+  Expression vector for mammalian cells an
in vitro transcription. It is also 
d 
functional as 
ker.umi
ch.edu/dlturner.vect
RNA or DNA in zebrafish embryos. 
http://sitema
ors 
pcDNA 3.1/Myc-His/ lacZ ng Invitrogen Eukaryotic expression vector  containi
the gene for β-Galactosidase. 
pcDNA3.1hygro+ Hdj1 
. 
 Haacke Expression vector for mammalian cells 
containing the gene for human Hdj1
Annette
pCDNA3.1-myc Htt20Q Expression vector for mammalian cells, 
containing the gene for huntingtin exon 1 
with 20 glutamines and a myc-tag. 
(Schaffar et al., 
2004) 
pCDNA3.1-myc Htt96Q 
the gene for huntingtin exon 1 
Expression vector for mammalian cells, 
containing 
with 96 glutamines and a myc-tag. 
(Schaffar et al., 
2004) 
p423Gal 1 et al., Yeast expression vector  (2µ, HIS3), GAL
promoter. 
(Mumberg 
1994) 
pCMV-AR65 
s. 
s et al., 
1997) 
Eukaryotic expression vector containing a 
human AR cDNA with 65 CAG repeat
(Brook
pARWT Yeast expression vector (2µ, TRP1), GPD 
promoter, containing a human AR cDNA 2003) 
with 27 CAG repeats fused to EYFP. 
(Ceraline et al., 
p423tet n vector (CEN6, HIS3), tetO Katja Siegers Yeast expressio
promoter. 
pCM184 vector (CEN6, TRP1), t al., 1997) Yeast expression 
tetO promoter. 
(Gari e
p415Gal et al., 
1994) 
Yeast expression vector (CEN6, Leu2), 
GAL1 promoter. 
(Mumberg 
pRS/ARE-Ade2 tegrative plasmid with URA3 as the 
 element 
(ARE). 
(Ceraline et al., Yeast in
selection marker and ADE2 linked to three 
copies of the androgen responsive
2003) 
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Plasmid Description Reference 
pSI421 µ, 
ntaining the gene for β-
Katja Siegers Yeast cytosolic stress reporter plasmid (2
URA3) co
Galactosidase linked to SSA3 promoter 
element. 
pGEM-luc Cassette vector being a source of luc gene 
encoding firefly luciferase. 
Promega 
p425ADH 
1994) 
Yeast expression vector (2µ, LEU2), ADH1 
promoter. 
(Mumberg et al., 
YEp105 Yeast expression vector (2µ, TRP2), CUP1 
promoter. 
(Ecker et al., 1987) 
 
3.1.5.2 Oligonuc
Name Nucleotide nce 
leotides 
seque
AR5M 5'-GGC GCG CAA TTG ATG GAA GTG CAG TTA GGG CTG 
GGA AGG G-3' 
AR3S 5'-GGC CGT GTC GAC CTG GGT GTG GAA ATA GAT GGG 
CTT GAC-3' 
AR2QN 5'- Pho-CAG CAG CAG CAA ACT GGC GC -3' 
AR2QC 5'- Pho-CAG CAA GAG ACT AGC CCC AG -3' 
p423TetA-5'AR T GAA CAA AAG CTT ATT 
G CAG TTA GGG C-3' 
5'-CGC GGA TCC CAA ATG TG
TCT GAA GAA GAC TTG GGT ATG CAG ATC CGC ATG 
GAA GT
p423TetA-3'155 5'-ATA GTT TAG CGG CCG CTC AGT CAT CCT CGT CCG 
GAG-3' 
YEp105-5'AR 5'-CGC GGA TCC GCC CAA AAA AGA AGA GAA AGG TAG 
AAT TAG GAA CAG CAA TGG AAG TGC AGT TAG GGC-3' 
YEp105-3'155 5'-CCG CTC GAG TCA GTC ATC CTC GTC CGG AG-3' 
p423TetA-MYC T GAA CAA AAG CTT ATT 5'-CGC GGA TCC CAA ATG TG
TCT GAA GAA GAC TTG GGT ATG CAG ATC TGC ATG 
GAA GTG CAG TTA GGG C-3' 
YEp105-5'ARb 5'-CGC GGA TCC GCA TGG AAG TGC AGT TAG GGC-3' 
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p423TetA-5'ARb 5'-CGC GGA TCC CAA ATG GAA GTG CAG TTA GGG C-3' 
p423TetA-3'WT  5'-ATA GTT TAG CGG CCG CTC ACT GGG TGT GGA AAT
AG-3' 
p423TetA-5'-FLAG GAC 
-3' 
5'-CGC GGA TCC CAA ATG GAC TAC AAA GAC GAT 
GAT AAA GCT GGA GAA TTC ATG GAA GTG CAG TTA 
GGG C
5'BamHI-myc  AAG C-3' 5'-CGC GGA TCC CAA ATG TGT GAA CAA
3'httBstAP 5'-TCC TAA GCA GTT GTT GCT GTT GGA AGC TTT TGA 
GG-3' 
I 
5'httNde 5'-TI TT CCT ATT GAC GTC ATA TGG G-3' 
 
3.1.6 Antibod
ry 
ies 
3.1.6.1 Prima antibodies 
Antibody Species Reference 
anti-myc (9E10)  mouse, monoclonal Santa Cruz, sc-40
anti-FLAG (M2) mouse, monoclonal Sigma F3165 
anti-FLAG (M2) rabbit, polyclonal 5 Sigma F742
anti-GFP al mouse, monoclon Roche 1814460 
anti-polyglutamine l 
(1C2) 
mouse, monoclona Chemikon 
MAB1574 
anti-luc goat, polyclonal Promega G7451 
anti-AR (Ab-3) 67 rabbit, polyclonal Oncogene PC1
anti-AR (N-20) rabbit, monoclonal Santa Cruz sc-816 
anti-hsp40 rat, polyclonal Stressgen SPA400 
anti-β-G mouse, polyclonal al Sigma G4644 
 
dary ant es 
es e 
3.1.6.2 Secon ibodi
Antibody Speci Referenc
anti-mouse-IgG-HRP goat Sigma A4416 
anti-mouse-CY3 goat Dianova 
anti-mouse-FITC goat Dianova 
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Antibody Species Reference 
anti-rabbit-IgG-HRP goat Sigma A9169 
anti-rabbit-CY3 goat Dianova 
anti-rabbit-FITC goat Dianova 
anti-goat-IgG-HRP rabbit Sigma  A5420 
 
3.2.1 
 and EndoFree-Plasmid-Maxi-Kit according to supplier’s instructions. 
The concentration was determined by a photometer at 260 nm (Beckman DU640 
Spectrophotomer). Constructs were verified by DNA sequencing (Sequiserve, 
gestion of DNA 
he restriction enzymes used for this study were purchased from New 
England Biolabs (NEB). Plasmids and PCR products were digested according to 
r’s
lation of 5’-protruding DNA ends 
o prevent religation of vector backbone the digested plasmids were 
treated with calf intestine alkaline phosphatase (CIP, NEB) according to the 
r’s instructions. 
3.2 Methods 
DNA subjected methods 
3.2.1.1 Plasmid preparation 
Overnight bacterial cultures carrying the plasmid of interest were 
grown at 37 °C at 240 rpm. Plasmid preparations were performed with Qiagen’s 
Mini-, Midi-
Germany). 
 
3.2.1.2 Restriction di
T
supplie  instructions. 
 
3.2.1.3 Dephosphory
T
supplie
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3.2.1.4 Agarose gelelectrophorese of DNA 
6 x Loading Dye Solution (Fermentas) was added to the DNA samples 
that subsequently, were separated by agarose gelelectrophoresis in 1 x TAE 
buffer at 90-120 V. The gelelectrophorese chamber was purchased from BioRad. 
The gels contained 0.7-1% agarose (in 1 x TAE buffer) and 1 µg/ml ethidium 
bromide (BioRad). The Gene Ruler 1 kb-DNA-Ladder (Fermentas) was used as size 
Biotech) and where 
required, extracted with 
nor 
modifications, when necessary.  PCR running conditions also followed a 
col, annealing temperature time varied according to 
composition and template len merase (Promega), Pfu-
rase (Promega) or the Expand Long Template system (Roche) was used.  A 
on with corresponding  conditions is shown below.  
 
ol each 
uffer 
e 
52 – 58 °C, 60 seconds 
Cycle stran
72 °C, 1 min per kbp of DNA 
Final exension 72 °C, 10 min 
Storage 4 °C or -20 °C 
marker. The DNA was visualized using UV light (MWG 
QIAquick (Qiagen) according to the supplier’s 
instructions. 
 
3.2.1.5 Polymerase chain reaction (PCR) 
PCR mediated amplification of DNA was performed in a T3 
Thermocycler (Biometra) according to a standard protocol with mi
standard proto  and extension 
primer gth. Taq-poly
Polyme
typical PCR reacti cycling
 
DNA template 25 ng – 250 ng 
Primer 20 pm
dNTPs 1 mM 
Polymerase b 1 x 
Polymerase 2.5 U 
Final volum 25µl, 50 µl or 100 µl 
Cycle count 30 
Initial strand separation 95 °C, 5 min 
Annealing 
d separation 95 °C, 60 seconds 
Extension 
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The PCR product was purified with the PCR Purification Kit (Qiagen) 
according to supplier’s instructions.   
 
3.2.1.6 NA ligation 
For ligation, vector DNA and DNA insert, at a ratio of 1:7, and 1 µl 
 T4 re incubated in ligase buffer at 25 °C for 2 h or, 
for increa
3.2.1.7  vitro transcription 
Vectors containing the gene of interest were linearized and in vitro 
ipti h the MessageMachine Kit (Ambion, TX) 
photometer (NanoDrop-1000
nation of protein concentration 
he protein concentration of protein extracts was determined 
photometrically (DU640 Spectrophotomer, Beckman) at a wavelength of 595 nm 
y Kit (BioRad). This assay is based on the method of 
Bradford (
3 S-PAGE 
SDS - PAGE (sodiumdodec e lyac ide gel 
electrophoresis) was performed usin  
1 tean 3 System electrophoresis chambers (BioRad). 
Polyacrylamide gels were prepared with a BioRad system.  
D
(100 U) -DNA-Ligase (NEB) we
sed efficiency, at 16 °C overnight and transformed into chemically 
competent E. coli SURE or DH5αF’cells. 
 
In
transcr on was performed wit
according to supplier’s instruction. The concentration was determined by a 
 Spectrophotometer, NanoDrop). 
 
3.2.2 Biochemical methods 
3.2.2.1 Determi
T
using the Protein Assa
Bradford, 1976). Before, a standard curve was made with know protein 
amounts of BSA.   
 
.2.2.2 SD
ylsulfat po rylam
g a discontinuous buffer system (Laemmli,
970) in Mini-Pro
Materials and Methods 52                                  
 
Chemicals Separatin acking gel 
 % 12.5% % 
    
crylamide 
 
s-HCl pH8.8 l l l l 
ris-HCl pH6.8 
10% SDS 83.5 µl 83.5 µl 83.5 µl 83.5 µl 35 µl 
TEMED 
DS loading buffer was added to protein samples to 1 x concentration. 
Samples were heated at 96 °C for three minutes and briefly centrifuged prior to 
0 V. Prestained 
Protein Marker
 
E gels 
DS-PAGE gels were treated with staining solution for 1 h at room 
o 
remove the 
before incubation with the secondary antibody in TBSt (at least 1 h). After 
g gel St
 8% 10 15 5% 
30% Acrylamide/        
0.8% Bisa
2.25 ml 2.85 ml 3.4 ml 4.25 ml 640 µl
1.875 M Tri 1.75 m 1.75 m 1.75 m 1.75 m - 
0.6 M T - - - - 1 ml 
5 µl 5 µl 5 µl 5 µl 5 µl 
10% APS  50 µl 50 µl 50 µl 50 µl 20 µl 
H2O   4.35 ml 3.75 ml 3.2 ml 2.37 ml 2.5 ml 
 
S
loading. Gelelectrophoresis was carried out at a voltage of 90-16
 (Fermentas) was used as size marker. 
3.2.2.3 Coomassie staining of SDS-PAG
S
temperature and subsequently, the gels were treated with destaining solution t
unbound stain. Where required, gels were dried overnight between 
two cellophane foils (GelAirDryer, BioRad). 
 
3.2.2.4 Western Blotting of SDS-PAGE gels and immunodetection 
Proteins were separated by SDS-PAGE and transferred to 
nitrocellulose membranes (Protran, Schleicher&Schuell) in a semi-dry western 
blotting unit (SemiPhore) at a constant current of 100 mA/gel (Towbin et al., 
1979) for 2 h. Nitrocellulose membranes were blocked in 5% skimmed milk 
powder in TBSt for 30 min or overnight. The membranes were then incubated 
with primary antibody in TBSt for at least 2 h and extensively washed in TBSt 
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extensive washing, protein bands were detected by incubating the membranes 
with ECL chemiluminescence solution or ECL+ (Amersham) and exposure on the 
Image Reader LAS 3000 (Fujifilm). Where required, the bound antibodies where 
removed upon incubation at 50 °C for 1 h in stripping buffer followed by 
assay was used to estimate the total amount of protein 
without earlier separation. 5 µg of total cell extract (yeast) was spotted directly 
onto nitrocellulose membrane. The membrane was then air-dried and processed 
 
 
initiate the aggregation reaction, 2.5 U PreScission Protease in buffer A (50 mM 
Tris-HCl, pH 7.4; 150 mM KCl) was added. Reactions were incubated at 30 ˚C for 
8 hours and 
of the apparatus (Hoefer) were washed 
several times with 0.1% SDS. The membrane was blocked in 5% skimmed milk 
intensive washes in TBSt.  
 
3.2.2.5 Dot blot assay 
Dot blot 
as described above. 
3.2.2.6 In vitro aggregation 
In vitro aggregation reactions were performed essentially as described 
(Schaffar et al., 2004). Briefly, purified GST-Htt exon 1 fusions (3 µM) were mixed 
with 3 or 30 µM Congo red, 313B02 (3), 293G02 (4), 306H03 (5), or DMSO.  To
then stopped by adding an equal volume of 4% SDS / 100 mM DTT. 
 
3.2.2.7 Filter retardation assay 
For the detection and quantification of aggregates the filter retardation 
assay (Scherzinger et al., 1997) was used. When analysing SDS-insoluble 
aggregates, an equal volume of 4% SDS / 100 mM DTT was added to benzonase 
(40 U, Merck) treated yeast, cell or zebrafish embryo extracts. The mixture was 
heated for 5 min at 96°C and  dilutions of between 25 and 1000 µg were filtered 
through a cellulose acetate membrane (pore size = 0.2 µm, Schleicher&Schuell) 
equilibrated in 0.1% SDS. The slots 
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powder in TBSt for 30 min or overnight and the subsequent immunodetection 
was carrie
 buffer, centrifuged at 100,000 x g for 15 min and 
either dissolved in SDS sample buffer or 100% formic acid.  The latter was 
incubated for 3 h at 37 °C with agitation (600 rpm), vacuum-dried, resuspended 
ed (Hazeki et al., 2000) and analyzed 
by SDS-PA
ate was subjected to size exclusion chromatography on FPLC 
system with Superdex200 column at 4 °C. The appropriate lysis buffer was used 
as running buffer. Fractions were analyzed by immunoblotting. The 
g een 25 kDa and 2,500 kDa determined by 
protein sta
arose beads slurry was added. The 
resulting protein G-Sepharose mix was incubated for 4 hours at 4 °C with 
agitation and subsequently washed extensively with cell lysis buffer. Finally, the 
d out as described in 3.2.2.4. 
 
3.2.2.8 Subcellular fractionation and formic acid treatment 
For subcellular fractionation, extracts were centrifuged at 100,000 x g 
for 30 min to obtain the supernate and pellet fractions. The pellet was washed 
once with the appropriate lysis
in SDS-sample buffer, as previously report
GE. 
 
3.2.2.9 Size exclusion chromatography 
Total cell extracts were centrifuged at 20.000 x g at 4 °C for 30 min and 
~2 mg of the supern
chromato raphic resolution was betw
ndards. 
 
3.2.2.10 Co-Immunoprecipitation 
Total cell extracts were centrifuged at 20.000 x g at 4 °C for 30 min and 
400 µg of the supernate was incubated with 2 µg of anti-myc antibody (Santa 
Cruz) overnight at 4 °C with agitation. 100 µl of protein G-Sepharose beads slurry 
was washed four times for 3 min at 660 x g at 4 °C with 1 ml of lysis buffer. The 
beads were resuspended in 100 µl of lysis buffer with 15% BSA and incubated 
overnight at 4 °C. After a washing step, the lysate was transferred to a  
minicolumn and 100 µl of protein G-Seph
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bound antibody and antigen complex was incubated in SDS loading buffer at 95 
°C for 10 m
20% TCA 
solution and incubated for 15 min at 4 °C. After centrifugation at 20,000 x g for 15 
min at 4 °C, pellets were washed three times with 900 µl of cold acetone and the 
 temperature after the last wash. Pellets were 
then resuspended in SDS loading buffer and boiled for 10 min at 95 °C. 
ls were grown in 800 ml TYM until midlog 
phase (OD
bated 
on ice for another 20 min. Cells were heat-shocked at 42 °C for 90 s and 
uently placed  min. 800 µl of LB medium was added and 
The transformation reaction was plated on 
d at 37 °C, until colonies have developed. 
fB I 
50 mM MnCl2 
cerol 
in and eluted by centrifugation. 
 
3.2.2.11 Trichloracetic acid (TCA)-precipitation 
TCA precipitation was performed to concentrate protein samples prior 
to SDS-PAGE analysis. Protein samples were mixed at 1:2 ratio with a 
resulting pellets were dried at room
  
3.2.3 Escherichia coli work 
3.2.3.1 Chemically competent E. coli cells and transformation 
E. coli SURE or DH5αF’ cel
600 ~0.6), chilled, centrifuged (4,000 x g) and carefully resuspended in 
100 ml cold, filter sterilized TfB I. Cells were pelleted (4,000 x g) again and 
resuspended in 20 ml cold, filter sterilized TfB II. 200 µl aliquots were frozen in 
liquid nitrogen and stored at -80 °C.  
For transformation, competent cells were thawn on ice. 50-200 µl cells 
were mixed with 1 µl plasmid DNA or 10-20 µl ligation reaction and incu
subseq  on ice for 2
incubated for 60 min at 37 °C. 
selective agar plates and incubate
T 30 mM KOAc 
 
 100 mM KCl 
 10 mM CaCl2 
 15% (v/v) gly
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TfB II 10 mM Na-MOPS pH 7.0 
 75 mM CaCl2 
M KCl 
) glycerol 
 
O the mixture was vortexed briefly and incubated for 15 min at room 
temperature. Heat shock was carried out at 42 °C for 15 min and the cells were 
pelleted at 10,000 x g for 30 sec. Most of the supernate was removed and the 
ed t e cells that were finally spread onto selective 
lates.  
 
PLATE solution 40% PEG 3350 
 0.1 M Lithium acetate 
M Tris/HCl pH 7.5 
 
 on ice to 
allow cooling down. Benzonase was added (75 U), and the extracts were 
incubated at 4 °C for 1 h with gentle agitation. Extracts were centrifuged at 2,000 
 10 m
 15% (v/v
3.2.4 Yeast work 
3.2.4.1 Transformation 
For yeast transformation, 1 ml of an overnight culture was spun down 
in a centrifuge for 30 sec at 10,000 x g. The supernate was discarded, 10 µl of 
carrier DNA plus 0.5-1 µg transforming DNA was added and vortexed. After the 
addition of 500 µl PLATE solution with subsequent vortexing, and addition of 57 
µl DMS
residual was us o resuspend th
p
 10 m
1 mM EDTA 
 
3.2.4.2 Yeast lysis 
Depending on the amount of yeast cells, yeast cultures were 
centrifuged at 1,000 x g for 20 min and the pellet was resuspended in 200-500 µl 
cold lysis buffer. An equal amount of glass beads was added and the 
preparations were vortexed for 4 x 1 min. On occasion, they were put
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x g for 3 min at 4 °C. The supernate was collected and protein concentration was 
etermined with a p  kit (Bio-Rad).   
 
 1 mM EDTA 
 5% Glycerol 
d rotein assay
Lysis buffer 25 mM Tris/HCl pH7.5 
 50 mM KCl 
 10 mM MgCl2 
 1 mM PMSF 
 1 x protease inhibitor cocktail (Roche) 
 
3.2.4.3 Immunofluorescence microscopy 
For the fixing, 1 ml of 1 M potassium phosphate (pH 6.5) and 1.2 ml 
formaldehyde were added to 10 ml of yeast culture and incubated for 1 h at room 
temperature. After addition of 1 ml cold SP the cells were centrifuged at 600 x g 
at 4 °C for 5 min. Cells were resuspended in 1 ml cold SP and transferred into a 
1.5 ml Eppendorf tube. They were washed five times by centrifugation at 600 x g 
at 4 °C for 5 min with subsequent resuspension in 1 ml of cold SP. Following the 
last washing the cells were resuspended in 900 µl of  SPβ and 100 µl of zymolyase 
solution was added. The cells were incubated for 2-3 h at 30 °C with agitation 
(650 rpm) followed by an incubation for 5 min on ice. The generated spheroblasts 
were washed again five times (see above) before they were finally resuspended 
in 100-200 µl of cold SP. For the staining, multi-well slides for microscopy were 
prepared by adding 20 µl of polylysine solution (0.5 mg/ml) to each well, 
followed by an incubation for 2 min at room temperature. The wells were 
washed five times with water and 20 µl spheroblasts were applied per well 
followed by an incubation for 10 min at room temperature. The spheroblasts 
were washed with 20 µl PBS-B. The slides were immersed in ice cold methanol 
for 5 min and afterwards, in ice cold acetone for 30 sec. After the slides got air-
dried, 20 µl PBS-B was applied to each well for 60 min at room temperature. The 
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wells were washed twice with PBS-B and 20 µl of primary antibody solution was 
added to each well. The slides were incubated in a wet chamber for 60 min at 
room temperature. Afterwards, the wells were washed six times with PBS-B 
before application of the second antibody solution. Again, the slides were 
incubated in a dark, wet chamber for 60 min. After six additional washes with 
f DAPI mounting medium was added to 
nd the slides were co  coverslips and sealed with nail polish. 
hey were put at -20 °C. 
P 4 pH 6.5 
1.2 M Sorbitol 
Pβ 14 µl Mercaptoethanol 
ymolyase solution 2.5 mg Zymolyase (20T) in 1 ml SPβ 
BS 
ou  Citifluor  
medium 25%
0.25 µg/ml DAPI (4',6-diamidino-2-phenylindole, dihydrochloride, Molecular Probes) 
Drop test 
4 µl of subsequent dilutions of 1:5, starting with an OD600 of 0.1, were 
and incubated at the indicated temperature. Growth 
was documented in regular time intervals with a gel documentation setup (MWG 
PBS-B the slides were air-dried. 4 µl o
each well a vered by
For long term storage t
S 0.1 M KPO
 
 
S
 10 ml SP 
 
Z
 
P 50 mM NaPO4 pH 7.5 
 300 mM NaCl  
 
PBS-B 50 mM NaPO4 pH 7.5 
 150 mM NaCl 
 1% BSA 
 
DAPI m nting  75%
 PBS 
 
3.2.4.4 
spotted on (selective) plates 
Biotech). 
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3.2.4.5 Luciferase assay 
To determine firefly luciferase activity in intact cells (Greer and Szalay, 
2002), yeast cultures were grown in presence or absence of galactose (2%) until 
exponential phase and DHT was added to a concentration of 5 µM for 2 h.  An 
aliquot was taken to determine firefly luciferase activity in intact cells by mixing 
with 5 volumes of 100 mM potassium-luciferin (Promega, Madison, USA) and 
measuring light emission for 10 sec using a Lumat LB 9507 luminometer (EG&G 
Berthold, Bad Wildbach, Germany). Values for luciferase activity were 
normalized to OD  of the yeast culture, and the results of the galactose induced 
nduced ones. 
ual amounts of  protein in 
100 µl yeast lysis buffer were transferred to an Eppendorf tube. A blank tube 
 µl yeast lysis buffer served as a control. 600 µl of Zβ buffer and 100 µl of 
 Zβ was added to the  the blank tubes. 
 buffer 4 (pH 7.0) 
40 mM NaH2PO4 
β buffer 4 (pH 7.0) 
10 mM KCl 
600
cultures were normalized to the uni
 
3.2.4.6 β-Galactosidase assay 
β-Galactosidase assays were performed essentially as described 
(Guarente, 1983). Equal amounts of protein extract were added to Zβ, ONPG-Z in 
Z buffer was added to a concentration of 615 µg/ml, and reactions were 
incubated at 30 °C for 50 min.  The reaction was stopped by the addition of 
Na2CO3 to 278 mM, and the A420 was measured relative to the blank, which 
contained yeast lysis buffer. Yeast extracts were prepared and protein 
concentration was determined as described above. Eq
with 100
2 x  reaction and
Z 60 mM Na2HPO
 
 10 mM KCl 
 1 mM MgSO4 
 
Z 60 mM Na2HPO
 40 mM NaH2PO4 
 
 1 mM MgSO4 
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 50 mM β-mercaptoethanol 
 x Zβ buffer 4 (pH 7.0) 
10 mM KCl 
100 mM β-mercaptoethanol 
 
Z Z buffer (pH 7.0) 
3.2.5 
ice with PBS 
and incubated with Trypsin/EDTA for 5 min at 37 °C. Trypsin was inactivated 
by the addition of fresh medium. Subsequently, the cells were resuspended by 
ing LipofectAMINE 
PlusTM (Life Technologies, Inc.) according to supplier’s instructions. After 
 
2 60 mM Na2HPO
 40 mM NaH2PO4 
 
 1 mM MgSO4 
 
ONPG- 4 mg/ml in 
 
Cell culture work 
3.2.5.1 Culturing 
The adherent cell lines used in this study were cultured in culture 
plates (Costar) of variable well size or in Cellstar tissue culture flasks (Greiner) in 
water vapour saturated 5% CO2 atmosphere at 37 °C. Frequently, upon reaching 
confluency, the cells were split as follows. The cells were washed tw
pipetting and 1:5 or 1:10 dilutions were cultured continuously.         
 
3.2.5.2 Determination of cell number and transient transfection 
One day before transfection, the cells were Trypsin/EDTA treated as 
described above and resuspended in supplemented medium. 20 µl of cells were 
mixed with 20 µl 0.4% Trypan Blue Solution (Sigma) and the number of living 
cells was determined using a counting chamber (Neubauer) and the inverted 
microscope Diavert (Leitz) according to supplier’s instructions. Cells were plated 
in supplemented medium so that they reached 50-90% confluency the next day. 
The cells were transfected by a liposome-mediated method us
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incubation of cells at 37 °C for 3 h, the transfection mixture was removed, and 
cells were
ashed twice with cold phosphate-buffered saline 
(PBS). 1 ml of cold lysis buffer was added, incubated for 10 min on ice, scraped 
from the plate and pelleted by centrifugation at 2,000 x g for 3 min at 4 °C. The 
nate was coll on was determined with a 
 
 H2O (pH 7.0) 
ysis buffer 0.5% TritonX-100 
 0.5% sodium deoxycholate 
il (Roche) 
 
 slides with ProLong® 
(Antifade Kit, Molecular Probes). Fluorescence was visualized with an 
 incubated with supplemented medium up to 48 h. 
 
3.2.5.3 Preparation of cell extracts 
The cells were w
super ected, and protein concentrati
protein assay kit (Bio-Rad).   
PBS 8 mM Na2HPO4 x 7
 2 mM NaH2PO4 x H2O 
 70 mM NaCl 
 
L
 1 x protease inhibitor cockta
in PBS 
 
3.2.5.4 Immunofluorescence microscopy 
The cells were seeded on coverslips in a 12-well plate one day before 
transfection. Transfection was carried out as described above. Thereafter, the 
coverslips containing the cells were washed three times with PBS and incubated 
in cold methanol on ice for 5 min.  After three additional washes with PBS, the 
cells were incubated in a 1:200 dilution of primary antibody (in PBS-B) for 1 h. 
The cells were washed three times in PBS for 10 min and incubated in a 1:350 
dilution of secondary antibody and 1:4000 dilution of DAPI (4',6-diamidino-2-
phenylindole, dihydrochloride, Molecular Probes) in PBS for 1h. After three 
additional washes, the coverslips were mounted onto
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Axiovert200M inverted fluorescence microscope (Zeiss, Jena, Germany). Images 
were captured digitally with a Zeiss AxioCam HRm camera and assembled in 
PhotosHop 8.0 (Adobe Systems, Mountain View, CA).   
3.2.5.5 rug treatment 
3 h after transfection the transfection medium was removed and 
e  containing 50 µM PGL-135, 10 µM 313B02, 10 µM 293G02, 
10µM 306H
mg/ml in serum-free DMEM) was added and incubation was continued for 
further 2h. 500 µl cell lysis buffer was added, and the MTT crystals were 
nm were determined 
(BioTek Instruments, Inc.).   
uffe ) sodium dodecyl sulphate (SDS)  
 50% (v/v) N,N-dimethylformamide  
3.2.6.1 Animal husbandry 
d raised as described (Mullins et 
al., 1994). 
PBS-B 1% BSA in PBS 
 
D
supplem nted medium
03, 5 µM DHT or DMSO as control, was added for up to 48 h. 
 
3.2.5.6 MTT assay 
One day before transfection, cells were plated in 24-well plates.  
Transfection was carried out as described above.  After total incubation of cells at 
37 °C for 48 h the  medium was removed and 500 µl of a MTT solution (0.42 
dissolved by repeated pipetting.  Absorbance values at 570 
with the Synergy HT Fluorescence Microplate Reader 
 
Lysis b r 20% (v/v
  
3.2.6 Zebrafish work 
Zebrafish were maintained, mated, an
 Embryos were kept at 28°C and staged as described (Kimmel et al., 
1995).   
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3.2.6.2 Agarose plates for holding embryos 
Liquefied 1.5% agarose was poured into a 100 mm plastic Petri dish to 
a depth of about 5 mm. A plastic mould was floated into the agarose. After 
solidification the mould was removed and the agarose was covered with E3 to 
 control or 0.5 µg/µl Hdj1 and 0.5 µg/µl Hsp70-YFP mRNA.  
Embryos were cultured at 28.5 °C in E3, unfertilized eggs were removed, and if 
required, embryos were scored 24 h post-fertilization according to their 
appearance.
 
d anesthetized with Tricaine 
(0.016% w/v). To assess apoptotic cell death, the embryos were immersed in 3 
um chloride hemi[zinc chloride]; AO; Molecular 
Probes) for 15 min a
hetized with Tricaine 
(0.016% w/v). For nuclear staining, embryos were immersed in 1:1000 dilution of 
robes) for 30 
min at room
inhibit over drying. 
 
3.2.6.3 Embryo injection 
Eggs were collected approximately 30 min after mating and placed in 
the slots of an agarose plate (preparation described above). mRNA was injected 
with the use of a microinjector (FemtoJet, Eppendorf) at a concentration of 1 
µg/µl into the yolk of embryos at the 1–2 cell stage. Co-injections were 
performed with 1 µg/µl polyglutamine-GFP mRNA and either 1 µg/µl β-Gal 
mRNA as a
 
3.2.6.4 Acridine Orange staining 
Zebrafish embryos were dechorionated an
µg/ml Acridine Orange (acridini
nd washed three times with E3.  
 
3.2.6.5 TOPRO-3 staining  
Zebrafish embryos were dechorionated and anest
TOPRO-3 stain (monomeric cyanine nucleic acid stain; Molecular P
 temperature and washed three times with E3.  
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3.2.6.6 Microscopy and time-lapse analysis 
Zebrafish embryos were dechorionated, anesthetized with Tricaine 
(0.016% w/v), and orientated in 3% methyl cellulose on coverslips.  Fluorescence 
was visualized with an LSM510 META inverted confocal microscope (Zeiss, 
Oberkochen, Germany).  An emission spectrum of 488 nm – 560 nm was chosen 
to detect GFP, YFP and Acridine Orange, for the detection of TOPRO-3 an 
emission spectrum of 633 nm – 670 nm was used. For 3D imaging, a stack of 10 
frames was collected at an interval of 10-24 µm between adjacent slices, and the 
images were assembled to obtain a 3D projection.  To dissociate the GFP/AO or 
GFP/YFP fluorescence signals, analysis was performed by emission 
fingerprinting in confocal lambda mode. Reference spectra of the single 
fluorochromes were taken and subsequently used to separate the overlapping 
emission spectra of the samples (linear unmixing, Dickinson et al. 2001). A stack 
of 2-3 frames of the embryonic tail region 24 h post-fertilization was collected at 
an interval of 20 µm, and the number of AO stained cells was counted to estimate 
the amount of apoptotic cells. For the time-lapse analysis of the living cells, 
zebrafish bryos 24 h post-fertilization were orientated in 1.2% low melting 
agarose (1.2% in E3 with Tricaine 0.09% w/v) and covered with E3. Images were 
28,
protein concentration was determined with a 
protein assay kit (Bio-Rad). For the detection of Hsp70-YFP (and Q102-GFP in 
Figure 18 B), embryos were first dechorionated and yolk dissected, as previously 
vans et al
 
em
taken 24,  and 32 hours post-fertilization. 
 
3.2.6.7 Fish lysis 
Injected embryos were resuspended in cold lysis buffer and lysed by 
passing through a 0.6 mm needle. After freezing and thawing the extracts, 
benzonase was added (75 U), and the extracts were incubated at 4 °C for 1 h with 
gentle agitation. Extracts were centrifuged at 2,000 x g for 3 min at 4 °C in the 
presence of glass beads to facilitate separation of the chorion debris. The 
supernate was collected and 
described (E ., 2005).   
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Lysis buffer 0.5% Triton X-100 
 0.5% sodium deoxycholate  
 1 x protease inhibitor cocktail (Roche) 
 in PBS 
 
Results 66                                  
 
4 Results 
A common feature of neurodegenerative diseases, such as Alzheimer’s 
disease, prion diseases, and polyglutamine diseases, including Huntington’s 
disease (HD) and SBMA, is the accumulation and deposition of characteristic 
amyloid or amyloid-like fibrils of the respective disease proteins in the brain 
(Aguzzi and Haass, 2003; Ross and Poirier, 2005). In HD and SBMA, the 
degeneration of neurons is associated with the intracellular deposition of 
inclusion bodies (IBs) that contain fibrillar aggregates of polyglutamine-
expanded huntingtin (htt) or androgen receptor (AR), respectively, and likely 
represent the final manifestation of a multi-step aggregation pathway involving 
several intermediate species (Poirier et al., 2002). The latter are suspected of 
causing cytotoxicity through various mechanisms including aberrant 
interactions, e.g. inactivation of essential transcription factors, and inhibition of 
the ubiquitin proteasome system (Bennett et al., 2005; Schaffar et al., 2004). A 
critical step in both fibril formation and toxicity is thought to be the generation of 
N-terminal fragments containing the pathogenic polyglutamine stretch (Davies et 
al., 1997; Lunkes et al., 2002). 
This study describes the development of a novel zebrafish model of 
HD to identify chemical compounds that suppress aggregation of amyloidogenic 
proteins. As a result, anti-prion compounds were identified as novel inhibitors of 
polyglutamine aggregation, suggesting that polyglutamine aggregates and 
prions may share common structural epitopes. In addition, this study presents a 
novel yeast model of SBMA revealing that N-terminal polyglutamine-containing 
fragments cause toxicity and inhibit androgen receptor transactivation capacity. 
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4.1 Development of a zebrafish model for 
polyglutamine disease suitable for whole 
organism validation of candidate compounds 
In the field of neurodegenerative disorders, there has been 
considerable debate about the role of aggregates. Although neither the structure 
of a polyglutamine fibril nor the mechanisms mediating toxicity are yet fully 
understood, much attention has been focused on identifying means to disrupt or 
alter the polyglutamine aggregation pathway (Di Prospero and Fischbeck, 2005). 
Many promising compounds with anti-aggregation activity have been identified 
in vitro and in cell based assays but further investigations with respect to their 
effect in a vertebrate organism are restricted to the expensive and time 
consuming rodent models (Heiser et al., 2002; Hockly et al., 2006). This study 
describes the establishment of an alternative vertebrate HD model in zebrafish 
suitable for whole organism validation of candidate compounds. 
 
4.1.1 The establishment and characterization of a zebrafish model 
of HD 
For the development of a zebrafish model of polyglutamine disease 
mRNA of various polyglutamine containing huntingtin constructs were injected 
in varying concentrations into the yolk of zebrafish embryos at the 1-2 cell stage. 
Unfertilized eggs were removed and the embryos were examined up to a week 
with regard to phenotypical abnormalities. Injection of the huntingtin constructs 
gave rise to a whole set of phenotypical abnormalities which were however, 
inconsistent and varying between the clutches, independent of the sequences 
flanking the polyglutamine stretch. Due to the lack of a clear phenotype, the 
research was limited to the GFP-tagged huntingtin fragments since the 
transparency of the zebrafish embryo permitted straightforward in vivo analysis 
of these constructs (Figure 9). The constructs used for this study consist of an N-
terminal fragment of htt containing 4, 25, or 102 Q fused to green fluorescent 
protein (Q4-GFP; Q25-GFP; Q102-GFP, respectively; Figure 9). Two constructs, 
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namely Q4-GFP and Q25-GFP, were used as a control since the polyglutamine 
stretch does not exceed the pathogenic threshold of about 38 Q. The third 
construct, Q102-GFP, exceeds this threshold and was therefore considered as the 
pathogenic species. 
 
Figure 9: Polyglutamine-fusions used in this study. 
Depicted are the constructs used in this study which consist of an N-terminal FLAG tag 
upstream of the first 16 amino acids of the huntingtin protein followed by a polyglutamine 
stretch with either 4, 25 or 102 Q fused to green fluorescent protein. 
 
4.1.1.1 Polyglutamine-expanded htt is deposited into inclusions of 
SDS-insoluble aggregates in D. rerio 
An essential step towards a zebrafish model of HD was to reproduce 
key features of HD. Embryos at the 1-2 cell stage were injected with mRNA of the  
constructs (Figure 9). Q4-GFP and Q25-GFP fusion proteins were diffusely 
distributed, whereas the mutant polyglutamine-expanded htt fusion protein, 
Q102-GFP, accumulated in inclusion body-like aggregates throughout most 
embryos after 24 h (Figure 10).  
 
Figure 10: Q102-GFP forms inclusions in D. rerio. 
Flourescent (top panels) and brightfield (bottom panels) images of zebrafish embryos 
expressing Q4-GFP, Q25-GFP, or Q102-GFP, 24 h post-fertilization. Scale bar, 200 µm. 
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To gain more insights into the cellular distribution of the constructs, 
the analysis was focused on the hatching gland, a monolayer of cells that is 
located on the pericardium (on the yolk sac ventral to the head). Hence, artificial 
signals from neighbored layers were avoided. Expression of Q102-GFP resulted 
in a massive appearance of inclusions in the hatching gland, unlike Q4-GFP (data 
not shown) and Q25-GFP (Figure 11).  
 
Figure 11: Aggregate formation in the hatching gland upon expression of Q102-
GFP. 
Brightfield and fluorescent images of zebrafish embryos expressing Q25-GFP (A) or 
Q102-GFP (B), 24 h post-fertilization at different magnifications.  
 
Higher magnification images of the hatching gland indicated that 
Q102-GFP, but not the shorter polyglutamine variants, accumulated in large, 
cytoplasmic inclusions adjacent to the nuclei (Figure 12).   
A 
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B 
 
Figure 12:  The inclusions formed by Q102-GFP are relatively large in size and 
perinuclearly localized. 
(A) High magnification images of polyglutamine-GFP expression patterns in the 
embryonic hatching gland. Scale bar, 10 µm. (B) Embryos expressing Q102-GFP stained 
with TOPRO (shown in blue) to visualize nuclei in the hatching gland. Scale bar, 10 µm. 
 
Analysis of embryos at later time points using time-lapse microscopy 
showed that Q102-GFP inclusions grew in size by efficient incorporation of 
soluble Q102-GFP, resulting in its depletion from the cytoplasm (Figure 13).  
 
 
Figure 13: The Q102-GFP inclusions grow in size by incorporation of soluble 
Q102-GFP. 
The dynamics of Q102-GFP aggregation, as monitored by time-lapse microscopy 24, 28, 
and 32 h post-fertilization. The formation of an aggregate structure (long arrow) and the 
incorporation of soluble Q102-GFP into pre-existing aggregates (short arrow) are 
indicated. These images have been corrected for photobleaching effects. Scale bar, 10 
µm.  
 
To get insights into the biochemical properties of the inclusions, total 
cellular extracts of injected embryos 24 h post-fertilization were subjected to high 
speed centrifugation. Both Q4- and Q25-GFP remained exclusively in the soluble 
supernate fraction, whereas a significant portion of Q102-GFP was found in the 
SDS-insoluble pellet fraction and could only be dissolved by formic acid 
treatment (Figure 14 A; Hazeki et al., 2000).  Analysis of total embryo extracts by 
an established filter trap assay (Scherzinger et al., 1997) confirmed that Q102-GFP, 
but not Q4-GFP or Q25-GFP, formed large SDS-insoluble aggregates that were 
retained by the 200 nm pore sized membrane (Figure 14 B). 
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B 
Figure 14: Q102-GFP forms SDS-insoluble aggregates in D. rerio. 
(A) Analysis of the solubility of the polyglutamine-GFP fusions. Extracts 
h post-fertilization) expressing Q4-GFP, Q25-GFP, or Q102-GFP were
speed centrifugation, and the resulting fractions were analyzed by
western blotting with anti-GFP antibody. T, total cell lysate; S, supernate
dissolved in SDS; FA, pellet fraction dissolved in formic acid. Asterisk, 
from the fusion protein. (B), Filter trap analysis of polyglutamine-GFP f
amounts (25 µg, 50 µg and 100 µg) of total cell extracts from (A) were
trap assay in the presence (bottom row) and absence (top row) of SDS/
 
4.1.1.2 Polyglutamine length dependent toxicity is in
detectable inclusions 
To determine whether the polyglutamine-GFP fusion 
toxicity, the phenotypes of embryos expressing Q4-, Q25-, or Q
evaluated 24 h post-fertilization. Due to the aforementioned dive
phenotypes, the embryos were scored as visibly normal, abn
Q102-GFP expression was associated with increased numbe← Q25-GFP 
← Q102-GFP  ← Q4-GFP 
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morphologically abnormal embryos when compared to Q4- or Q25-GFP 
expression (Figure 15 A). Noteworthy among the abnormal embryos, a 
characteristic ‘cyclopic’ phenotype was increasingly observed in embryos 
expressing Q102-GFP (Figure 15 B).   
A 
 
B 
 
Figure 15: Expression of Q102-GFP causes toxicity in zebrafish embryos. 
Embryos were injected at the 1-2 cell stage with mRNA encoding the indicated GFP 
fusions. (A) Normal (wt), abnormal, and dead embryos were counted 24 h post-
fertilization. Data are mean values of n=12-20 experiments ± S.D. *, p < 0.01 versus Q4-
GFP or Q25-GFP injected embryos (Bonferroni’s post hoc test). (B) Brightfield images of 
a wildtype embryo and an embryo expressing Q102-GFP, 48 h post-fertilization. Scale 
bar, 100 µm. 
 
This mutant phenotype is characterized by fusion of the eyefields 
yielding a single eye in the midline (Blader and Strahle, 1998). Since only a subset 
of embryos showed this phenotype, it was not suitable for any kind of screening. 
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Acridine Orange staining of embryos indicated that Q102-GFP expression caused 
increased apoptosis. Low levels of apoptosis and abnormal phenotypes in 
embryos expressing Q4-GFP and Q25-GFP were also observed, which was likely 
due to background toxicity caused by these fusion proteins (Figure 16 A). 
Injection of a similar construct, huntingtin exon 1 containing 96 glutamines 
(HttEx1Q96), confirmed the elevated apoptotic activity upon expression of 
polyglutamine-expanded fragments (Figure 16 B).   
A 
 
B 
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Figure 16: Expression of polyglutamine-expanded protein is associated with 
increased apoptosis. 
(A) Fluorescent images of Acridine Orange stained embryos expressing the indicated 
polyglutamine-GFP fusions 24 h post-fertilization and subsequent quantification of 
apoptotic cells. As a negative control, uninjected embryos expressing no polyglutamine-
GFP fusion were also analyzed (Uninj.). Scale bar, 100 µm. Data are mean values of 
n=3-4 experiments ± S.D. (C) Fluorescence images of Acridine Orange stained embryos 
expressing the indicated htt constructs 24 h post-fertilization und subsequent quantitation. 
As a negative control, uninjected embryos were also analyzed (Uninjected). Scale bar, 
100 µm. The values are the means ± S.D.  
 
Interestingly, further analyses showed that nearly all (~95%) of the 
apoptotic cells were devoid of visible inclusions, which must be > ~0.5 µm in 
diameter for detection in the experimental setup used in this study. On the other 
hand, almost all cells containing detectable inclusions were non-apoptotic 
(~99%), suggesting that pre-fibrillar Q102-GFP may instead be the toxic agent 
(Figure 17 A). Indeed, apoptotic cells containing diffusely distributed Q102-GFP 
were detected (Figure 17 B). Thus, these results indicate that expression of 
polyglutamine-expanded htt is toxic to the zebrafish embryo, but toxicity is not 
associated with the presence of visible inclusions. 
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Figure 17: Apoptotic cells are largely devoid of visible inclusions.   
(A), Confocal images of Acridine Orange stained embryos expressing the indicated 
polyglutamine-GFP fusions 24 h post-fertilization that demonstrate that aggregate 
structures containing Q102-GFP are in the majority of cases not detectable in apoptotic 
cells. Scale bar, 20 µm. Quantitation of apoptotic cells with and without inclusions, as well 
as quantitation of cells containing inclusions that are apoptotic verses non-apoptotic is 
also shown. Data are mean values of n=3 experiments ± S.D. (B), Higher magnification 
images of the embryonic hatching gland showing an apoptotic cell with diffusely 
distributed Q102-GFP. Neighboring cells containing aggregates are not apoptotic. Scale 
bar, 10 µm.  
 
4.1.1.3 Hsp70 and Hsp40 suppress both polyglutamine aggregation and 
toxicity 
Molecular chaperones are known to modulate both polyglutamine 
aggregation and toxicity (Barral et al., 2004).  To evaluate whether this important 
feature can be reproduced in the zebrafish embryo, the effect of the human 
chaperones Hsp70 and Hsp40 on Q102-GFP aggregation and toxicity were tested. 
1-2 cell staged embryos were injected with mRNA of Q102-GFP and β-
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Galactosidase as a control, or Q102-GFP and both Hsp40 and Hsp70 fused to YFP 
(Hsp70-YFP). Co-expression of Hsp40 and Hsp70-YFP reduced the amount of 
SDS-insoluble aggregates of Q102-GFP, as judged by the filter trap assay, while 
total protein levels of Q102-GFP were not detectably altered (Figure 18 A and B). 
Fluorescence microscopy revealed that Hsp70-YFP associated with inclusions of 
Q102-GFP (Figure 18 C), suggesting that the chaperone machinery recognized 
Q102-GFP as an aberrantly folded species.  
A  B 
 
C 
 
Figure 18: Hsp40 and Hsp70-YFP suppress polyglutamine aggregation. 
(A), Filter trap analysis of total extracts derived from embryos injected with Q102-GFP 
mRNA together with β-Galactosidase mRNA (control) or Hsp40 and Hsp70-YFP mRNA at 
the 1-2 cell stage. Total SDS-insoluble aggregates trapped on the membrane were 
detected with anti-GFP and quantified. Signal intensity resulting from the co-injection of 
Q102-GFP mRNA with β-Galactosidase mRNA was defined as 100%. (B), Western blot 
analysis of total extracts from (A) to detect β-Galactosidase, Hsp40, Hsp70-YFP, and 
SDS-soluble Q102-GFP. (C) Confocal images showing that Hsp70-YFP colocalizes with 
Q102-GFP inclusions, as assessed by emission fingerprinting. Scale bar, 20 µm.   
 
Among the reduction of SDS-insoluble aggregates, expression of Hsp40 and 
Hsp70-YFP reduced the number of detectable inclusions (~41.8% of control, data 
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not shown), apoptotic cells (~80% of control, data not shown), and dead embryos 
(Figure 19), while increasing the number of phenotypically normal embryos 
expressing Q102-GFP. Aggregation and toxicity associated with Q102-GFP 
expression in zebrafish is partially suppressed by Hsp40 and Hsp70. 
 
 
Figure 19: Hsp40 and Hsp70-YFP suppress polyglutamine mediated toxicity. 
Quantitation of normal (wt), abnormal, and dead embryos 24 h post-fertilization, after 
injection at the 1-2 cell stage with Q102-GFP and β-Galactosidase or Hsp40/Hsp70-YFP 
mRNA. Data are mean values of n=20 experiments ± S.D. *, p < 0.01 versus Q102-
GFP/β-Galactosidase injected embryos (ANOVA). 
 
4.1.2 Identification of compounds that inhibit polyglutamine 
aggregation   
Expression of polyglutamine-expanded htt gave rise to the formation of 
large, SDS-insoluble inclusions and was associated with enhanced apoptosis, as 
well as pronounced morphological defects and reduced viability of zebrafish 
embryos, reproducing a key feature of HD pathology. Chaperones are able to 
suppress polyglutamine mediated aggregation and toxicity in zebrafish. Hence, 
the newly established zebrafish model proved useful in evaluating the 
effectiveness of compounds in inhibiting polyglutamine aggregation and toxicity 
in the context of a whole vertebrate organism.  
Drug absorption into the zebrafish embryo is likely facilitated by its 
aqueous environment and lack of blood brain barrier at early stages in 
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development; therefore, compounds could be tested for their effect on 
polyglutamine aggregation while minimizing complicating factors that impede 
absorption. Importantly, the zebrafish model system allows for the evaluation of 
drug effectiveness in a whole organism, taking into account the stability and 
cellular targeting of the tested compound, as well as the assessment of potential 
side effects of the drug at active concentrations. The unique feature that drug 
testing can be performed within two days made this model a cost and time 
efficient alternative to existing rodent models of HD.  
 
4.1.2.1 Evaluation of known inhibitors of the polyglutamine aggregation 
process in D. rerio 
The effect of known inhibitors on Q102-GFP aggregation was tested in 
this vertebrate system (Figure 20). PGL-135 and Congo red (Hockly et al., 2006; 
Sanchez et al., 2003) reduced Q102-GFP aggregation in zebrafish, as judged by the 
filter trap assay (Figure 22). In contrast, Isoproterenol HCl did not alter Q102-
GFP aggregation in the zebrafish embryo, consistent with a recent study in a cell 
culture model (Wang et al., 2005). Surprisingly, Mycophenolic acid, a compound 
known to suppress htt inclusion formation in cell culture (Wang et al., 2005), had 
no effect on Q102-GFP aggregation in zebrafish at the maximum tolerated dose. 
Thus, in the case of PGL-135, Congo red, and Isoproterenol HCl, the results 
substantiate observations in other HD models. However, in contrast to data 
obtained in cell culture (Wang et al., 2005), these findings suggest that 
Mycophenolic acid is not an effective inhibitor of polyglutamine aggregation in 
the vertebrate system.  
Results 79                                  
 
Mycophenolic 
acid 
306H03 
293G02 
313B02 
Congo red 
PGL-135 
Isoproterenol 
HCl 
NN
O
Br
H2N NH2
O
HCl
OH
HO
OH H
N
HCl
HCl
HO
N
S
NH2
NH2
S
N N
OO
O-
2
N
H
N
O
N
H
N
O
OH
OH
Cl
O
O
O
OH
O-
O
 
Figure 20: Molecular structures of the compounds tested. 
 
4.1.2.2 Identification of new compounds that inhibit polyglutamine 
aggregation 
Considering the hypothesis that polyglutamine and PrPSc aggregates 
have similar amyloid core structures (Govaerts et al., 2004; Stork et al., 2005), three 
compounds (313B02, 293G02, and 306H03) that were previously identified in in 
vitro screens for inhibitors of prion propagation (Bertsch et al., 2005; pers. comm. 
A. Giese) were evaluated. All three of these compounds inhibited the aggregation 
of polyglutamine-expanded htt in vitro (Figure 21), indicating these compounds 
interact directly with mutant htt to reduce its aggregation.  
Results 80                                  
 
 
Figure 21:  N’-benzylidene-benzohydrazides inhibit Q102-GFP aggregation in 
vitro. 
Effect of the indicated chemical compounds on HA-HttEx1Q53 aggregation in vitro, as 
assessed by the filter trap assay (anti-HA) with quantitation. The signal intensity from the 
control sample containing solvent alone was set to 100%. Data are mean values of n=3 
experiments ± S.D. 
 
 However, only 293G02 and 306H03, both derivatives of N’-
benzylidene-benzohydrazide (NBB), also inhibited the formation of detergent 
insoluble aggregates of Q102-GFP in vivo (Figure 22). Interestingly, 306H03 was a 
more effective inhibitor of polyglutamine aggregation than 293G02 in vivo, but 
not in vitro (Figure 22 and Figure 21).  Notably, none of the studied compounds 
suppressed the abnormal morphology and death associated with Q102-GFP 
expression in zebrafish embryos (data not shown). Thus, the NBBs may interfere 
with the formation of large SDS-resistant polyglutamine aggregates downstream 
of the accumulation of toxic polyglutamine species. 
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Figure 22:  N’-benzylidene-benzohydrazides inhibit Q102-GFP aggregation D. 
rerio. 
Filter trap analysis of extracts derived from embryos expressing Q102-GFP in the 
presence and absence of the indicated compounds. Embryos expressing Q102-GFP 
were treated for 24 h with DMSO or H2O (solvent), 30 µM PGL-135, 100 µM Congo red, 
100 µM 313B02, 50 µM 293G02, 50 µM 306H03, 1 µM Mycophenolic acid, or 10 µM 
Isoproterenol HCl. Extracts of embryos were analyzed using the filter trap assay (anti-
GFP), followed by densitometric quantitation. The signal intensity from controls subjected 
to solvent alone was set to 100%. The data are mean values of n=3-5 independent 
injections ± S.D. 
 
4.1.2.3 Confirmation of the effect of NBBs on polyglutamine aggregation in 
a mammalian neuroblastoma cell line 
To substantiate the effect of NBBs on polyglutamine aggregation, a 
similar model of HD in mammalian neuroblastoma cells (N2a) was set up. N2a 
cells were transiently transfected with the same constructs that were also used in 
the zebrafish studies. In N2a cells, expression of Q102-GFP, but not Q4-GFP or 
Q25-GFP, resulted in the formation of large, perinuclear inclusions containing 
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SDS-insoluble aggregates; however, Q102-GFP was not overtly toxic to these cells 
under the tested conditions (Figure 23).   
A 
 
B 
 
C 
 
Figure 23: Q102-GFP forms SDS-insoluble aggregates in N2a mouse 
neuroblastoma cells but does not cause significant toxicity. 
(A), Brightfield and fluorescent images of N2a mouse neuroblastoma cells expressing 
empty vector (pCS2+), Q4-GFP, Q25-GFP, or Q102-GFP, 48 h post-transfection. To 
visualize nuclei, the cells were stained with DAPI. Scale bar, 20 µm. (B), Extracts from 
N2a cells expressing the indicated constructs 48 h post transfection were analyzed by 
filter trap assay (anti-GFP; lower panel). (C), Cell viability assessment of N2a cells 
expressing the indicated constructs 48 h post-transfection. Cell viability was assessed via 
the MTT reduction assay. MTT reduction of N2a cells transfected with empty vector 
(pCS2+) was set to 100%. Data are mean values of n=4 experiments ± S.D. 
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In accordance with the results from the zebrafish system, NBBs proved 
efficient in suppressing Q102-GFP aggregation in N2a cells (Figure 24). Taken 
together, these data suggest that NBBs represent a new class of compounds that 
effectively inhibit polyglutamine aggregation.   
 
Figure 24: N’-benzylidene-benzohydrazides inhibit Q102-GFP aggregation in N2a 
mouse neuroblastoma cells. 
Effect of the indicated chemical compounds on Q102-GFP aggregation in N2a mouse 
neuroblastoma cells, as assessed by the filter trap assay (anti-GFP) with quantitation. 
The signal intensity from the control sample containing solvent alone was set to 100%. 
Data are mean values of n=3 experiments ± S.D. 
 
4.2 N-terminal polyglutamine-containing fragments 
inhibit androgen receptor transactivation 
function in a yeast model of SBMA 
It is widely accepted that neuronal dysfunction and death in 
polyglutamine diseases is caused by the expanded polyglutamine repeat in the 
respective protein. Several non-exclusive hypotheses were proposed to explain 
polyglutamine mediated cytotoxicity which include among others, the inhibition 
of the ubiquitin proteasome system, formation of ion channels, impairment of 
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axonal trafficking but also the inactivation of essential transcription factors. For 
the latter, it was proposed that polyglutamine-expanded species, monomers but 
also oligomers, interact with glutamine-rich regions of transcriptional regulators 
and as a consequence, inactivate them (Cha, 2000; Sakahira et al., 2002b; Schaffar 
et al., 2004). In addition to this toxic gain-of-function mechanism shared by all 
polyglutamine diseases, a loss of function mechanism could contribute to 
polyglutamine disease pathogenesis, e.g. by rendering particular neurons 
exquisitely sensitive to the toxic gain-of-function effects that a polyglutamine 
expansion imparts to the disease protein (Thomas et al., 2006). 
This study presents the establishment of a yeast model for SBMA, which 
in addition to the possibility of investigating the toxic gain-of-function effects of 
polyglutamine containing AR fragments, also enables  monitoring potential loss-
of-function of the AR protein itself.     
 
4.2.1 Development and characterization of a yeast model for SBMA  
For the development of a yeast model of SBMA full-length constructs 
of the AR protein containing 2, 27, 65, or 102 Q (ARQ2; ARQ27; ARQ65; ARQ102, 
respectively) were expressed in S. cerevisiae YPH499 (Figure 25). Former studies 
proposed that proteolytic cleavage of polyglutamine-expanded AR at the 
potential caspase-3 cleavage site 152DEDD155 is a crucial event in SBMA 
pathogenesis unmasking the cytotoxicity of AR (Butler et al., 1998; Cowan and 
Raymond, 2006; Ellerby et al., 1999; Kobayashi et al., 1998; Li et al., 2007; 
Wellington et al., 1998). For this reason N-terminal fragments of AR (amino acid 
1-155) containing polyglutamine stretches in the non-pathogenic range (2 Q or 27 
Q) or pathogenic range (65 Q or 102 Q), with or without a nuclear localization 
signal (NLS) were also expressed in S. cerevisiae YPH499 (Figure 26).  
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Figure 25: Schematic diagram of the constructs used in this study. 
The full-length AR constructs and N-terminal fragments are shown. The ligand-binding 
domain (LBD) and DNA-binding domain (DBD) are highlighted as well as the 
polyglutamine tract with the number of glutamines (Q) as indicated. The polyglutamine 
stretch of the ~65 Q constructs is coded by an unstable CAG repeat, which lead to 
slightly different amount of glutamines in the respective constructs. For a better 
understanding, these constructs are named as Q65. The fragments which are meant to 
be targeted to the nucleus have an N-terminal nuclear localization signal (NLS). The full-
length constructs contain an N-terminal FLAG tag whereas the fragments contain an N-
terminal myc tag. The calculated molecular weights are shown on the right. 
 
4.2.1.1 Polyglutamine-expanded N-terminal AR fragments cause toxicity in 
S. cerevisiae 
The expression of full-length AR proteins containing polyglutamine 
stretches in the pathogenic range (ARQ65 or ARQ102) neither caused toxicity nor 
did they form detectable aggregates in yeast cells (Figure 26).   
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Figure 26:  Expression of polyglutamine-expanded full-length AR neither cause 
toxicity nor forms SDS-insoluble aggregates in yeast.  
(A), Growth analysis of wild-type yeast cells upon expression of full-length AR proteins 
varying in the size of the polyglutamine stretch. Growth of wild-type yeast cells in the 
presence or absence of FLAG-tagged AR constructs was examined by 5-fold serial 
dilutions after 3 days at 30 °C on plates lacking (induction) or containing (no induction) 
Doxycycline, respectively. (B), Filter trap analysis (anti-FLAG and anti-AR, respectively) 
of full-length ARs with 2, 27, 65 and 102 glutamines, full-length ARQ65 in the presence of 
Doxycycline and of the aggregating N-terminal fragment 155-Q65. 750 µg of total cell 
extracts were analyzed in the presence of SDS/DTT at 95 °C. Expression of the 
constructs was checked by SDS-PAGE and western blotting (data not shown).  
 
In contrast, expression of the fragments caused polyglutamine length-
dependent toxicity in yeast, which was enhanced when the fragments were 
targeted to the nucleus, with NLS155-Q102 conferring the most severe toxicity 
(Figure 27). The observed inhibition of cell growth was not dependent on the 
presence of androgens, such as DHT (data not shown). Thus, it seems that the 
mutant polyglutamine stretch is no longer toxic in the protective context of the 
full-length protein, which is consistent with results from other model systems 
(Cowan et al., 2003; Ellerby et al., 1999).  
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Figure 27:  Expression of polyglutamine-expanded N-terminal AR fragments 
cause toxicity in yeast. 
The expression of myc-tagged N-terminal AR fragments (± NLS) with 2, 27, 65 and 102 
glutamines was induced on plates containing Galactose. Growth was examined after 3 
days at 30 °C. 
 
As yeast prions are thought to influence polyglutamine toxicity 
(Meriin et al., 2002), yeast strains were also evaluated after being cured of prions 
by guanidinium hydrochloride (GuHCl). Toxicity caused by expression of either 
155-Q102 or NLS155-Q102 persisted after GuHCl treatment (Figure 28 A). In the 
absence of Hsp104p, which is known to be required for prion propagation 
(Chernoff et al., 1995), both 155-Q102 and NLS155-Q102 likewise remained toxic 
(Figure 28 B). These results indicate that toxicity caused by N-terminal fragments 
of polyglutamine-expanded AR is not reliant on yeast prions. 
A 
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Figure 28: Toxicity caused by N-terminal fragments of polyglutamine-expanded 
AR is not reliant on yeast prions. 
(A), Growth defect of prion-cured yeast cells upon expression of 102 Q containing N-
terminal AR fragments. Cells were raised in GuHCl and growth was examined after 3 
days at 30 °C. (B), Growth defect of hsp104∆::LEU2 strain upon expression of 102Q 
containing N-terminal AR fragments. Growth was examined as in (A). 
 
4.2.1.2 Enhanced toxicity is associated with soluble polyglutamine 
oligomers, and not insoluble aggregates 
To determine whether polyglutamine-dependent toxicity correlates 
with the presence of large insoluble aggregates, the intracellular distribution of 
the AR fragments in yeast cells was initially analyzed by immunofluorescence 
microscopy using an antibody against the N-terminal myc epitope of the AR 
fragments. As expected, fragments containing non-pathogenic polyglutamine 
stretches, 155-Q2 and 155-Q27, were mainly diffusely distributed; while 155-Q65 
accumulated in large, round foci or inclusion bodies (IBs, Figure 29). 
Unexpectedly, 155-Q102 did not efficiently accumulate in IBs, but instead formed 
dispersed, irregularly shaped foci. Nuclear targeting did not substantially alter 
the localization of the fragments containing 2 or 27 Q (NLS155-Q2, NLS155-Q27, 
respectively), but did promote a more diffuse distribution of fragments 
containing a pathogenic polyglutamine stretch, and in the case of NLS155-Q102, 
efficient targeting to the nucleus. 
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Figure 29: The expression of polyglutamine-expanded N-terminal AR fragments 
cause the formation of visible inclusions.   
Wild-type yeast cells expressing myc-tagged N-terminal AR fragments (±NLS) with 2, 27, 
65 and 102 Q were analyzed by indirect immunofluorescence. The myc-tagged fragments 
were immunolabeled with anti-myc antibody coupled to Cy3-conjugated secondary 
antibody, and nuclei were counterstained with DAPI. 
 
Analysis of whole cell extracts using SDS-PAGE and western blotting 
revealed stable fragments of the expected size, taking into consideration that the 
effect of polyglutamine tract length on protein migration is greater than might be 
predicted by protein length alone (Merry et al., 1998; Figure 29). Additional SDS-
insoluble material containing 155-Q27 and 155-Q65 was detected in the stacking 
gel (data not shown). The filter trap assay was used to assess the accumulation of 
AR fragments in large SDS-insoluble aggregates, which are retained by the 0.2 
µm pore-sized filter (Scherzinger et al., 1997). Surprisingly, only 155-Q65 formed 
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substantial amounts of aggregates that were detergent resistant, a characteristic 
of polyglutamine amyloid fibrils (Figure 30 B). 
A 
 
B 
 
Figure 30: 155-Q65 forms SDS-insoluble aggregates in yeast. 
(A), Analysis of the solubility of the AR fragments. Extracts from yeast cells expressing 
myc-tagged N-terminal AR fragments (±NLS) with 2, 27, 65 and 102 Q were analyzed by 
SDS-PAGE and western blotting with anti-myc antibody. The effect of polyglutamine tract 
length on protein migration is greater than might be predicted by protein length alone, 
consistent with what has been noted by others (Merry et al., 1998). Asterisk, not specified 
additional product. (B), Filter trap analysis of N-terminal AR fragments. 750 µg of total cell 
extracts from (A) were analyzed by filter trap assay in the presence of SDS/DTT at 95ºC. 
 
 The polyglutamine-expanded AR fragments with the greatest toxicity 
(155-Q102 and NLS155-Q102; Figure 27), had the least propensity to form large 
SDS-insoluble fibrillar aggregates. To confirm this result and to exclude artifacts 
due to unequal expression rates, 155-Q65 was expressed under control of a 
titratable yeast promoter. The dot blot assay was used to assess the total amount 
of AR fragments in the cell extracts (Figure 31 lower panel) and the filter trap 
assay was done in parallel to monitor the amount of aggregates (Figure 31 upper 
panel). Even reducing the expression of 155-Q65 (Dox) to 2% of total 155-Q102 
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(Gal) and 155-Q65 (Gal), respectively, still resulted in aggregate formation. Thus, 
the discrepancy in accumulation of 155-Q65 versus 155-Q102 in SDS-insoluble 
aggregates was not caused by dissimilar expression levels.   
 
 
Figure 31: 155-Q65 but not 155-Q102 forms SDS-insoluble aggregates in yeast. 
Filter trap analysis of N-terminal AR fragments (upper panel). 750 µg of total cell extracts 
from yeast cells expressing 155-Q65 or 155-Q102 under the control of a galactose 
inducible promoter or, expressing 155-Q65 under the control of a doxycycline regulatable 
promoter (in the presence of 0.02, 0.04, or 0.08 µg/ml doxycycline)  were analyzed by 
filter trap assay with anti-myc antibody in the presence of SDS/DTT at 95ºC. 4 µg of each 
lysate was spotted on a nitrocellulose membrane to compare the total amount of protein 
with anti-myc antibody (lower panel). 
 
Consistent with the filter trap results, high speed centrifugation 
revealed that both 155-Q102 and NLS155-Q102 in contrast to 155-Q65 
fractionated almost exclusively in the soluble supernatant fraction (Figure 32 
and data not shown). These data suggest that pronounced toxicity is associated 
with soluble forms of 155-Q102 and NLS155-Q102. 
Results 92                                  
 
 
Figure 32: Polyglutamine-expanded N-terminal AR fragments, 155-Q102 and 
NLS155-Q102, fractionate almost exclusively in the supernatant fraction.   
Extracts from yeast cells expressing myc-tagged N-terminal AR fragments (±NLS) with 
102Q were subjected to high speed centrifugation, and the resulting fractions were 
analyzed by SDS-PAGE and western blotting with anti-myc. T, total cell lysate; S, 
supernate; and P, pellet fraction. *, stacking gel. 
 
In recent studies about HD but also SBMA it was hypothesized that 
soluble oligomers of polyglutamine containing fragments are the main toxic 
species causing neurodegeneration (Behrends et al., 2006; Li et al., 2007). The 
results revealed that the most toxic fragment, namely NLS155-Q102, is largely 
soluble in yeast (Figure 30). Further characterization of these toxic soluble forms 
was accomplished using a gel filtration approach. Supernatant fractions of yeast 
cell extracts of NLS155-Q102 or NLS155-Q2 as a control were subjected to size-
exclusion chromatography after centrifugation at 20,000 x g. In comparison to 
NLS155-Q2 that showed a single, dominant fraction at ~50-100 kDa, NLS155-
Q102 fragment fractionated as 200-500 kDa species (Figure 33).  Thus, toxicity 
caused by NLS155-Q102 is associated with soluble oligomers in the 200-500 kDa 
size range. 
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Figure 33: Oligomer formation of NLS155-Q102. 
Size-exclusion chromatography on a Superdex 200 column of soluble fractions from 
yeast cells expressing NLS155-Q2 and NLS155-Q102 which were detected with anti-myc 
antibody. 
 
4.2.1.3 Expression of polyglutamine-expanded N-terminal AR fragments 
activates a cytosolic stress reporter  in S. cerevisiae  
Next, a stress reporter was applied to determine if expression of the 
polyglutamine constructs causes cellular stress in yeast cells. This stress reporter 
consists of a heat shock response element of the SSA3 promoter which is fused to 
lacZ (HSE-lacZ) (Boorstein and Craig, 1990). To test the responsiveness of the 
stress reporter, a control strain expressing a non-stress related protein, Gim3p, 
was subjected to heat shock (37 °C). This caused a ~2.5 fold increase in β-
galactosidase activity compared to untreated control (Figure 34). When 
expressing either 155-Q102 or NLS155-Q102, a ~2 fold increase in β-galactosidase 
activity relative to strains expressing their 2 Q counterparts was detected (Figure 
Figure 34). These data indicate that the toxic accumulation of 155-Q102 and 
NLS155-Q102 as soluble misfolded species elicits a substantial heat shock 
response in yeast. 
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Figure 34: The expression of polyglutamine expanded N-terminal AR fragments 
cause cellular stress in yeast. 
The β-Galactosidase activity of extracts from a stress reporter yeast strain expressing 
Gim3 at 30 °C and 37 °C as a control and from yeast cells expressing myc-tagged N-
terminal AR fragments (±NLS) with 2, 27, 65 and 102 Q was determined. The 
Galactosidase activity from Gim3 at 30 °C, 155-Q2 and NLS155-Q2 was set to 100%. 
The data are mean values of n=3 independent experiments ± S.D. 
 
4.2.2 A newly established reporter system to evaluate the effect of 
the polyglutamine stretch on AR transactivation capacity 
Increasing evidence suggests an impairment of AR function in SBMA, 
but the underlying mechanism is not understood. As a possible explanation, it 
has been hypothesized that AR containing expanded polyglutamine is inherently 
deficient in activity (Buchanan et al., 2004).   
 
4.2.2.1 Setup of a reporter system to analyze AR transactivation capacity  
To monitor AR transactivation capacity and elucidate the mechanism 
of its inactivation, a yeast reporter system was established, in which the 
luciferase gene is under control of androgen response elements (ARE-luc). As has 
been shown for similar reporter systems (Ceraline et al., 2003), the production of 
active luciferase, which can be detected in live yeast cells using fluorimetry, 
depends on both the addition of androgen to yeast media and the presence of 
functional AR (Figure 35).  
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Figure 35: The AR-mediated production of active luciferase requires the ligand 
(DHT) and the expression of functional AR. 
(A), Yeast cells expressing full-length AR with 27 Q were grown until mid-log phase. DHT 
was added at the indicated concentrations for two hours and luciferase activity was 
determined. (B), Yeast cells expressing full-length AR with 2 Q were grown until mid-log 
phase in the presence of doxycycline (represses the expression) at the indicated 
concentrations. DHT (5 µM) was added for three hours and luciferase activity was 
determined. 
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4.2.2.2 Transactivation function of AR is polyglutamine-independent 
Since the reporter system proved useful, the transactivation function of 
full-length AR with increasing polyglutamine lengths (ARQ2, ARQ27, ARQ65, 
ARQ102) was assayed in yeast cells containing ARE-luc. For all strains, a dose 
response curve was taken by the addition of several amounts of DHT (0 – 5 µM 
final concentration) to the media for 2 h. In all conditions, active luciferase was 
similarly produced in a manner dependent on the concentration of the DHT 
androgen (Figure 36 A and B). The half-maximal response (EC50) of DHT was 
calculated to be 14.3e-3 µM for ARQ2, 5.2e-3 µM for ARQ27, 6.7e-3 µM for 
ARQ65, and 11.9e-3 µM for ARQ102, respectively. Equal expression levels of AR 
constructs in the analyzed strain subjected to 5 µM DHT was confirmed using 
SDS-PAGE and western blotting (Figure 36 C). These data indicate that the 
transactivation function of AR in yeast is polyglutamine-independent. Therefore, 
polyglutamine-expanded AR is intrinsically functional, but is likely inactivated 
during disease progression. 
A 
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Figure 36: The size of the polyglutamine stretch has no impact on AR 
transactivation capacity. 
(A), Yeast cells expressing full-length AR with 2, 27, 65 and 102 Q were grown in 
duplicate until mid-log phase. DHT was added to one set of cells for two hours and 
luciferase activity of all constructs was determined. The data are mean values of n=3 
independent experiments ± S.D. (B), Dose response curves of the full-length ARs with the 
respective data taken from (A). (C), cell extracts from (A) were analyzed by SDS-PAGE 
and western blotting with anti-myc antibody to check expression levels. 
 
4.2.3 Analysis of the effect of N-terminal polyglutamine-containing 
AR fragments on AR transactivation capacity 
Since these results do not support a linear decrease of intrinsic AR 
activity with progressive expansion of the polyglutamine stretch probably factors 
in trans significantly alter the transactivation capacity of polyglutamine-
expanded AR during SBMA progression such that signs of mild-to-moderate AIS 
appear. The fact that the course of AIS, namely slowly progressive, resembles 
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neurological symptoms suggests a common origin. Interestingly, it was shown 
that neurodegeneration in SBMA originates from oligomers comprised of N-
terminal polyglutamine-containing AR fragments in a mouse model of SBMA (Li 
et al., 2007). On the other hand, polyglutamine-expanded species aggregate and 
sequester polyglutamine containing proteins and were also shown to interact 
with glutamine-rich regions of transcriptional regulators disturbing the activity 
of the latter (Cha, 2000; Sakahira et al., 2002b; Schaffar et al., 2004; Stenoien et al., 
1999). This proposes N-terminal polyglutamine-expanded AR fragments to be 
the origin of both neurodegeneration and partial AIS in SBMA. 
   
4.2.3.1 Full-length AR is recruited into SDS-insoluble aggregates composed 
of  the polyglutamine-expanded N-terminal AR fragments  
In yeast, full-length polyglutamine-expanded AR is not toxic and does 
not efficiently form insoluble aggregates either (Figure 26). Most likely, the 
sequences surrounding the polyglutamine stretch protect intact AR from 
initiating the aggregation process, as predicted from other findings (Adachi et al., 
2007; Butler et al., 1998; Cowan et al., 2003; Davies et al., 1997; Ellerby et al., 1999). 
To determine whether full-length polyglutamine-expanded AR is also protected 
from co-aggregation or recruitment processes, full-length ARQ65 were co-
expressed with the aggregating 155-Q65 fragment in yeast grown in the presence 
or absence of DHT. Analysis of yeast extracts using the filter assay, followed by 
immunodetection with an antibody against the N-terminal FLAG tag of full-
length AR proteins, revealed that full-length ARQ65 was partially recruited into 
SDS-insoluble aggregates of 155-Q65 in a hormone-independent manner (Figure 
37). As expected, full-length ARQ2 was not retained with the 155-Q65 aggregates 
demonstrating that the recruitment phenomenon is polyglutamine-dependent. 
Consistently, fluorescence microscopy of yeast strains revealed ARQ65, but not 
ARQ2, colocalized with aggregates of 155-Q65 in yeast cells in the presence and 
absence of DHT (Figure 37).  
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Figure 37: Recruitment of full-length ARQ65 into SDS-insoluble aggregates of 
155-Q65. 
(A), Filter trap analysis of N-terminal AR fragments. 500 µg of total cell extracts of wild-
type yeast cells co-expressing myc-tagged 155-Q65 and FLAG-tagged AR65Q or AR2Q 
as a control, were analyzed by filter trap assay in the absence (right) and presence (left) 
of DHT (5 µM). (B), Wild-type yeast cells from (A) were analyzed by indirect 
immunofluorescence. The myc-tagged fragments were immunolabeled with anti-myc 
antibody coupled to Cy3-conjugated secondary antibody, the FLAG-tagged full-length AR 
constructs were immunolabeled with anti-FLAG antibody coupled to FitC and nuclei were 
counterstained with DAPI. 
 
4.2.3.2 Polyglutamine-expanded N-terminal fragments impair activity of 
the corresponding full-length AR   
As a next step, the toxic polyglutamine fragments were analyzed on 
their ability to inactivate full-length AR. Clinical evidence points to an 
impairment of AR function in SBMA (Dejager et al., 2002), but the mechanism is 
not yet understood. To monitor AR function in a simulated disease state, the 
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activity of full-length AR was analyzed in the presence of its aggregating 
fragment derivatives.  AR activity was therefore monitored in ARE-luc yeast co-
expressing either full-length ARQ27, ARQ65, or ARQ102 with its corresponding 
N-terminal fragment using the luciferase assay. To eliminate growth rate 
dependent artifacts, luciferase measurements were normalized to those obtained 
from co-expression of the fragments with full-length ARQ2, which would not be 
susceptible to polyglutamine-mediated effects. Luciferase activity mediated by 
ARQ65 was slightly reduced by the aggregating fragments, 155-Q65 and NLS155-
Q65 (Figure 38 B). However, more pronounced reduction in luciferase activity 
mediated by ARQ102 was observed in the presence of its soluble, aggregating 
derivatives, especially NLS155-Q102, which primarily forms soluble oligomers 
(Figure 38 C). In control reactions, luciferase activity mediated by full-length AR 
containing a non-pathogenic polyglutamine stretch, ARQ27, was not reduced in 
the presence of its respective fragment 155-Q27, and was slightly reduced in the 
presence of NLS155-Q27 (Figure 38 A). The latter result might come from a 
general impairment of transcription when these fragments are targeted to the 
nucleus. In summary, these results indicate that the transactivation function of 
full-length ARQ102 is compromised by its N-terminal fragments in a 
polyglutamine-dependent manner.  
A 
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Figure 38: Luciferase activity mediated by polyglutamine-expanded AR is 
decreased by its N-terminal polyglutamine-expanded fragments.   
Yeast cells expressing full-length AR with 27, 65 or 102 Q with their respective fragments 
(155-Q27/Q65/Q102 and NLS155-Q27/Q65/Q102) or empty vector (p423) were grown in 
duplicate until mid-log phase. DHT was added to one set of cells for two hours and 
luciferase activity of all samples was determined. In parallel, all fragments were co-
expressed with ARQ2 as a control. Luciferase activity upon co-expression of empty 
vector p423 was set to 100%.  Means ± SD of 3 independent experiments are shown. *, p 
< 0.05 versus empty vector control (unpaired t-test). 
 
To substantiate these results, and to eliminate potential interference 
with luciferase folding caused by polyglutamine fragments, steady-state levels of 
luciferase protein present in extracts derived ARE-luc yeast co-expressing full-
length AR with its corresponding fragment were analyzed. As controls, extracts 
from yeast co-expressing ARQ2 with the polyglutamine fragments were again 
determined in parallel to assess artifactual changes in luciferase levels (Figure 
39). In cells expressing full length ARQ102, luciferase accumulated to 
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significantly lower levels in the presence of its corresponding mutant 
polyglutamine fragments, 155-Q102 and NLS155-Q102, relative to analogous 
ARQ2 conditions (Figure 39 C). A similar tendency was observed for conditions 
with full-length ARQ65 (Figure 39 B). In contrast, in cells expressing full-length 
ARQ27 with its corresponding fragments (155-Q27 or NLS155Q-27), the level of 
luciferase did not significantly change (Figure 39 A). These results mirror those 
obtained in Figure 38, and suggest that fragments of polyglutamine-expanded 
AR have the capacity to inactivate their full-length counterparts during 
pathogenesis. Furthermore, the most substantial reduction in luciferase activity 
was associated with the 155-Q102 and NLS155-Q102 fragments, which 
accumulate as toxic, soluble species, rather than detergent-insoluble aggregates. 
A 
 
B 
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Figure 39: Luciferase protein levels produced by polyglutamine-expanded AR are 
decreased by its N-terminal polyglutamine-expanded fragments. 
Yeast cells expressing full-length AR with 27 (A), 65 (B) and 102 Q (C) were grown with 
the respective fragments (155-Q27/Q65/Q102 and NLS155-Q27/Q65/Q102) or empty 
vector (p423) in duplicate until mid-log phase. In parallel, all fragments were co-
expressed with ARQ2 as a control. DHT was added to one set of cells for two hours and 
cell extracts were analyzed by SDS-PAGE and Western blotting using anti-luciferase with 
subsequent quantitation. The total amount of luciferase protein upon co-expression of 
empty vector p423 was set to 100%. Means ± SD of 3-4 independent experiments are 
shown. *, p < 0.05 versus empty vector control (unpaired t-test). 
 
4.2.3.3 Soluble forms of 155-Q102 and NLS155-Q102 interact with full-
length AR in a polyglutamine-dependent manner 
To address the mechanism of inactivation of full-length AR by the 155-
Q102 and NLS155-Q102 fragments, immunoprecipitation experiments were 
conducted. Extracts of yeast cells co-expressing 155-Q102 or NLS155-Q102 with 
full-length ARQ102 or ARQ2 were subjected to high-speed centrifugation.  
Fragments were precipitated from the supernatant fraction using an anti-myc 
antibody, and the amount of co-precipitated full-length protein was assessed by 
SDS-PAGE and western blotting. Significant amounts of ARQ102, but not ARQ2, 
were bound specifically to soluble 155-Q102 and NLS155-Q102 (Figure 40).  
Thus, the data suggest that soluble forms of 155-Q102 and NLS155-Q102 interact 
with full-length AR in a polyglutamine-dependent manner. Since NLS155-Q102 
primarily accumulates as toxic oligomers in the 200-500 kDa range (Figure 33), it 
seems that these species are the primary toxic agents that bind to and inactivate 
full-length AR. 
Results 104                                
 
 
Figure 40: Full-length AR co-immunoprecipitates with soluble forms of its N-
terminal fragments in a polyglutamine-dependent manner.   
Whole extracts of yeast cells co-expressing myc-tagged 155-Q102 (±NLS) and FLAG-
tagged AR102Q or AR2Q (as a control) grown until mid-log phase were subjected to 
high-speed centrifugation. The resulting supernatant fraction was incubated with anti-myc 
and Sepharose G beads, and immunoprecipitated complexes were isolated. Soluble 
fractions of cell extracts (Input) and the immunoprecipitated complexes (Co-IP) were 
analyzed by SDS-PAGE and western blotting with anti-AR. The amount of co-
immunoprecipitated full-length AR was quantified (bottom panel). Means ± SD of 3-4 
independent experiments are shown. *, p < 0.05 versus absence of anti-myc antibody 
(unpaired t-test). 
 
4.2.4 Analysis of the effect of polyglutamine-expanded huntingtin 
exon 1 on AR transactivation capacity  
It is hypothesized that the protein context of the expanded 
polyglutamine stretch bias disease-specific processes, as flanking regions were 
shown to affect the toxicity of the polyglutamine stretch (Dehay and Bertolotti, 
2006; Duennwald et al., 2006a).  
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Recent work has demonstrated testicular degeneration in mouse 
models of HD and specific testicular pathology, e.g. a significant decrease in 
spermatogenesis, in HD patients (Papalexi et al., 2005; Van Raamsdonk et al., 
2007). Interestingly, the authors suggest the onset of the testicular phenotype  
occurs later in life due to a direct toxic effect of polyglutamine-expanded 
huntingtin in the testis (Van Raamsdonk et al., 2007). This is supported by the fact 
that huntingtin and the AR protein are highly expressed in the testis (Guo et al., 
2003). It might be possible that polyglutamine-expanded huntingtin fragments, 
analogous to polyglutamine-expanded N-terminal AR fragments, impair the 
transactivation capacity of full-length AR resulting in testicular pathology in HD 
patients. Hence, the polyglutamine stretch, despite different flanking regions, 
mediates toxicity that leads to testicular pathology in both, HD and SBMA 
patients.  
 
4.2.4.1 Polyglutamine-expanded huntingtin exon 1 fragments recruit full-
length AR into SDS-insoluble aggregates  
To determine whether full-length AR is recruited into aggregates 
composed of polyglutamine-expanded huntingtin fragments as observed for N-
terminal polyglutamine containing AR fragments, full-length ARQ2, ARQ27, or 
ARQ65 were co-expressed with the aggregating httEx1-Q96 ± NLS or httEx1-Q20 
± NLS as a control in yeast. Analysis of yeast extracts using the filter assay, 
followed by immunodetection with an antibody against the N-terminal FLAG tag 
of full-length AR proteins, revealed that full-length AR with 27 Q and 65 Q 
(AR65Q) was partially recruited into SDS-insoluble aggregates of httEx1-Q96 and 
NLShttEx1-Q96, respectively (Figure 41 A and data not shown). Full-length AR 
with 2 Q (AR2Q) was not retained with the aggregates demonstrating that the 
recruitment phenomenon is polyglutamine-dependent. Consistently, 
fluorescence microscopy of yeast strains revealed ARQ65 and ARQ27 but not 
ARQ2, colocalized with aggregates of httEx1-Q96 and NLShttEx1-Q96 in yeast 
cells (Figure 41 B, C and data not shown). These results indicate that full-length 
AR is recruited via its polyglutamine stretch into SDS-insoluble aggregates of 
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httEx1-Q96 (and NLShttEx1-Q96) in analogy to the recruitment into SDS-
insoluble aggregates of N-terminal polyglutamine-expanded AR fragments.  
A 
 
 
B 
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Figure 41: Recruitment of full-length ARQ27 into SDS-insoluble aggregates of 
httEx1-Q96 ± NLS. 
(A), Filter trap analysis of httEx1 fragments. 50 µg of total cell extracts of wild-type yeast 
cells co-expressing FLAG-tagged ARQ27 (upper panel) or ARQ2 (lower panel) as a 
control and myc-tagged httEx1 fragments (httEx1-Q20 ± NLS and httEx1-Q96 ± NLS) 
were analyzed by filter trap assay with anti-FLAG antibody. (B, C), Wild-type yeast cells 
from (A) were analyzed by indirect immunofluorescence. The myc-tagged fragments were 
immunolabeled with anti-myc antibody coupled to Cy3-conjugated secondary antibody, 
the FLAG-tagged full-length ARQ27 (B) and ARQ2 (C) constructs were immunolabeled 
with anti-FLAG antibody coupled to FitC and nuclei were counterstained with DAPI. 
 
4.2.4.2 The transactivation capacity of full-length polyglutamine containing 
ARs is impaired by polyglutamine-expanded huntingtin exon 1 
fragments   
To analyze the impact of the regions flanking the polyglutamine 
stretch on AR transactivation capacity full-length ARQ102 was co-expressed with 
either httEx1-Q96 ± NLS or httEx1-Q20 ± NLS as a control. To eliminate growth 
rate dependent artifacts, luciferase measurements were normalized to those 
obtained from co-expression of the fragments with full-length ARQ2. The 
analysis revealed that luciferase activity mediated by full-length ARQ102 was 
substantially reduced in the presence of httEx1-Q96 and NLShttEx1-Q96, to ~66% 
and 58% of its normal activity whereas the presence of httEx1-Q20 and 
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NLShttEx1-Q20 did not (~90% and 99%, respectively; Figure 42). This result 
indicates that the transactivation function of full-length AR102 is also 
compromised by polyglutamine-expanded huntingtin fragments and suggests 
that the transactivation function of polyglutamine-expanded AR is compromised 
in the presence of polyglutamine-containing fragments.  
A 
 
B 
 
Figure 42: Polyglutamine-expanded huntingtin fragments decrease AR mediated 
luciferase activity. 
Yeast cells expressing full-length AR with 102 Q were grown with huntingtin fragments 
containing a non-pathogenic polyglutamine stretch (A, httEx1-Q20 and NLShttEx1-Q20) 
or a pathogenic polyglutamine stretch (B, httEx1-Q96 and NLShttEx1-Q96) or empty 
vector (p423) in duplicate until mid-log phase. DHT was added to one set of cells for two 
hours and luciferase activity of all constructs was determined. In parallel, all fragments 
were co-expressed with ARQ2 as a control. The luciferase activity upon co-expression of 
empty vector p423 was set to 100%. The data are mean values of n=3 independent 
experiments ± S.D.  
 
To verify these results, the amount of luciferase present in extracts 
derived from ARE-luc yeast co-expressing full-length AR with httEx1 fragments 
was analyzed. As controls, extracts from yeast co-expressing ARQ2 with the 
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httEx1 fragments were determined in parallel to assess artifactual changes in 
luciferase levels (Figure 43). In cells expressing full length ARQ102, luciferase 
accumulated to significantly lower levels (~80% and 59%) in the presence of 
polyglutamine-expanded httEx1, httEx1-96Q and NLShttEx1-96Q, whereas the 
presence of httEx1 with a non-pathogenic polyglutamine stretch, httEx1-Q20 and 
NLShttEx1-Q20, had no significant impact (~90% and 99%, respectively; Figure 
43). Taken together, these results indicate that the expanded polyglutamine 
stretch and not the sequences flanking the polyglutamine stretch, of aggregating 
fragments mediate inactivation of full-length AR. 
A 
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Figure 43: Polyglutamine-expanded huntingtin fragments decrease AR mediated 
total amount of luciferase protein.  
Yeast cells expressing full-length AR with 102 Q were grown with huntingtin fragments 
containing a non-pathogenic polyglutamine stretch (A, httEx1-Q20 and NLShttEx1-Q20) 
or a pathogenic polyglutamine stretch (B, httEx1-Q96 and NLShttEx1-Q96) or empty 
vector (p423) in duplicate until mid-log phase. In parallel, all fragments were co-
expressed with ARQ2 as a control. DHT was added to one set of cells for two hours and 
cell extracts were analyzed by SDS-PAGE and western blotting with anti-luciferase 
antibody with subsequent quantitation. The total amount of luciferase protein upon co-
expression of empty vector p423 was set to 100%. The data are mean values of n=3 
independent experiments ± S.D.  
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5 Discussion 
Studies worldwide revealed that currently at least 15 percent of the 
population over 65 in western countries suffer from neurodegeneration. In the 
U.S. alone, the total cost of Alzheimer's disease, the most common 
neurodegenerative disease, in 2002 has been estimated at $100 billion per year 
(http://focus.hms.harvard.edu/2002/June21_2002/forum.html), and as the 
human life span increases, the number of people over 65 will double over the 
next 30 years. These are worrisome facts that force research to focus on 
neurodegeneration and thus, the aberrant folding of proteins.  
When research started in that field decades ago, the proteinaceous 
deposits in patients composed of amyloidogenic aggregates were soon declared 
the toxic species responsible for the degeneration of neuronal cells, since they are 
a common hallmark of all the amyloidoses. In Alzheimer’s disease, for example, 
the Aβ peptide misfolds and forms highly ordered fibrillar aggregates. Similar 
aggregates are also formed by proteins with an expanded polyglutamine stretch, 
e.g. huntingtin in Huntington’s disease or AR in SBMA. This ‘aggregate 
hypothesis’ persisted for a long time, and it is only recently that this view has 
begun to change. The poor overlap between neurons with visible inclusions and 
neurons actually undergoing degeneration on the one hand and studies showing 
aggregate formation being benign on the other started a process of rethinking. 
Currently, soluble oligomeric folding intermediates of the disease proteins are 
suspected to exert neurotoxicity, which was shown for Aβ oligomers and 
polyglutamine-expanded proteins (Arrasate et al., 2004; Behrends et al., 2006; 
Cleary et al., 2005; Ross and Poirier, 2005; Walsh et al., 2002). But it might well be 
that neurodegeneration is the result of an interplay of numerous non-exclusive 
mechanisms mediated by different species formed in the pathway towards 
mature fibrils, including monomers and the mature fibrils themselves (Michalik 
and Van Broeckhoven, 2003). These species seem to have features which are 
independent of the protein context and lead to similar toxic phenotypes for  
intrinsically unrelated proteins such as Aβ peptide, prion protein, or the 
polyglutamine-expanded huntingtin and AR protein (Kayed et al., 2003). 
Discussion 111                                
 
The molecular mechanisms underlying neurodegeneration are also far 
from being fully understood. In the case of polyglutamine diseases, it is most 
probably a gain-of-function mechanism of the aggregation prone proteins that 
causes cytotoxicity, as supported by the dominant inheritance pattern, together 
with extensive studies on cell culture and animal models of these diseases 
(Piccioni et al., 2001; Zoghbi and Orr, 2000). This is most evident in patients of 
complete androgen insensitivity syndrome (CAIS), who lack functional AR 
protein due to a mutation in the gene coding for AR. Although they suffer from 
disturbances in various androgen-mediated mechanisms, they do not develop 
neurodegenerative symptoms. Thus, it is likely that it is the expanded 
polyglutamine repeat that confers toxicity at the neuronal level in SBMA (Brooks 
and Fischbeck, 1995; Piccioni et al., 2001).  However, sequences flanking the 
polyglutamine repeat might also influence pathogenesis (Duennwald et al., 
2006a). So far, several non-exclusive hypotheses were proposed to explain 
polyglutamine mediated neurodegeneration, which include transcriptional 
dysregulation (Cha, 2000; Sakahira et al., 2002b; Schaffar et al., 2004), inhibition of 
the ubiquitin proteasome system (Bennett et al., 2007; Pandey et al., 2007), 
sequestration of cytoplasmic and nuclear proteins (Harjes and Wanker, 2003; Li 
and Li, 2004), plasma membrane damages (Hirakura et al., 2000; Monoi et al., 
2000; Trushina and McMurray, 2007), and impairment of axonal and dendritic 
trafficking (Lee et al., 2004; Piccioni et al., 2002). Various species of polyglutamine-
expanded protein, including monomers, oligomers or large aggregates, were 
shown to be involved in at least one of these processes.  
Regardless of the specific oligomeric state, the overall activity of the 
disease causing protein is altered either due to intrinsic properties of the 
elongated polyglutamine stretch or a reduction in the total amount of the 
respective protein due to aggregation. The resulting loss-of-function effect of the 
disease protein might contribute to disease pathogenesis and explain differences 
in pathology among polyglutamine diseases (Dragatsis et al., 2000; Leavitt et al., 
2001; Leavitt et al., 2006b; Thomas et al., 2006).  
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5.1 Danio rerio, a new model organism to identify 
inhibitors of polyglutamine aggregation 
In polyglutamine diseases, major effort has been put into identifying 
means to disrupt or alter the polyglutamine aggregation pathway with the 
overall goal to suppress polyglutamine mediated toxicity (Di Prospero and 
Fischbeck, 2005). As the aggregation pathway accounts for the generation of toxic 
species, several screens were carried out, most of them in vitro or in cell based 
assays, to identify inhibitors of the aggregation process. Since it is unclear which 
step of the aggregation pathway the compound has to inhibit in order to prevent 
cytotoxicity, these compounds have to be reevaluated in terms of their capacity to 
suppress toxicity. Ideally this should be done in a whole organism to allow the 
simultaneous analysis of potential adverse effects. So far, further investigations 
with respect to the effect of drug candidates in a vertebrate organism are 
restricted to rodent models (Heiser et al., 2002; Hockly et al., 2006). As these 
experiments are expensive and time consuming, the reevaluation of all promising 
drug candidates is not feasible and effective compounds may remain 
undiscovered. 
 
5.1.1 Zebrafish model for HD 
This study describes the establishment of a zebrafish HD model 
system suitable for the whole organism validation of candidate compounds. The 
zebrafish has several key advantages over other in vivo models of HD. In 
comparison to Drosophila melanogaster or Caenorhabditis elegans, it is a vertebrate 
organism and contains homologues to many human genes, including the htt gene 
(Figure 8), making it a valuable tool to model human diseases such as HD 
(Karlovich et al., 1998). Unlike the established rodent HD models, in vivo drug 
tests can be performed in a time and cost efficient way. Additional advantages 
include the robustness of the embryos that facilitates experimental manipulation, 
the transparency of zebrafish embryos allowing for the visualization of 
morphological and physiological features in the live embryo, and the aqueous 
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environment of the zebrafish, which facilitates drug administration (Zon and 
Peterson, 2005). In contrast to cell culture, the zebrafish model system allows for 
the evaluation of drug effectiveness in a whole organism, taking into account the 
stability and cellular targeting of the tested compound, as well as the assessment 
of potential side effects of the drug at effective concentrations.  
The zebrafish model of HD described in this study is based on the 
expression of mRNA of N-terminal fragments of htt containing 4, 25 or 102 Q 
fused to green fluorescent protein (Figure 9). The mRNA was injected at the 1-2 
cell stage. As the intensity of the GFP-signal decreased after 48 h most likely due 
to degradation and translation (data not shown), the analysis was restricted to 
zebrafish embryos up to 36 h. The advantage of mRNA injection over DNA 
injection in zebrafish is the homogenous distribution of the mRNA upon cell 
division. As a consequence thereof, the expression of the constructs is ubiquitous 
and mimics the overall expression of htt in humans (Difiglia et al., 1995; 
Gutekunst et al., 1995; Trottier et al., 1995).  
As expected, the constructs were homogenously expressed throughout 
the embryo with polyglutamine-expanded htt (Q102-GFP) giving rise to the 
formation of large inclusions (Figure 10, Figure 11 and Figure 12).  These 
inclusions turned out to be composed of predominantly SDS-insoluble 
aggregates (Figure 14), a hallmark of HD that has also been observed in patients 
and in animal models of HD (Davies et al., 1997; DiFiglia et al., 1997; Jackson et al., 
1998; Satyal et al., 2000). The inclusions, which are perinuclear and relatively 
large in size (Figure 12) grew by efficient incorporation of soluble Q102-GFP, 
resulting in its depletion from the cytoplasm (Figure 13).  
 Aggregation was not restricted to a specific region as aggregates were 
detected throughout the entire embryo. However, a certain threshold 
concentration of Q102-GFP is required to initiate aggregation, since only a subset 
of cells expressing Q102-GFP shows aggregate formation (Figure 12). 
Expression of Q102-GFP was also associated with pronounced 
morphological defects and reduced viability of zebrafish embryos (Figure 15). 
Thus, another characteristic of HD, namely polyglutamine mediated toxicity, 
could be reproduced in the zebrafish model. Interestingly, among the visibly 
Discussion 114                                
 
abnormal embryos, a characteristic ‘cyclopic’ phenotype was increasingly 
observed in embryos expressing Q102-GFP (Figure 15). This mutant phenotype 
is characterized by fusion of the eyefields yielding a single eye in the midline 
(Blader and Strahle, 1998) and has recently been found to be associated with 
defects in Ca2+ homeostasis of the endoplasmic reticulum in zebrafish (Creton, 
2004). The observed enhancement of the cyclopic phenotype may therefore reflect 
an adverse effect of Q102-GFP on Ca2+ homeostasis. Indeed, perturbed Ca2+ 
homeostasis is hypothesized to be involved in HD pathogenesis (Bezprozvanny 
and Hayden, 2004).   
In concordance with the morphological defects, the expression of 
Q102-GFP was also associated with enhanced apoptosis (Figure 16). The 
increased apoptosis upon expression of Q4-GFP and Q25-GFP in comparison to 
the untreated embryos is most probably a result of the injection process itself 
(Figure 16). This might also explained the increased occurrence of dead and 
morphologically abnormal embryos (Figure 15).  
Previous studies in cell culture suggested that polyglutamine toxicity 
is not primarily caused by detectable inclusions (Arrasate et al., 2004; Schaffar et 
al., 2004). In the zebrafish model the majority of apoptotic cells were devoid of 
visible inclusions. Hence, in line with the aforementioned studies, inclusions of 
polyglutamine-expanded htt do not contribute directly to toxicity in a vertebrate 
organism. Probably, smaller inclusions/aggregates with a diameter < ~0.5 µm, 
which would escape detection using the experimental setup in this study, are 
involved in causing toxicity in the zebrafish system. 
An important observation was that both the aggregation and toxicity 
of mutant htt was suppressed by the molecular chaperones, Hsp40 and Hsp70, 
mimicking observations from other HD models (Barral et al., 2004). Thus, key 
features of HD are reproduced in this zebrafish model, which make it a valid 
model organism for identifying factors that influence disease pathogenesis. 
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5.1.2 The anti-prion compounds inhibit the aggregation of 
polyglutamine-expanded fragments 
Drug absorption into the zebrafish embryo is likely facilitated by its 
aqueous environment and lack of blood brain barrier at early stages in 
development; therefore, compounds can be tested for their effect while 
minimizing complicating factors that impede absorption. To evaluate the 
suitability of the zebrafish model to identify inhibitors of polyglutamine 
mediated aggregation and toxicity, known inhibitors of the polyglutamine 
aggregation process were analyzed for their effect in the zebrafish model. 
Subsequent to mRNA injection the clutches were divided in two groups, half of 
which was treated with the drug and the other half with the respective solvent as 
a control.  
The effect of PGL-135, Congo red and Isoproterenol HCl in the 
zebrafish model is consistent with studies in other HD models (Hockly et al., 
2006; Sanchez et al., 2003; Wang et al., 2005). Surprisingly, Mycophenolic acid, a 
compound known to suppress htt inclusion formation in cell culture (Wang et al., 
2005), had no effect on Q102-GFP aggregation in zebrafish at the maximum 
tolerated dose (Figure 22). Since Mycophenolic acid caused pronounced 
apoptosis in the brain region of the zebrafish embryo at higher doses (data not 
shown), concentrations shown to have an effect on polyglutamine aggregation in 
cell culture (Wang et al., 2005) could not be tested. Therefore, the zebrafish model 
also permits evaluation of whether a compound causes toxic side effects when 
present at effective concentrations in a whole organism. In summary, the 
obtained results for the known inhibitors of polyglutamine aggregation confirm 
the use of the zebrafish model to evaluate and identify inhibitors of 
polyglutamine mediated aggregation.  
Two of the candidate compounds, 313B02 and 293G02, were 
previously identified as inhibitors of the recruitment of prion monomers into 
PrPSc aggregates (Bertsch et al., 2005), while compound 306H03 has since been 
discovered in a similar screen (A. Giese, pers. comm.).  PrPSc and mutant htt are 
neurodegenerative disease proteins that accumulate in structurally similar 
fibrillar aggregates that may have a common beta-helical amyloid core structure 
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(Govaerts et al., 2004; Stork et al., 2005). Taking such analogies into consideration, 
inhibitors of the aggregation of PrPSc may also be effective in preventing 
polyglutamine protein aggregation. As hypothesized, it turned out that anti-
prion compounds are indeed potent inhibitors of polyglutamine aggregation not 
only in vitro but also in zebrafish (Figure 21 and Figure 22).  This observation 
suggests that polyglutamine aggregates and prions share common structural 
epitopes. To substantiate the effect of the tested drugs, their ability to suppress 
polyglutamine aggregation was additionally evaluated in a N2a neuroblastoma 
cell culture model of HD (Figure 23). The obtained results confirmed those from 
zebrafish and propose NBBs as effective inhibitors of polyglutamine aggregation 
and further established the zebrafish system as a valid model to study human 
disease  (Figure 24). Taken together, these finding reinforces the view that 
common mechanisms underlie the pathogenesis of diverse neurodegenerative 
diseases and suggests that common therapeutic targets may exist.   
The newly established zebrafish model proved useful in evaluating the 
effectiveness of compounds in inhibiting polyglutamine aggregation and toxicity 
in the context of a whole vertebrate organism. The unique feature that drug 
testing can be performed within two days would make this model a cost and 
time efficient alternative to existing mouse models of HD. The ability to 
differentiate between effects on polyglutamine mediated aggregation verses 
toxicity is another advantage of the zebrafish system, which is lacking in several 
other HD models, such as the N2a cell culture model tested in this study (Figure 
23). The zebrafish model also takes into account the stability and the cellular 
targeting of compounds in an organism. For example, one of the tested 
compounds, 313B02, was effective in inhibiting polyglutamine aggregation in 
vitro, but was not effective as an aggregation inhibitor in vivo (Figure 21 and 
Figure 22), suggesting that this compound is not stable and/or not targeted 
efficiently in the zebrafish. In addition, the zebrafish model also enables to 
analyze whether a compound caused side effects when present at active 
concentrations in a whole organism as observed for Mycophenolic acid.  
 Based on this study, NBBs may constitute a new class of compounds 
with “generic” anti-aggregation activity, perhaps preventing the misfolding and 
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aggregation of a wide variety of neurodegenerative disease proteins. NBBs 
provide a novel and promising lead structure for the development of new 
therapeutics in several regards.  The NBBs used in this study satisfy Lipinski’s 
‘rule of 5’ for drug-likeness by having fewer than 5 H-bond donors, 10 H-bond 
acceptors, a molecular weight smaller than 500, and a calculated Log P (cLogP) 
smaller than 5, which would predict efficient absorption or permeation (Lipinski 
et al., 2001).  Importantly, the results indicate that in a vertebrate organism, NBBs 
can reach the cytoplasm in active concentrations without causing overt toxic side 
effects up to the limits of their solubility in water. Furthermore, the analyses 
indicate that the hydroxyl groups of the NBB compounds, which were shown to 
be crucial for anti-prion activity in vitro (Bertsch et al., 2005), are not essential for 
inhibition of polyglutamine aggregation in vivo. In fact, 293G02, although 
exhibiting the highest potency in vitro, was a less effective inhibitor of 
polyglutamine aggregation than 306H03 in vivo (Figure 21, Figure 22 and Figure 
24).  Most likely, the presence of a chloride group, rather than hydroxyl groups, 
enhances cell permeability by decreasing the total polar surface area (tPSA) from 
81.92 Å2 (293G02) to 41.46 Å2 (306H03) and increasing the hydrophobicity cLogP 
from 2.94 (293G02) to 4.67 (306H03). Thus, NBBs such as 306H03 may be 
developed that are more likely to cross the blood brain barrier efficiently.  
Presumably, the disease-modifying therapeutic effect of aggregation inhibitors in 
protein aggregation diseases also depends on the nature of the toxic species and 
whether toxicity occurs primarily through a loss-of-function or gain-of-function 
mechanism. New classes of drugs which interfere with aggregate formation at 
the molecular level such as the NBBs may provide valuable tools to further 
dissect the molecular steps involved in disease pathogenesis in vivo. 
 The nature of the toxic species may explain why NBBs could suppress 
the formation of SDS-insoluble aggregates without detectably suppressing 
polyglutamine toxicity (Figure 22). Presumably, NBBs effectively inhibit 
primarily later stages of Q102-GFP aggregation. Thus, early soluble intermediates 
in the htt aggregation pathway associated with toxicity may still accumulate. In 
line with this assumption, upon addition of NBBs a shift in the total amount of 
SDS-insoluble to SDS-soluble aggregates was observed (data not shown). Hence, 
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it seems likely, that the NBBs inhibit the conversion of SDS-soluble 
polyglutamine-oligomers into SDS-insoluble, amyloidogenic fibrils. In support of 
this possibility, results that were published after this study showed that Congo 
red inhibits the growth of oligomers, but not the initial formation of fibrils 
(Takahashi et al., 2007). In concordance, in the zebrafish model of HD Congo red 
inhibited aggregate formation but not toxicity analogous to the NBBs (Figure 22 
and data not shown). A computer-based simulation of NBB docking to a 
polyglutamine protofibril predicts that NBBs as well as Congo red specifically 
bind to the ends of the polyglutamine helices, a mechanism that would prevent 
fibril growth (Thomas Hirschberger, pers. comm.). Future studies aimed at 
assaying structural derivatives of NBBs may lead to the identification of more 
effective suppressors of polyglutamine toxicity.     
Large scale screens will continue to identify promising compounds 
that inhibit aggregation processes in vitro or in cell culture. A systematic 
approach for validating such candidate compounds should include the judicious 
use of vertebrate model systems to evaluate efficacy against polyglutamine 
aggregation and toxicity before proceeding to clinical trials. Cost and time-
efficient drug testing using the zebrafish model described here is likely to prove 
useful for this purpose.   
The establishment of a transgenic zebrafish line expressing a 
pathogenic polyglutamine construct should also be taken into consideration. By 
taking advantage of the same genetic background in a transgenic line, direct 
screening for compounds that inhibit polyglutamine-mediated aggregation and 
toxicity could be performed using ideally only one fish per compound. Due to a 
constant expression of the pathogenic construct the analyses would not be 
restricted to the embryonic state and compounds might be identified that 
ameliorate symptoms at later stages. In this way such a transgenic zebrafish line 
could also deliver insights on age-related toxic effects caused by polyglutamine 
containing fragments.  
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5.2 Saccharomyces cerevisiae, a model organism to 
study mechanisms of polyglutamine mediated 
toxicity  
The molecular mechanisms underlying polyglutamine mediated 
cytotoxicity are not yet fully understood. Based on studies in various models  of 
polyglutamine disease, hypotheses were proposed to explain polyglutamine 
mediated cytotoxicity which include, among others, the inhibition of the 
ubiquitin proteasome system, formation of ion channels, impairment of axonal 
trafficking but also the inactivation of essential transcription factors. As a 
possible reason the polyglutamine-expanded proteins are thought to adopt new 
characteristics that trigger toxicity, a process that is known as a toxic gain-of-
function mechanism. The impact that a partial loss of its intrinsic function could 
have on disease pathogenesis is unclear but studies on HD and also on SBMA 
revealed considerable evidence for a pathogenic role of diminished normal 
function of disease proteins containing polyglutamine repeat expansions 
(Dragatsis et al., 2000; Leavitt et al., 2001; Leavitt et al., 2006b; Thomas et al., 2006).  
 
5.2.1 A yeast model for SBMA 
S. cerevisiae has been frequently used to investigate aspects of 
polyglutamine toxicity because of its easy handling and maintenance, the short 
generation time and the ease of manipulating the genome, which allows 
biochemical studies from a single genetically defined cell (Drubin, 1989). 
Despite the low genomic complexity in comparison to higher eukaryotic 
organisms, it proved useful in reproducing and investigating key 
characteristics of polyglutamine disease, such as mechanisms of polyglutamine 
cytotoxicity and the formation and accumulation of polyglutamine aggregates 
(Dehay and Bertolotti, 2006; Duennwald et al., 2006a; Krobitsch and Lindquist, 
2000; Meriin et al., 2002; Muchowski et al., 2000). These studies which focused 
on Huntington’s disease confirmed the correlation between the size of the 
polyglutamine stretch and aggregation propensity, analyzed the effect of 
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molecular chaperones on polyglutamine oligomerization, aggregation and 
toxicity, and also investigated polyglutamine mediated transcriptional 
dysregulation (Behrends et al., 2006; Krobitsch and Lindquist, 2000; Muchowski 
et al., 2000; Schaffar et al., 2004). Thus, investigations on polyglutamine diseases 
in yeast lead to important contributions to the understanding of molecular 
mechanisms underlying cytotoxicity. 
This study established a yeast model of SBMA amenable to analysis 
of the toxic gain-of-function effects of polyglutamine containing AR fragments 
and potential loss-of-function of the AR protein itself. The yeast model of 
SBMA is based on the expression of either full-length AR containing 2Q, 27Q, 
65Q or 102Q and/or the respective N-terminal fragments of AR in S. cerevisiae. 
Expression of full-length ARs with varying polyglutamine stretches were not 
toxic to yeast cells nor did they aggregate (Figure 26). This was probably 
because the N-terminus of full-length AR was not efficiently liberated by 
proteolysis (Figure 26), an event that is crucial to SBMA pathogenesis and was 
shown to be mediated by caspase-3 (Ellerby et al., 1999; Kobayashi et al., 1998; 
Wellington et al., 1998). Since no yeast homologue of caspase-3 was identified 
(Madeo et al., 2002), this could explain the lack of toxicity upon expression of 
polyglutamine-expanded full-length AR. In contrast, the N-terminal AR 
fragments caused polyglutamine length-dependent toxicity in yeast, which 
was enhanced when the constructs were targeted to the nucleus (Figure 27). 
The latter is concordant with observations in SBMA patients as well as in 
cellular and animal models (Adachi et al., 2005; Gatchel and Zoghbi, 2005). The 
indispensable role cleavage plays in SBMA pathogenesis is also reflected in the 
missing effect upon addition of the ligand DHT, which neither resulted in 
toxicity nor in aggregation in yeast cells expressing full-length AR. Although it 
has been demonstrated that ligand-mediated targeting of the AR into the 
nucleus has a dramatic impact on SBMA pathogenesis (Katsuno et al., 2006; 
Takeyama et al., 2002), it seems that the crucial event which leads to toxicity is 
the proteolytic cleavage of AR that was shown to be both, polyglutamine- and 
ligand-dependent (LaFevre-Bernt and Ellerby, 2003).  
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Work on yeast prions proposed that in a yeast model of 
Huntington’s disease, toxicity depends on polyglutamine aggregation 
mediated by a prion-like protein Rnq1 (Meriin et al., 2002). Such a dependency 
on yeast prions was not observed in this yeast model of SBMA. The absence of 
both aggregated Rnq1 or Hsp104p had no obvious effect on toxicity, thus, 
suggesting a different mechanism of toxicity (Figure 28). 
In recent studies in yeast, aggregation and toxicity of polyglutamine 
stretches within the pathological range was shown to be largely affected by it’s 
flanking sequences (Dehay and Bertolotti, 2006; Duennwald et al., 2006b). Upon 
analyzing the aggregation characteristics of the N-terminal AR fragments, the 
most striking observation was the decreased propensity of the 102 glutamine 
AR fragment (155-Q102) to form SDS-insoluble aggregates comparing to the 
fragment containing 65 glutamines (155-Q65;  Figure 30, Figure 31 and Figure 
33). So far, this is the first study that contradicts the correlation between the 
size of the polyglutamine stretch and aggregation propensity. It remains 
unclear why the aggregation pathways of these constructs differ, but  flanking 
sequences may sterically hinder the aggregation pathway of the Q102 
constructs.  In any event, these data suggest soluble oligomers, and not 
detergent insoluble fibrils, are the primary toxic agent, in line with other 
studies of polyglutamine proteins (Arrasate et al., 2004; Li et al., 2007; Schaffar 
et al., 2004). That toxicity does not necessarily correlate with aggregation was 
also observed upon addition of  an NLS to the N-terminal AR fragments. 
Aggregate-like structures were barely detected, nonetheless NLS constructs 
showed an increased toxicity compared to their respective untagged 
counterparts (Figure 27, Figure 29 and Figure 30).  In line with these 
observations, another study showed that aggregate morphology alone does not 
determine polyglutamine toxicity (Duennwald et al., 2006b). Nevertheless, a 
major toxic role of SDS-insoluble aggregates seen upon expression of 155-Q65 
is highly unlikely, since expression of other constructs, for instance 155-Q102, 
was more toxic although no SDS-insoluble aggregates were detected (Figure 
27 and Figure 30). This is in agreement with the currently postulated benign 
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and perhaps even protective role of aggregates in polyglutamine diseases 
(Arrasate et al., 2004; Schaffar et al., 2004). 
Recent studies have shown that polyglutamine-expanded AR 
fragments elicit a cellular stress response in cell culture (Cowan et al., 2003).  To 
determine the capability of the polyglutamine fragments to cause cellular stress 
a previously identified reporter of cellular stress was used in yeast (Boorstein 
and Craig, 1990). Since the expression of 155-Q102 and NLS155-Q102 also 
activated a stress response in yeast cells, it seems likely that the underlying 
mechanism of polyglutamine fragment-mediated cellular stress response is not 
only restricted to mammalian cells (Figure 34). This observation confirmed the 
yeast system to be a valid model to study human disease.   
5.2.2 N-terminal polyglutamine-expanded AR fragments decrease 
AR transactivation capacity 
Due to its lack of endogenous AR and associated co-factors, the yeast 
system was an optimal choice for direct assessment of the function of human 
polyglutamine-expanded AR, both in isolation and in the presence of 
aggregating polyglutamine species as part of a simulated disease state.  
The reporter system to monitor AR transactivation capacity in yeast is 
based on the luciferase gene being under control of androgen response elements 
(ARE-luc) and requires active AR as well as ligand (Figure 35). Although it was 
set up to analyze the effect of the polyglutamine-expanded AR fragments on the 
respective full-length constructs it also enabled to determine the intrinsic 
transactivation function of the full-length AR constructs used in this study. 
Strikingly, all full-length AR constructs were fully functional, suggesting that the 
polyglutamine-stretch in AR does not influence the intrinsic function of AR 
(Figure 36). This result contradicts numerous studies that report a linear 
decrease of transactivation function with progressive expansion of the 
polyglutamine repeat (Chamberlain et al., 1994; Dejager et al., 2002; Kazemi-
Esfarjani et al., 1995; Thomas et al., 2006; Tut et al., 1997). Unlike this work, the 
other studies were carried out in cell lines (Chamberlain et al., 1994; Kazemi-
Esfarjani et al., 1995; Thomas et al., 2006; Tut et al., 1997) or are the result of a 
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study on SBMA patients (Dejager et al., 2002), thus in cellular environments that 
are adapted to AR function. Since yeast has no homologue to AR, cofactors or 
miscellaneous interacting proteins are unlikely to exist. Therefore, AR 
transactivation capacity in this yeast system is most likely based on the intrinsic 
functionality of the AR protein and is not influenced by additional factors. These 
data suggest that AIS in SBMA is not a result of the intrinsic dysfunction of 
polyglutamine-expanded AR. 
 It is largely accepted that aggregates composed of polyglutamine-
expanded fragments sequester, and as a consequence thereof, inactivate proteins 
containing polyglutamine stretches in the non pathogenic range (Chai et al., 2002; 
Kim et al., 2002; McCampbell et al., 2000; Perez et al., 1998; Rajan et al., 2001). In an 
experimental setup that resembled an SBMA patient situation with an AR of 
~65Q recruitment of full-length AR (ARQ65) into aggregates composed of the 
respective fragment (155-Q65) was detected (Figure 37). Artifacts can be ruled 
out since ARQ65 does not aggregate on its own and does not undergo cleavage 
(Figure 26 and data not shown). However, the recruitment does not seem to be 
very efficient, as co-localization was only detectable in some cells and the 
majority of full-length AR protein remained soluble. This is not surprising given 
that the AR exists in a complex with chaperones which, as a side-effect, probably 
shield AR from being recruited (Pratt and Toft, 1997; Freeman and Yamamoto, 
2001; Pratt et al., 2004). Even the presence of DHT did not significantly increase 
the susceptibility of AR to sequestration into the aggregates. This might again be 
a consequence of chaperones since after ligand binding, the AR remains in a 
complex with chaperones (Picard, 2006; Prescott and Coetzee, 2006).  
As characteristics of AIS in SBMA develop progressively over a long 
period of time, similar to the neurodegeneration that appears later in life 
(Brinkmann, 2001; Dejager et al., 2002), the aggregation prone, N-terminal 
polyglutamine-containing fragments that were recently proposed to be the cause 
of neurodegeneration in SBMA might play a major role in AIS (Li et al., 2007). 
Indeed, a polyglutamine length-dependent effect of the fragments on full-length 
AR that increased with the number of glutamines could be observed in a scenario 
that mimics the SBMA disease state in yeast by expressing full-length 
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polyglutamine-expanded AR with its ~155 amino acid N-terminal fragment, 
which is thought to be generated after caspase-3 cleavage during SBMA 
pathogenesis (Figure 38 and Figure 39;  Ellerby et al., 1999; Kobayashi et al., 1998; 
Wellington et al., 1998). This reflects the situation in SBMA patients, who are 
mainly male, where expression of an X-linked mutant gene leads to accumulation 
of polyglutamine-expanded AR and its toxic N-terminal cleavage products 
(Adachi et al., 2007; Ellerby et al., 1999). The results indicate that full-length 
polyglutamine-expanded AR is substantially inactivated by its N-terminal 
fragments, especially the oligomer-forming NLS155-Q102 fragment (Figure 38). 
A minor effect on the activity of full-length ARQ27 caused by its fragments was 
also observed using luciferase activity as a read-out (Figure 38); however, direct 
measurement of steady-state luciferase protein levels revealed no indication of 
significant change in AR activity among conditions (Figure 39).  This could mean 
that 155-Q27 and NLS155-Q27 affect luciferase folding/activity levels through an 
indirect mechanism unresolved by our studies. Taken together, our results 
provide the first evidence that polyglutamine-expanded N-terminal fragments, 
especially those that form soluble oligomers, substantially inactivate full-length 
polyglutamine-expanded AR, likely giving rise to AIS symptoms in SBMA. 
It seems less likely that the observed decrease in transactivation 
capacity can be attributed to the possible recruitment of full-length AR into 
aggregates, as proposed (Butler et al., 1998; Stenoien et al., 1999) and observed in 
our study (Figure 37). As mentioned before, sequestration does not seem to be 
very efficient and 155-Q102 formed far less aggregates than for instance, 155-Q27 
or 155-Q65, however it exerted the most prominent effect on AR transactivation 
capacity (Figure 38). The impact of the NLS tagged fragments on AR 
transactivation capacity was more prominent comparing to the untagged 
fragments (Figure 38).  
Clinical data supports the proposed effect of polyglutamine-expanded 
N-terminal fragments on full-length AR in these studies. For instance, it was 
observed that impaired spermatogenesis becomes discernible late in adulthood 
in SBMA patients (Dejager et al., 2002). AR is highly expressed in testis (Li et al., 
1998b) and was shown to be indispensable for spermatogenesis (De Gendt et al., 
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2004; Eacker et al., 2007). In SBMA patients, aggregates composed of N-terminal 
AR fragments were detected not only in neural tissue but also in testis (Adachi et 
al., 2005; Li et al., 1998b). Thus, aggregating polyglutamine-expanded fragments 
of AR are present in testis, where they would be ideally positioned to negatively 
affect AR activity required for spermatogenesis.  This mechanism would explain 
why both SBMA and infertility are usually diagnosed late in life when 
aggregating N-terminal fragments of polyglutamine-expanded AR have 
accumulated to toxic levels, and often after the patients have fathered at least one 
child (Dejager et al., 2002). 
Recent studies suggest that aggregation and toxicity of polyglutamine 
stretches within the pathological range are largely affected by it’s flanking 
sequences (Dehay and Bertolotti, 2006; Duennwald et al., 2006b). As 
polyglutamine-expanded huntingtin exon 1 (httEx1-Q96 and NLShttEx1-Q96) 
showed a comparable impact on full-length AR with 102 Q (ARQ102) as 
polyglutamine-expanded N-terminal AR fragments (155-Q102 and NLS155-
Q102), the inhibitory effect on AR transactivation capacity appear to be mainly 
driven by the polyglutamine stretch  (Figure 38, Figure 39, Figure 42 and Figure 
43). The startling implication of this result is that AR inactivation and associated 
AIS symptoms could also be an inherent aspect of Huntington’s disease (HD).  
Several intriguing lines of evidence support this notion. Human huntingtin for 
instance, is highly expressed not only in neural tissue, but also in testis (Strong et 
al., 1993; Van Raamsdonk et al., 2007). Strikingly, males affected with HD are 
frequently sexually dysfunctional as well as have testicular abnormalities and in 
analogy to the AIS in SBMA the testicular phenotype in HD occurs later in life 
(Fedoroff et al., 1994; Van Raamsdonk et al., 2007). Furthermore, testicular 
atrophy resulting in infertility, in parallel with cognitive and motor deficits was 
shown in mouse models of HD that express a polyglutamine expanded exon-1 
encoded fragment of huntingtin or, full-length polyglutamine-expanded 
huntingtin, respectively (Mangiarini et al., 1996; Sathasivam et al., 1999; Van 
Raamsdonk et al., 2006; Van Raamsdonk et al., 2005). This effect was not rescued 
upon over-expression of wild-type huntingtin (Mangiarini et al., 1996; 
Sathasivam et al., 1999; Van Raamsdonk et al., 2006; Van Raamsdonk et al., 2005). 
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The earlier proposed assumptions of decreased testosterone levels or loss of 
GnRH neurons in the hypothalamus resulting in sexual dysfunction and 
testicular atrophy could not be maintained (Papalexi et al., 2005; Van Raamsdonk 
et al., 2007). A novel explanation of these observations suggested by this study is 
that polyglutamine-expanded fragments of huntingtin inactivate AR in HD 
mouse models and patients. This would give rise to the observed testicular 
abnormalities, which in comparison to the AIS in SBMA are however far less 
frequently reported in the literature. This might be due to the fact that in SBMA, 
inactivation of AR follows a two step mechanism. Primarily, the expanded 
polyglutamine stretch confers the AR to be more prone to aggregation and to 
cleavage which reduces the amount of functional AR available (Kobayashi et al., 
1998; LaFevre-Bernt and Ellerby, 2003). According to the results of this study, the 
arising polyglutamine-expanded AR fragments inactivate full-length AR in a 
second step, which leads to an amplification of AR inactivation. In HD, the AR is 
solely susceptible to the second mechanism, inactivation by polyglutamine-
expanded (huntingtin) fragments, because of its polyglutamine stretch in the 
normal range. Furthermore, the non-pathogenic length of the polyglutamine 
stretch in AR is between 9 and ~30  repeats (Chamberlain et al., 1994; Sartor et al., 
1999) and co-aggregation has been shown to be less efficient as the 
polyglutamine stretch gets smaller (Figure 37, Figure 41;  Schaffar et al., 2004). 
Indeed, no significant decrease in transactivation capacity of AR containing 27 Q 
upon expression of polyglutamine-expanded huntingtin exon 1 was observed 
(data not shown). 
Nevertheless, this study and others have shown that proteins with 
polyglutamine stretches in the non-pathogenic range are recruited into 
aggregates composed of polyglutamine-expanded huntingtin exon 1 and become 
inactivated by polyglutamine-expanded species (Figure 41; Cha, 2000; Sakahira 
et al., 2002b; Schaffar et al., 2004). 
This study also addressed the mechanism of AR inactivation by N-
terminal polyglutamine fragments. Toxic NLS155-Q102 fragments that caused 
the greatest AR dysfunction predominantly formed soluble oligomers (Figure 27, 
Figure 33 and Figure 38). Co-Immunoprecipitation analyses revealed AR 
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inactivation correlated with enhanced binding of NLS155-Q102 oligomers to full-
length AR (Figure 40), suggesting that oligomers are likely the species directly 
involved in AR inactivation.  It may be that small amounts of these oligomers are 
also present in the 155-Q65 and NLS155-Q65 conditions and cause the mild 
decrease in AR activity (Figure 38).  Such a mild reduction in AR activity could 
indeed lead to AIS in SBMA patients, especially considering disease duration 
may span several decades.  
This study and others showed that aggregating polyglutamine-
expanded fragments have the capacity to induce misfolding of full-length disease 
proteins (Figure 37; Haacke et al., 2006). Therefore, it is likely that oligomers that 
bind to full-length AR cause dysfunction by detrimentally altering its 
conformation although it is possible that other species, such as soluble monomers 
and detergent insoluble aggregates, also participate to some degree in 
inactivation of AR. 
In summary, data derived from this yeast model system suggests dual 
mechanisms of cytotoxicity in SBMA. The polyglutamine-expansion mutation in 
AR promotes a gain-of-function mechanism that results in the formation of toxic 
oligomers, which in turn cause loss-of-function through direct interaction with 
full-length AR. Future studies exploiting this yeast model may enrich our 
understanding of SBMA and associated AIS through the identification of factors 
that modulate toxic oligomer formation and specifically protect AR from 
polyglutamine-mediated inactivation. 
 
5.3 Perspective 
This study suggests soluble polyglutamine species, and not detergent 
insoluble fibrils, are the primary toxic agent in polyglutamine diseases. 
Additionally, this work provides evidence for common structural mechanisms of 
aggregation in prion and polyglutamine diseases. This leads to the assumption 
that the toxic species and molecular mechanisms mediating cytotoxicity may be 
shared among many, if not most, amyloidoses. 
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Future studies will focus on a further characterization of the toxic 
species and how they mediate cytotoxicity. It still remains unclear if some form 
of soluble aggregate or even the misfolded monomer itself causes toxicity. Once 
identified, it will be only a matter of time until the molecular mechanisms 
mediating cytotoxicity are resolved. With regard to the common mechanisms 
underlying the amyloidoses more generally, it seems likely that progress on one 
disease will be transferable to others, which should accelerate the identification 
of the basic structural and pathogenic properties of toxic species. 
Large scale screens to identify promising compounds should 
nevertheless continue despite the present lack in knowledge about the nature of 
the toxic species. Compounds that suppress polyglutamine-mediated cytotoxicity 
might serve as tools in the analysis of toxic species and toxicity mechanisms. 
Since so far no promising compound has been developed into an effective drug, 
the hunt for therapeutical agents is mandatory. It will be important to learn 
whether suppressing aggregation or enhancing aggregation will be the road to 
success. 
 
 
 
 
 
References 129                                
 
6 References 
Abou-Sleymane, G., Chalmel, F., Helmlinger, D., Lardenois, A., Thibault, C., Weber, C., 
Merienne, K., Mandel, J.L., Poch, O., Devys, D. and Trottier, Y. (2006) Polyglutamine 
expansion causes neurodegeneration by altering the neuronal differentiation program. 
Human Molecular Genetics, 15, 691-703. 
Adachi, H., Katsuno, M., Minamiyama, M., Waza, M., Sang, C., Nakagomi, Y., Kobayashi, Y., 
Tanaka, F., Doyu, M., Inukai, A., Yoshida, M., Hashizume, Y. and Sobue, G. (2005a) 
Widespread nuclear and cytoplasmic accumulation of mutant androgen receptor in SBMA 
patients. Brain, 128, 659-670. 
Adachi, H., Waza, M., Katsuno, M., Tanaka, F., Doyu, M. and Sobue, G. (2007) Pathogenesis and 
molecular targeted therapy of spinal and bulbar muscular atrophy. Neuropathol Appl 
Neurobiol, 33, 135-151. 
Aguzzi, A. and Haass, C. (2003) Games played by rogue proteins in prion disorders and 
Alzheimer's disease. Science, 302, 814-818. 
Alberti, S., Esser, C. and Hohfeld, J. (2003) BAG-1--a nucleotide exchange factor of Hsc70 with 
multiple cellular functions. Cell Stress Chaperones, 8, 225-231. 
Alexandrescu, A.T. (2005) Amyloid accomplices and enforcers. Protein Science, 14, 1-12. 
Anderson, K.D., Panayotatos, N., Corcoran, T.L., Lindsay, R.M. and Wiegand, S.J. (1996) Ciliary 
neurotrophic factor protects striatal output neurons in an animal model of Huntington 
disease. Proc Natl Acad Sci U S A, 93, 7346-7351. 
Anfinsen, C.B. (1973) Principles that govern the folding of protein chains. Science, 181, 223-230. 
Arrasate, M., Mitra, S., Schweitzer, E.S., Segal, M.R. and Finkbeiner, S. (2004) Inclusion body 
formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature, 431, 
805-810. 
Bachoud-Levi, A.C., Maison, P., Bartolomeo, P., Boisse, M.F., Dalla Barba, G., Ergis, A.M., 
Baudic, S., Degos, J.D., Cesaro, P. and Peschanski, M. (2001) Retest effects and cognitive 
decline in longitudinal follow-up of patients with early HD. Neurology, 56, 1052-1058. 
Barral, J.M., Broadley, S.A., Schaffar, G. and Hartl, F.U. (2004) Roles of molecular chaperones in 
protein misfolding diseases. Seminars in Cell & Developmental Biology, 15, 17-29. 
Bates, G. (2000) Huntington's disease. In reverse gear. Nature, 404, 944-945. 
Bates, G. (2003) Huntingtin aggregation and toxicity in Huntington's disease. Lancet, 361, 1642-
1644. 
Bauer, H.H., Aebi, U., Haner, M., Hermann, R., Muller, M. and Merkle, H.P. (1995) Architecture 
and polymorphism of fibrillar supramolecular assemblies produced by in vitro 
aggregation of human calcitonin. Journal of Structural Biology, 115, 1-15. 
Becher, M.W., Kotzuk, J.A., Sharp, A.H., Davies, S.W., Bates, G.P., Price, D.L. and Ross, C.A. 
(1998) Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and 
pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG 
triplet repeat length. Neurobiol Dis, 4, 387-397. 
References 130                                
 
Behrends, C., Langer, C.A., Boteva, R., Bottcher, U.M., Stemp, M.J., Schaffar, G., Rao, B.V., 
Giese, A., Kretzschmar, H., Siegers, K. and Hartl, F.U. (2006) Chaperonin TRiC 
promotes the assembly of polyQ expansion proteins into nontoxic oligomers. Molecular 
Cell, 23, 887-897. 
Bence, N.F., Sampat, R.M. and Kopito, R.R. (2001) Impairment of the ubiquitin-proteasome 
system by protein aggregation.[see comment]. Science, 292, 1552-1555. 
Bennett, E.J., Bence, N.F., Jayakumar, R. and Kopito, R.R. (2005) Global impairment of the 
ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes 
inclusion body formation. Molecular Cell, 17, 351-365. 
Bennett, E.J., Shaler, T.A., Woodman, B., Ryu, K.Y., Zaitseva, T.S., Becker, C.H., Bates, G.P., 
Schulman, H. and Kopito, R.R. (2007) Global changes to the ubiquitin system in 
Huntington's disease. Nature, 448, 704-708. 
Ben-Zvi, A.P. and Goloubinoff, P. (2001) Review: mechanisms of disaggregation and refolding of 
stable protein aggregates by molecular chaperones. Journal of Structural Biology, 135, 
84-93. 
Bertsch, U., Winklhofer, K.F., Hirschberger, T., Bieschke, J., Weber, P., Hartl, F.U., Tavan, P., 
Tatzelt, J., Kretzschmar, H.A. and Giese, A. (2005) Systematic Identification of Antiprion 
Drugs by High-Throughput Screening Based on Scanning for Intensely Fluorescent 
Targets. J. Virol., 79, 7785-7791. 
Bezprozvanny, I. and Hayden, M.R. (2004) Deranged neuronal calcium signaling and Huntington 
disease. Biochem Biophys Res Commun, 322, 1310-1317. 
Blader, P. and Strahle, U. (1998) Casting an eye over cyclopia. Nature, 395, 112-113. 
Boado, R.J., Kazantsev, A., Apostol, B.L., Thompson, L.M. and Pardridge, W.M. (2000) 
Antisense-mediated down-regulation of the human huntingtin gene. J Pharmacol Exp 
Ther, 295, 239-243. 
Bodner, R.A., Outeiro, T.F., Altmann, S., Maxwell, M.M., Cho, S.H., Hyman, B.T., McLean, P.J., 
Young, A.B., Housman, D.E. and Kazantsev, A.G. (2006) Pharmacological promotion of 
inclusion formation: A therapeutic approach for Huntington's and Parkinson's diseases. 
Proceedings of the National Academy of Sciences of the United States of America, 103, 
4246-4251. 
Bonelli, R.M. and Hofmann, P. (2007) A systematic review of the treatment studies in 
Huntington's disease since 1990. Expert Opin Pharmacother, 8, 141-153. 
Boorstein, W.R. and Craig, E.A. (1990) Transcriptional regulation of SSA3, an HSP70 gene from 
Saccharomyces cerevisiae. Molecular & Cellular Biology, 10, 3262-3267. 
Borrell-Pages, M., Zala, D., Humbert, S. and Saudou, F. (2006) Huntington's disease: from 
huntingtin function and dysfunction to therapeutic strategies. Cell Mol Life Sci, 63, 2642-
2660. 
Brinkmann, A.O. (2001) Molecular basis of androgen insensitivity. Molecular & Cellular 
Endocrinology, 179, 105-109. 
Brinkmann, A.O., Faber, P.W., van Rooij, H.C., Kuiper, G.G., Ris, C., Klaassen, P., van der 
Korput, J.A., Voorhorst, M.M., van Laar, J.H., Mulder, E. and et al. (1989) The human 
References 131                                
 
androgen receptor: domain structure, genomic organization and regulation of expression. 
J Steroid Biochem, 34, 307-310. 
Brooks, B.P. and Fischbeck, K.H. (1995) Spinal and bulbar muscular atrophy - a trinucleotide-
repeat expansion neurodegenerative disease. Trends in Neurosciences, 18, 459-461. 
Brooks, B.P., Paulson, H.L., Merry, D.E., Salazar-Grueso, E.F., Brinkmann, A.O., Wilson, E.M. 
and Fischbeck, K.H. (1997) Characterization of an expanded glutamine repeat androgen 
receptor in a neuronal cell culture system. Neurobiology of Disease, 3, 313-323. 
Broome, B.M. and Hecht, M.H. (2000) Nature disfavors sequences of alternating polar and non-
polar amino acids: implications for amyloidogenesis. Journal of Molecular Biology, 296, 
961-968. 
Bucciantini, M., Giannoni, E., Chiti, F., Baroni, F., Formigli, L., Zurdo, J., Taddei, N., Ramponi, 
G., Dobson, C.M. and Stefani, M. (2002) Inherent toxicity of aggregates implies a 
common mechanism for protein misfolding diseases.[see comment]. Nature, 416, 507-
511. 
Buchanan, G., Yang, M., Cheong, A., Harris, J.M., Irvine, R.A., Lambert, P.F., Moore, N.L., 
Raynor, M., Neufing, P.J., Coetzee, G.A. and Tilley, W.D. (2004) Structural and 
functional consequences of glutamine tract variation in the androgen receptor. Human 
Molecular Genetics, 13, 1677-1692. 
Butler, R., Leigh, P.N., McPhaul, M.J. and Gallo, J.M. (1998) Truncated forms of the androgen 
receptor are associated with polyglutamine expansion in X-linked spinal and bulbar 
muscular atrophy. Human Molecular Genetics, 7, 121-127. 
Canet, D., Last, A.M., Tito, P., Sunde, M., Spencer, A., Archer, D.B., Redfield, C., Robinson, 
C.V. and Dobson, C.M. (2002) Local cooperativity in the unfolding of an amyloidogenic 
variant of human lysozyme. Nature Structural Biology, 9, 308-315. 
Caplan, A.J. and Douglas, M.G. (1991) Characterization of YDJ1: a yeast homologue of the 
bacterial dnaJ protein. J Cell Biol, 114, 609-621. 
Cattaneo, E. (2003) Dysfunction of wild-type huntingtin in Huntington disease. News Physiol Sci, 
18, 34-37. 
Cattaneo, E., Rigamonti, D., Goffredo, D., Zuccato, C., Squitieri, F. and Sipione, S. (2001) Loss of 
normal huntingtin function: new developments in Huntington's disease research. Trends 
Neurosci, 24, 182-188. 
Ceraline, J., Erdmann, E., Erbs, P., Deslandres-Cruchant, M., Jacqmin, D., Duclos, B., Klein-
Soyer, C., Dufour, P. and Bergerat, J.P. (2003) A yeast-based functional assay for the 
detection of the mutant androgen receptor in prostate cancer. European Journal of 
Endocrinology, 148, 99-110. 
Cha, J.H. (2000) Transcriptional dysregulation in Huntington's disease. Trends in Neurosciences, 
23, 387-392. 
Chai, Y., Shao, J., Miller, V.M., Williams, A. and Paulson, H.L. (2002) Live-cell imaging reveals 
divergent intracellular dynamics of polyglutamine disease proteins and supports a 
sequestration model of pathogenesis. Proceedings of the National Academy of Sciences of 
the United States of America, 99, 9310-9315. 
References 132                                
 
Chamberlain, N.L., Driver, E.D. and Miesfeld, R.L. (1994) The length and location of CAG 
trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation 
function. Nucleic Acids Research, 22, 3181-3186. 
Charrin, B.C., Saudou, F. and Humbert, S. (2005) Axonal transport failure in neurodegenerative 
disorders: the case of Huntington's disease. Pathol Biol (Paris), 53, 189-192. 
Chernoff, Y.O., Lindquist, S.L., Ono, B., Inge-Vechtomov, S.G. and Liebman, S.W. (1995) Role 
of the chaperone protein Hsp104 in propagation of the yeast prion-like factor [psi+]. 
Science, 268, 880-884. 
Chiti, F., Calamai, M., Taddei, N., Stefani, M., Ramponi, G. and Dobson, C.M. (2002a) Studies of 
the aggregation of mutant proteins in vitro provide insights into the genetics of amyloid 
diseases. Proceedings of the National Academy of Sciences of the United States of 
America, 99 Suppl 4, 16419-16426. 
Chiti, F. and Dobson, C.M. (2006) Protein misfolding, functional amyloid, and human disease. 
Annual Review of Biochemistry, 75, 333-366. 
Chiti, F., Stefani, M., Taddei, N., Ramponi, G. and Dobson, C.M. (2003) Rationalization of the 
effects of mutations on peptide and protein aggregation rates. Nature, 424, 805-808. 
Chiti, F., Taddei, N., Baroni, F., Capanni, C., Stefani, M., Ramponi, G. and Dobson, C.M. (2002b) 
Kinetic partitioning of protein folding and aggregation. Nature Structural Biology, 9, 137-
143. 
Choong, C.S., Kemppainen, J.A., Zhou, Z.X. and Wilson, E.M. (1996) Reduced androgen receptor 
gene expression with first exon CAG repeat expansion. Molecular Endocrinology, 10, 
1527-1535. 
Chow, M.K., Ellisdon, A.M., Cabrita, L.D. and Bottomley, S.P. (2004) Polyglutamine expansion 
in ataxin-3 does not affect protein stability: implications for misfolding and disease. 
Journal of Biological Chemistry, 279, 47643-47651. 
Ciechanover, A. and Brundin, P. (2003) The ubiquitin proteasome system in neurodegenerative 
diseases: sometimes the chicken, sometimes the egg. Neuron, 40, 427-446. 
Cleary, J.P., Walsh, D.M., Hofmeister, J.J., Shankar, G.M., Kuskowski, M.A., Selkoe, D.J. and 
Ashe, K.H. (2005) Natural oligomers of the amyloid-beta protein specifically disrupt 
cognitive function. Nat Neurosci, 8, 79-84. 
Colby, D.W., Chu, Y., Cassady, J.P., Duennwald, M., Zazulak, H., Webster, J.M., Messer, A., 
Lindquist, S., Ingram, V.M. and Wittrup, K.D. (2004) Potent inhibition of huntingtin 
aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular 
antibody. Proc Natl Acad Sci U S A, 101, 17616-17621. 
Conway, K.A., Harper, J.D. and Lansbury, P.T., Jr. (2000) Fibrils formed in vitro from alpha-
synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. 
Biochemistry, 39, 2552-2563. 
Cowan, C.M. and Raymond, L.A. (2006) Selective neuronal degeneration in Huntington's disease. 
Current Topics In Developmental Biology, 75, 25-71. 
Cowan, K.J., Diamond, M.I. and Welch, W.J. (2003) Polyglutamine protein aggregation and 
toxicity are linked to the cellular stress response. Human Molecular Genetics, 12, 1377-
1391. 
References 133                                
 
Craufurd, D., Thompson, J.C. and Snowden, J.S. (2001) Behavioral changes in Huntington 
Disease. Neuropsychiatry Neuropsychol Behav Neurol, 14, 219-226. 
Creighton, T.E. (1990) Protein folding. Biochemical Journal, 270, 1-16. 
Creton, R. (2004) The calcium pump of the endoplasmic reticulum plays a role in midline 
signaling during early zebrafish development. Brain Res Dev Brain Res, 151, 33-41. 
Cummings, C.J., Mancini, M.A., Antalffy, B., DeFranco, D.B., Orr, H.T. and Zoghbi, H.Y. (1998) 
Chaperone suppression of aggregation and altered subcellular proteasome localization 
imply protein misfolding in SCA1. Nat Genet, 19, 148-154. 
Daggett, V. and Fersht, A.R. (2003) Is there a unifying mechanism for protein folding? Trends in 
Biochemical Sciences, 28, 18-25. 
Danek, A., Witt, T.N., Mann, K., Schweikert, H.U., Romalo, G., La Spada, A.R. and Fischbeck, 
K.H. (1994) Decrease in androgen binding and effect of androgen treatment in a case of 
X-linked bulbospinal neuronopathy. Clinical Investigator, 72, 892-897. 
Davies, S.W., Turmaine, M., Cozens, B.A., DiFiglia, M., Sharp, A.H., Ross, C.A., Scherzinger, E., 
Wanker, E.E., Mangiarini, L. and Bates, G.P. (1997) Formation of neuronal intranuclear 
inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. 
Cell, 90, 537-548. 
Davies, T.H., Ning, Y.M. and Sanchez, E.R. (2002) A new first step in activation of steroid 
receptors: hormone-induced switching of FKBP51 and FKBP52 immunophilins. J Biol 
Chem, 277, 4597-4600. 
de Almeida, L.P., Ross, C.A., Zala, D., Aebischer, P. and Deglon, N. (2002) Lentiviral-mediated 
delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology 
modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. 
J Neurosci, 22, 3473-3483. 
De Gendt, K., Swinnen, J.V., Saunders, P.T., Schoonjans, L., Dewerchin, M., Devos, A., Tan, K., 
Atanassova, N., Claessens, F., Lecureuil, C., Heyns, W., Carmeliet, P., Guillou, F., 
Sharpe, R.M. and Verhoeven, G. (2004) A Sertoli cell-selective knockout of the androgen 
receptor causes spermatogenic arrest in meiosis. Proc Natl Acad Sci U S A, 101, 1327-
1332. 
Dehay, B. and Bertolotti, A. (2006) Critical role of the proline-rich region in Huntingtin for 
aggregation and cytotoxicity in yeast. Journal of Biological Chemistry, 281, 35608-
35615. 
Dejager, S., Bry-Gauillard, H., Bruckert, E., Eymard, B., Salachas, F., LeGuern, E., Tardieu, S., 
Chadarevian, R., Giral, P. and Turpin, G. (2002) A comprehensive endocrine description 
of Kennedy's disease revealing androgen insensitivity linked to CAG repeat length. 
Journal of Clinical Endocrinology & Metabolism, 87, 3893-3901. 
Di Prospero, N.A. and Fischbeck, K.H. (2005) Therapeutics development for triplet repeat 
expansion diseases. Nat Rev Genet., 6, 756-765. 
Difiglia, M., Sapp, E., Chase, K., Schwarz, C., Meloni, A., Young, C., Martin, E., Vonsattel, J.P., 
Carraway, R., Reeves, S.A., Boyce, F.M. and Aronin, N. (1995) Huntingtin is a 
cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron, 14, 
1075-1081. 
References 134                                
 
DiFiglia, M., Sapp, E., Chase, K.O., Davies, S.W., Bates, G.P., Vonsattel, J.P. and Aronin, N. 
(1997) Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic 
neurites in brain. Science, 277, 1990-1993. 
Dobson, C.M. (1999) Protein misfolding, evolution and disease. Trends in Biochemical Sciences, 
24, 329-332. 
Dobson, C.M. (2003) Protein folding and misfolding. Nature, 426, 884-890. 
Dragatsis, I., Levine, M.S. and Zeitlin, S. (2000) Inactivation of Hdh in the brain and testis results 
in progressive neurodegeneration and sterility in mice. Nat Genet, 26, 300-306. 
Drubin, D. (1989) The yeast Saccharomyces cerevisiae as a model organism for the cytoskeleton 
and cell biology. Cell Motil Cytoskeleton, 14, 42-49. 
Duennwald, M.L., Jagadish, S., Muchowski, P.J. and Lindquist, S. (2006a) Flanking sequences 
profoundly alter polyglutamine toxicity in yeast. Proceedings of the National Academy of 
Sciences of the United States of America, 103, 11045-11050. 
Duennwald, M.L., Jagadish, S., Muchowski, P.J. and Lindquist, S. (2006b) Flanking sequences 
profoundly alter polyglutamine toxicity in yeast. Proceedings of the National Academy of 
Sciences of the United States of America, 103, 11045-11050. 
Eacker, S.M., Shima, J.E., Connolly, C.M., Sharma, M., Holdcraft, R.W., Griswold, M.D. and 
Braun, R.E. (2007) Transcriptional profiling of androgen receptor (AR) mutants suggests 
instructive and permissive roles of AR signaling in germ cell development. Mol 
Endocrinol, 21, 895-907. 
Ecker, D.J., Khan, M.I., Marsh, J., Butt, T.R. and Crooke, S.T. (1987) Chemical synthesis and 
expression of a cassette adapted ubiquitin gene. J Biol Chem, 262, 3524-3527. 
Ellerby, L.M., Hackam, A.S., Propp, S.S., Ellerby, H.M., Rabizadeh, S., Cashman, N.R., Trifiro, 
M.A., Pinsky, L., Wellington, C.L., Salvesen, G.S., Hayden, M.R. and Bredesen, D.E. 
(1999) Kennedy's disease: caspase cleavage of the androgen receptor is a crucial event in 
cytotoxicity. Journal of Neurochemistry, 72, 185-195. 
Ellis, R.J. (2001) Macromolecular crowding: obvious but underappreciated. Trends in Biochemical 
Sciences, 26, 597-604. 
Ellis, R.J. and Hartl, F.U. (1996) Protein folding in the cell: competing models of chaperonin 
function. FASEB Journal, 10, 20-26. 
Evans, T.G., Yamamoto, Y., Jeffery, W.R. and Krone, P.H. (2005) Zebrafish Hsp70 is required for 
embryonic lens formation. Cell Stress Chaperones, 10, 66-78. 
Faber, P.W., Kuiper, G.G., van Rooij, H.C., van der Korput, J.A., Brinkmann, A.O. and Trapman, 
J. (1989) The N-terminal domain of the human androgen receptor is encoded by one, 
large exon. Mol Cell Endocrinol, 61, 257-262. 
Fan, C.Y., Ren, H.Y., Lee, P., Caplan, A.J. and Cyr, D.M. (2005) The type I Hsp40 zinc finger-
like region is required for Hsp70 to capture non-native polypeptides from Ydj1. J Biol 
Chem, 280, 695-702. 
Fandrich, M. and Dobson, C.M. (2002) The behaviour of polyamino acids reveals an inverse side 
chain effect in amyloid structure formation. EMBO Journal, 21, 5682-5690. 
References 135                                
 
Faux, N.G., Bottomley, S.P., Lesk, A.M., Irving, J.A., Morrison, J.R., de la Banda, M.G. and 
Whisstock, J.C. (2005) Functional insights from the distribution and role of homopeptide 
repeat-containing proteins. Genome Research, 15, 537-551. 
Fedoroff, J.P., Peyser, C., Franz, M.L. and Folstein, S.E. (1994) Sexual disorders in Huntington's 
disease. J Neuropsychiatry Clin Neurosci, 6, 147-153. 
Ferrao-Gonzales, A.D., Souto, S.O., Silva, J.L. and Foguel, D. (2000) The preaggregated state of 
an amyloidogenic protein: hydrostatic pressure converts native transthyretin into the 
amyloidogenic state. Proceedings of the National Academy of Sciences of the United 
States of America, 97, 6445-6450. 
Fersht, A.R. (2000) Transition-state structure as a unifying basis in protein-folding mechanisms: 
contact order, chain topology, stability, and the extended nucleus mechanism. 
Proceedings of the National Academy of Sciences of the United States of America, 97, 
1525-1529. 
Folstein, S.E., Leigh, R.J., Parhad, I.M. and Folstein, M.F. (1986) The diagnosis of Huntington's 
disease. Neurology, 36, 1279-1283. 
Freeman, B.C., Felts, S.J., Toft, D.O. and Yamamoto, K.R. (2000) The p23 molecular chaperones 
act at a late step in intracellular receptor action to differentially affect ligand efficacies. 
Genes Dev, 14, 422-434. 
Freeman, B.C. and Yamamoto, K.R. (2001) Continuous recycling: a mechanism for modulatory 
signal transduction. Trends Biochem Sci, 26, 285-290. 
Froesch, B.A., Takayama, S. and Reed, J.C. (1998) BAG-1L protein enhances androgen receptor 
function. J Biol Chem, 273, 11660-11666. 
Frydman, J. and Hartl, F.U. (1996) Principles of chaperone-assisted protein folding: differences 
between in vitro and in vivo mechanisms.[see comment]. Science, 272, 1497-1502. 
Frydman, J. and Hohfeld, J. (1997) Chaperones get in touch: the Hip-Hop connection. Trends 
Biochem Sci, 22, 87-92. 
Fusco, F.R., Chen, Q., Lamoreaux, W.J., Figueredo-Cardenas, G., Jiao, Y., Coffman, J.A., 
Surmeier, D.J., Honig, M.G., Carlock, L.R. and Reiner, A. (1999) Cellular localization of 
huntingtin in striatal and cortical neurons in rats: lack of correlation with neuronal 
vulnerability in Huntington's disease. J Neurosci, 19, 1189-1202. 
Gari, E., Piedrafita, L., Aldea, M. and Herrero, E. (1997) A set of vectors with a tetracycline-
regulatable promoter system for modulated gene expression in Saccharomyces cerevisiae. 
Yeast, 13, 837-848. 
Gatchel, J.R. and Zoghbi, H.Y. (2005) Diseases of unstable repeat expansion: mechanisms and 
common principles. Nature Reviews Genetics, 6, 743-755. 
Gauthier, L.R., Charrin, B.C., Borrell-Pages, M., Dompierre, J.P., Rangone, H., Cordelieres, F.P., 
De Mey, J., MacDonald, M.E., Lessmann, V., Humbert, S. and Saudou, F. (2004) 
Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF 
vesicular transport along microtubules. Cell, 118, 127-138. 
Geissler, S., Siegers, K. and Schiebel, E. (1998) A novel protein complex promoting formation of 
functional alpha- and gamma-tubulin. EMBO Journal, 17, 952-966. 
References 136                                
 
Gelmann, E.P. (2002) Molecular biology of the androgen receptor. Journal of Clinical Oncology, 
20, 3001-3015. 
Georget, V., Terouanne, B., Nicolas, J.C. and Sultan, C. (2002) Mechanism of antiandrogen 
action: key role of hsp90 in conformational change and transcriptional activity of the 
androgen receptor. Biochemistry, 41, 11824-11831. 
Gerber, H.P., Seipel, K., Georgiev, O., Hofferer, M., Hug, M., Rusconi, S. and Schaffner, W. 
(1994) Transcriptional activation modulated by homopolymeric glutamine and proline 
stretches. Science, 263, 808-811. 
Gervais, F.G., Singaraja, R., Xanthoudakis, S., Gutekunst, C.A., Leavitt, B.R., Metzler, M., 
Hackam, A.S., Tam, J., Vaillancourt, J.P., Houtzager, V., Rasper, D.M., Roy, S., Hayden, 
M.R. and Nicholson, D.W. (2002) Recruitment and activation of caspase-8 by the 
Huntingtin-interacting protein Hip-1 and a novel partner Hippi. Nat Cell Biol, 4, 95-105. 
Goldberg, A.L. (2003) Protein degradation and protection against misfolded or damaged proteins. 
Nature, 426, 895-899. 
Gonzalez-Alegre, P. (2007) Therapeutic RNA interference for neurodegenerative diseases: From 
promise to progress. Pharmacol Ther, 114, 34-55. 
Govaerts, C., Wille, H., Prusiner, S.B. and Cohen, F.E. (2004) Evidence for assembly of prions 
with left-handed beta-helices into trimers. Proc Natl Acad Sci U S A, 101, 8342-8347. 
Graham, R.K., Deng, Y., Slow, E.J., Haigh, B., Bissada, N., Lu, G., Pearson, J., Shehadeh, J., 
Bertram, L., Murphy, Z., Warby, S.C., Doty, C.N., Roy, S., Wellinpton, C.L., Leavitt, 
B.R., Raymond, L.A., Nicholson, D.W. and Hayden, M.R. (2006) Cleavage at the 
caspase-6 site is required for neuronal dysfunction and degeneration due to mutant 
huntingtin. Cell, 125, 1179-1191. 
Greer, L.F., 3rd and Szalay, A.A. (2002) Imaging of light emission from the expression of 
luciferases in living cells and organisms: a review. Luminescence, 17, 43-74. 
Guarente, L. (1983) Yeast promoters and lacZ fusions designed to study expression of cloned 
genes in yeast. Methods in Enzymology, 101, 181-191. 
Guijarro, J.I., Sunde, M., Jones, J.A., Campbell, I.D. and Dobson, C.M. (1998) Amyloid fibril 
formation by an SH3 domain. Proceedings of the National Academy of Sciences of the 
United States of America, 95, 4224-4228. 
Guo, J., Zhu, P., Wu, C., Yu, L., Zhao, S. and Gu, X. (2003) In silico analysis indicates a similar 
gene expression pattern between human brain and testis. Cytogenet Genome Res, 103, 58-
62. 
Gutekunst, C.A., Levey, A.I., Heilman, C.J., Whaley, W.L., Yi, H., Nash, N.R., Rees, H.D., 
Madden, J.J. and Hersch, S.M. (1995) Identification and localization of huntingtin in 
brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. 
Proceedings of the National Academy of Sciences of the United States of America, 92, 
8710-8714. 
Haacke, A., Broadley, S.A., Boteva, R., Tzvetkov, N., Hartl, F.U. and Breuer, P. (2006) 
Proteolytic cleavage of polyglutamine-expanded ataxin-3 is critical for aggregation and 
sequestration of non-expanded ataxin-3. Human Molecular Genetics, 15, 555-568. 
References 137                                
 
Hackam, A.S., Yassa, A.S., Singaraja, R., Metzler, M., Gutekunst, C.A., Gan, L., Warby, S., 
Wellington, C.L., Vaillancourt, J., Chen, N., Gervais, F.G., Raymond, L., Nicholson, 
D.W. and Hayden, M.R. (2000) Huntingtin interacting protein 1 induces apoptosis via a 
novel caspase-dependent death effector domain. J Biol Chem, 275, 41299-41308. 
Haque, N. and Isacson, O. (1997) Antisense gene therapy for neurodegenerative disease? Exp 
Neurol, 144, 139-146. 
Haque, N.S., Borghesani, P. and Isacson, O. (1997) Therapeutic strategies for Huntington's disease 
based on a molecular understanding of the disorder. Mol Med Today, 3, 175-183. 
Hardy, J. and Orr, H. (2006) The genetics of neurodegenerative diseases. Journal of 
Neurochemistry, 97, 1690-1699. 
Harjes, P. and Wanker, E.E. (2003) The hunt for huntingtin function: interaction partners tell many 
different stories. Trends Biochem Sci, 28, 425-433. 
Harper, J.D., Lieber, C.M. and Lansbury, P.T., Jr. (1997a) Atomic force microscopic imaging of 
seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-beta 
protein. Chemistry & Biology, 4, 951-959. 
Harper, J.D., Wong, S.S., Lieber, C.M. and Lansbury, P.T. (1997b) Observation of metastable 
Abeta amyloid protofibrils by atomic force microscopy. Chemistry & Biology, 4, 119-
125. 
Hartl, F.U. and Hayer-Hartl, M. (2002) Molecular chaperones in the cytosol: from nascent chain to 
folded protein. Science, 295, 1852-1858. 
Hasholt, L., Abell, K., Norremolle, A., Nellemann, C., Fenger, K. and Sorensen, S.A. (2003) 
Antisense downregulation of mutant huntingtin in a cell model. J Gene Med, 5, 528-538. 
Hazeki, N., Tukamoto, T., Goto, J. and Kanazawa, I. (2000) Formic acid dissolves aggregates of 
an N-terminal huntingtin fragment containing an expanded polyglutamine tract: applying 
to quantification of protein components of the aggregates. Biochem Biophys Res 
Commun, 277, 386-393. 
He, B., Bai, S., Hnat, A.T., Kalman, R.I., Minges, J.T., Patterson, C. and Wilson, E.M. (2004) An 
androgen receptor NH2-terminal conserved motif interacts with the COOH terminus of 
the Hsp70-interacting protein (CHIP). J Biol Chem, 279, 30643-30653. 
Heiser, V., Engemann, S., Brocker, W., Dunkel, I., Boeddrich, A., Waelter, S., Nordhoff, E., Lurz, 
R., Schugardt, N., Rautenberg, S., Herhaus, C., Barnickel, G., Bottcher, H., Lehrach, H. 
and Wanker, E.E. (2002) Identification of benzothiazoles as potential polyglutamine 
aggregation inhibitors of Huntington's disease by using an automated filter retardation 
assay. Proc Natl Acad Sci U S A., 99, 16400-16406. 
Hersch, S.M. and Ferrante, R.J. (2004) Translating therapies for Huntington's disease from genetic 
animal models to clinical trials. NeuroRx, 1, 298-306. 
Hershko, A. and Ciechanover, A. (1998) The ubiquitin system. Annual Review of Biochemistry, 
67, 425-479. 
Hirakura, Y., Azimov, R., Azimova, R. and Kagan, B.L. (2000) Polyglutamine-induced ion 
channels: a possible mechanism for the neurotoxicity of Huntington and other CAG 
repeat diseases. J Neurosci Res, 60, 490-494. 
References 138                                
 
Hirschfield, G.M. and Hawkins, P.N. (2003) Amyloidosis: new strategies for treatment. 
International Journal of Biochemistry & Cell Biology, 35, 1608-1613. 
Ho, L.W., Brown, R., Maxwell, M., Wyttenbach, A. and Rubinsztein, D.C. (2001) Wild type 
Huntingtin reduces the cellular toxicity of mutant Huntingtin in mammalian cell models 
of Huntington's disease. J Med Genet, 38, 450-452. 
Hockly, E., Tse, J., Barker, A.L., Moolman, D.L., Beunard, J.L., Revington, A.P., Holt, K., 
Sunshine, S., Moffitt, H., Sathasivam, K., Woodman, B., Wanker, E.E., Lowden, P.A. and 
Bates, G.P. (2006) Evaluation of the benzothiazole aggregation inhibitors riluzole and 
PGL-135 as therapeutics for Huntington's disease. Neurobiol Dis., 21, 228-236. 
Hohfeld, J., Minami, Y. and Hartl, F.U. (1995) Hip, a novel cochaperone involved in the 
eukaryotic Hsc70/Hsp40 reaction cycle. Cell, 83, 589-598. 
Hoogeveen, A.T., Willemsen, R., Meyer, N., Derooij, K.E., Roos, R.A.C., Vanommen, G.J.B. and 
Galjaard, H. (1993) Characterization and localization of the huntington disease gene 
product. Human Molecular Genetics, 2, 2069-2073. 
Hsiao, P.W., Lin, D.L., Nakao, R. and Chang, C. (1999) The linkage of Kennedy's neuron disease 
to ARA24, the first identified androgen receptor polyglutamine region-associated 
coactivator. Journal of Biological Chemistry, 274, 20229-20234. 
Irvine, R.A., Ma, H., Yu, M.C., Ross, R.K., Stallcup, M.R. and Coetzee, G.A. (2000) Inhibition of 
p160-mediated coactivation with increasing androgen receptor polyglutamine length. 
Human Molecular Genetics, 9, 267-274. 
Jackson, G.R., Salecker, I., Dong, X., Yao, X., Arnheim, N., Faber, P.W., MacDonald, M.E. and 
Zipursky, S.L. (1998) Polyglutamine-expanded human huntingtin transgenes induce 
degeneration of Drosophila photoreceptor neurons. Neuron, 21, 633-642. 
Jaenicke, R. (1991) Protein folding: local structures, domains, subunits, and assemblies. 
Biochemistry, 30, 3147-3161. 
Jahn, T.R. and Radford, S.E. (2005) The Yin and Yang of protein folding. FEBS Journal, 272, 
5962-5970. 
Jakob, U. and Buchner, J. (1994) Assisting spontaneity: the role of Hsp90 and small Hsps as 
molecular chaperones. Trends Biochem Sci, 19, 205-211. 
Janknecht, R. (2002) The versatile functions of the transcriptional coactivators p300 and CBP and 
their roles in disease. Histol Histopathol, 17, 657-668. 
Jia, K., Hart, A.C. and Levine, B. (2007) Autophagy genes protect against disease caused by 
polyglutamine expansion proteins in Caenorhabditis elegans. Autophagy, 3, 21-25. 
Johansen, K.L. (2004) Testosterone metabolism and replacement therapy in patients with end-
stage renal disease. Semin Dial, 17, 202-208. 
Kalchman, M.A., Koide, H.B., McCutcheon, K., Graham, R.K., Nichol, K., Nishiyama, K., 
Kazemi-Esfarjani, P., Lynn, F.C., Wellington, C., Metzler, M., Goldberg, Y.P., 
Kanazawa, I., Gietz, R.D. and Hayden, M.R. (1997) HIP1, a human homologue of S. 
cerevisiae Sla2p, interacts with membrane-associated huntingtin in the brain. Nat Genet, 
16, 44-53. 
References 139                                
 
Karlovich, C.A., John, R.M., Ramirez, L., Stainier, D.Y. and Myers, R.M. (1998) Characterization 
of the Huntington's disease (HD) gene homologue in the zebrafish Danio rerio. Gene, 217, 
117-125. 
Karplus, M. (1997) The Levinthal paradox: yesterday and today. Folding & Design, 2, S69-75. 
Katsuno, M., Adachi, H., Tanaka, F. and Sobue, G. (2004) Spinal and bulbar muscular atrophy: 
ligand-dependent pathogenesis and therapeutic perspectives. J Mol Med, 82, 298-307. 
Katsuno, M., Adachi, H., Waza, M., Banno, H., Suzuki, K., Tanaka, F., Doyu, M. and Sobue, G. 
(2006) Pathogenesis, animal models and therapeutics in spinal and bulbar muscular 
atrophy (SBMA). Experimental Neurology, 200, 8-18. 
Kayed, R., Head, E., Thompson, J.L., McIntire, T.M., Milton, S.C., Cotman, C.W. and Glabe, 
C.G. (2003) Common structure of soluble amyloid oligomers implies common 
mechanism of pathogenesis.[see comment]. Science, 300, 486-489. 
Kayed, R., Sokolov, Y., Edmonds, B., McIntire, T.M., Milton, S.C., Hall, J.E. and Glabe, C.G. 
(2004) Permeabilization of lipid bilayers is a common conformation-dependent activity of 
soluble amyloid oligomers in protein misfolding diseases. Journal of Biological 
Chemistry, 279, 46363-46366. 
Kazemi-Esfarjani, P., Trifiro, M.A. and Pinsky, L. (1995) Evidence for a repressive function of the 
long polyglutamine tract in the human androgen receptor: possible pathogenetic relevance 
for the (CAG)n-expanded neuronopathies. Human Molecular Genetics, 4, 523-527. 
Kegel, K.B., Meloni, A.R., Yi, Y., Kim, Y.J., Doyle, E., Cuiffo, B.G., Sapp, E., Wang, Y., Qin, 
Z.H., Chen, J.D., Nevins, J.R., Aronin, N. and DiFiglia, M. (2002) Huntingtin is present 
in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, 
and represses transcription. J Biol Chem, 277, 7466-7476. 
Kegel, K.B., Sapp, E., Yoder, J., Cuiffo, B., Sobin, L., Kim, Y.J., Qin, Z.H., Hayden, M.R., 
Aronin, N., Scott, D.L., Isenberg, F., Goldmann, W.H. and DiFiglia, M. (2005) 
Huntingtin associates with acidic phospholipids at the plasma membrane. Journal of 
Biological Chemistry, 280, 36464-36473. 
Kelly, J.W. (1998) The alternative conformations of amyloidogenic proteins and their multi-step 
assembly pathways. Current Opinion in Structural Biology, 8, 101-106. 
Kennedy, W.R., Alter, M. and Sung, J.H. (1968) Progressive proximal spinal and bulbar muscular 
atrophy of late onset. A sex-linked recessive trait. Neurology, 18, 671-680. 
Kim, M., Lee, H.S., LaForet, G., McIntyre, C., Martin, E.J., Chang, P., Kim, T.W., Williams, M., 
Reddy, P.H., Tagle, D., Boyce, F.M., Won, L., Heller, A., Aronin, N. and DiFiglia, M. 
(1999) Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion 
formation and neuronal survival by caspase inhibition. J Neurosci, 19, 964-973. 
Kim, S., Nollen, E.A., Kitagawa, K., Bindokas, V.P. and Morimoto, R.I. (2002) Polyglutamine 
protein aggregates are dynamic. Nature Cell Biology, 4, 826-831. 
Kimmel, C.B., Ballard, W.W., Kimmel, S.R., Ullmann, B. and Schilling, T.F. (1995) Stages of 
embryonic development of the zebrafish. Dev Dyn, 203, 253-310. 
Kisselev, A.F., Akopian, T.N., Woo, K.M. and Goldberg, A.L. (1999) The sizes of peptides 
generated from protein by mammalian 26 and 20 S proteasomes. Implications for 
References 140                                
 
understanding the degradative mechanism and antigen presentation. Journal of Biological 
Chemistry, 274, 3363-3371. 
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., 
Mizuno, Y. and Shimizu, N. (1998) Mutations in the parkin gene cause autosomal 
recessive juvenile parkinsonism.[see comment]. Nature, 392, 605-608. 
Kleizen, B. and Braakman, I. (2004) Protein folding and quality control in the endoplasmic 
reticulum.[erratum appears in Curr Opin Cell Biol. 2004 Oct;16(5):597]. Current Opinion 
in Cell Biology, 16, 343-349. 
Kobayashi, Y., Kume, A., Li, M., Doyu, M., Hata, M., Ohtsuka, K. and Sobue, G. (2000) 
Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured 
neuronal cells expressing truncated androgen receptor protein with expanded 
polyglutamine tract. J Biol Chem, 275, 8772-8778. 
Kobayashi, Y., Miwa, S., Merry, D.E., Kume, A., Mei, L., Doyu, M. and Sobue, G. (1998) 
Caspase-3 cleaves the expanded androgen receptor protein of spinal and bulbar muscular 
atrophy in a polyglutamine repeat length-dependent manner. Biochemical & Biophysical 
Research Communications, 252, 145-150. 
Kopito, R.R. (2000) Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol, 10, 
524-530. 
Krobitsch, S. and Lindquist, S. (2000) Aggregation of huntingtin in yeast varies with the length of 
the polyglutamine expansion and the expression of chaperone proteins. Proc Natl Acad 
Sci U S A, 97, 1589-1594. 
Kuemmerle, S., Gutekunst, C.A., Klein, A.M., Li, X.J., Li, S.H., Beal, M.F., Hersch, S.M. and 
Ferrante, R.J. (1999) Huntington aggregates may not predict neuronal death in 
Huntington's disease. Ann Neurol, 46, 842-849. 
La Spada, A.R., Wilson, E.M., Lubahn, D.B., Harding, A.E. and Fischbeck, K.H. (1991) 
Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. 
Nature, 352, 77-79. 
Laemmli, U.K. (1970) Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4. Nature, 227, 680-685. 
LaFevre-Bernt, M.A. and Ellerby, L.M. (2003) Kennedy's disease. Phosphorylation of the 
polyglutamine-expanded form of androgen receptor regulates its cleavage by caspase-3 
and enhances cell death. Journal of Biological Chemistry, 278, 34918-34924. 
Langer, T., Lu, C., Echols, H., Flanagan, J., Hayer, M.K. and Hartl, F.U. (1992) Successive action 
of DnaK, DnaJ and GroEL along the pathway of chaperone-mediated protein folding. 
Nature, 356, 683-689. 
Larson, J., Lynch, G., Games, D. and Seubert, P. (1999) Alterations in synaptic transmission and 
long-term potentiation in hippocampal slices from young and aged PDAPP mice. Brain 
Research, 840, 23-35. 
Leavitt, B.R., Guttman, J.A., Hodgson, J.G., Kimel, G.H., Singaraja, R., Vogl, A.W. and Hayden, 
M.R. (2001) Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in 
vivo. Am J Hum Genet, 68, 313-324. 
References 141                                
 
Leavitt, B.R., van Raamsdonk, J.M., Shehadeh, J., Fernandes, H., Murphy, Z., Graham, R.K., 
Wellington, C.L., Raymond, L.A. and Hayden, M.R. (2006a) Wild-type huntingtin 
protects neurons from excitotoxicity. Journal of Neurochemistry, 96, 1121-1129. 
Leavitt, B.R., van Raamsdonk, J.M., Shehadeh, J., Fernandes, H., Murphy, Z., Graham, R.K., 
Wellington, C.L., Raymond, L.A. and Hayden, M.R. (2006b) Wild-type huntingtin 
protects neurons from excitotoxicity. J Neurochem, 96, 1121-1129. 
Lee, W.C., Yoshihara, M. and Littleton, J.T. (2004) Cytoplasmic aggregates trap polyglutamine-
containing proteins and block axonal transport in a Drosophila model of Huntington's 
disease. Proc Natl Acad Sci U S A, 101, 3224-3229. 
Levine, B. and Klionsky, D.J. (2004) Development by self-digestion: molecular mechanisms and 
biological functions of autophagy. Developmental Cell, 6, 463-477. 
Levinthal, C. (1969) How to Fold Graciously. In DeBrunner, J.T.P. and Munck, E. (eds.), 
Mossbauer Spectroscopy in Biological Systems: Proceedings of a meeting held at 
Allerton House. University of Illinois Press, Monticello, Illinois, pp. 22-24. 
Li, M., Chevalier-Larsen, E.S., Merry, D.E. and Diamond, M.I. (2007) Soluble androgen receptor 
oligomers underlie pathology in a mouse model of spinobulbar muscular atrophy. J Biol 
Chem, 282, 3157-3164. 
Li, M., Miwa, S., Kobayashi, Y., Merry, D.E., Yamamoto, M., Tanaka, F., Doyu, M., Hashizume, 
Y., Fischbeck, K.H. and Sobue, G. (1998a) Nuclear inclusions of the androgen receptor 
protein in spinal and bulbar muscular atrophy. Annals of Neurology, 44, 249-254. 
Li, M., Nakagomi, Y., Kobayashi, Y., Merry, D.E., Tanaka, F., Doyu, M., Mitsuma, T., 
Hashizume, Y., Fischbeck, K.H. and Sobue, G. (1998b) Nonneural nuclear inclusions of 
androgen receptor protein in spinal and bulbar muscular atrophy. American Journal of 
Pathology, 153, 695-701. 
Li, S.H. and Li, X.J. (2004) Huntingtin-protein interactions and the pathogenesis of Huntington's 
disease. Trends Genet, 20, 146-154. 
Li, X.J., Li, S.H., Sharp, A.H., Nucifora, F.C., Schilling, G., Lanahan, A., Worley, P., Snyder, S.H. 
and Ross, C.A. (1995) A huntingtin-associated protein enriched in brain with implications 
for pathology. Nature, 378, 398-402. 
Lipinski, C.A., Lombardo, F., Dominy, B.W. and Feeney, P.J. (2001) Experimental and 
computational approaches to estimate solubility and permeability in drug discovery and 
development settings. Adv Drug Deliv Rev, 46, 3-26. 
Lubahn, D.B., Joseph, D.R., Sullivan, P.M., Willard, H.F., French, F.S. and Wilson, E.M. (1988) 
Cloning of human androgen receptor complementary DNA and localization to the X 
chromosome. Science, 240, 327-330. 
Lunkes, A., Lindenberg, K.S., Ben-Haiem, L., Weber, C., Devys, D., Landwehrmeyer, G.B., 
Mandel, J.L. and Trottier, Y. (2002) Proteases acting on mutant huntingtin generate 
cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol Cell, 
10, 259-269. 
Lyon, M.F. and Hawkes, S.G. (1970) X-linked gene for testicular feminization in the mouse. 
Nature, 227, 1217-1219. 
Ma, D. (2001) Applications of yeast in drug discovery. Prog Drug Res, 57, 117-162. 
References 142                                
 
MacLean, H.E., Choi, W.T., Rekaris, G., Warne, G.L. and Zajac, J.D. (1995) Abnormal androgen 
receptor binding affinity in subjects with Kennedy's disease (spinal and bulbar muscular 
atrophy). Journal of Clinical Endocrinology & Metabolism, 80, 508-516. 
Madeo, F., Herker, E., Maldener, C., Wissing, S., Lachelt, S., Herlan, M., Fehr, M., Lauber, K., 
Sigrist, S.J., Wesselborg, S. and Frohlich, K.U. (2002) A caspase-related protease 
regulates apoptosis in yeast. Molecular Cell, 9, 911-917. 
Maier, T., Ferbitz, L., Deuerling, E. and Ban, N. (2005) A cradle for new proteins: trigger factor at 
the ribosome. Current Opinion in Structural Biology, 15, 204-212. 
Malisauskas, M., Ostman, J., Darinskas, A., Zamotin, V., Liutkevicius, E., Lundgren, E. and 
Morozova-Roche, L.A. (2005) Does the cytotoxic effect of transient amyloid oligomers 
from common equine lysozyme in vitro imply innate amyloid toxicity? Journal of 
Biological Chemistry, 280, 6269-6275. 
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., 
Trottier, Y., Lehrach, H., Davies, S.W. and Bates, G.P. (1996) Exon 1 of the HD gene 
with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype 
in transgenic mice. Cell, 87, 493-506. 
Martin, J.B. and Gusella, J.F. (1986) Huntington's disease. Pathogenesis and management. N Engl 
J Med, 315, 1267-1276. 
Martin-Benito, J., Boskovic, J., Gomez-Puertas, P., Carrascosa, J.L., Simons, C.T., Lewis, S.A., 
Bartolini, F., Cowan, N.J. and Valpuesta, J.M. (2002) Structure of eukaryotic prefoldin 
and of its complexes with unfolded actin and the cytosolic chaperonin CCT. EMBO 
Journal, 21, 6377-6386. 
McCampbell, A., Taylor, J.P., Taye, A.A., Robitschek, J., Li, M., Walcott, J., Merry, D., Chai, Y., 
Paulson, H., Sobue, G. and Fischbeck, K.H. (2000) CREB-binding protein sequestration 
by expanded polyglutamine. Human Molecular Genetics, 9, 2197-2202. 
Meriin, A.B., Zhang, X., He, X., Newnam, G.P., Chernoff, Y.O. and Sherman, M.Y. (2002) 
Huntington toxicity in yeast model depends on polyglutamine aggregation mediated by a 
prion-like protein Rnq1.[erratum appears in J Cell Biol 2002 Aug 5;158(3):591]. Journal 
of Cell Biology, 157, 997-1004. 
Merry, D.E., Kobayashi, Y., Bailey, C.K., Taye, A.A. and Fischbeck, K.H. (1998) Cleavage, 
aggregation and toxicity of the expanded androgen receptor in spinal and bulbar muscular 
atrophy. Human Molecular Genetics, 7, 693-701. 
Meyer, A.S., Gillespie, J.R., Walther, D., Millet, I.S., Doniach, S. and Frydman, J. (2003) Closing 
the folding chamber of the eukaryotic chaperonin requires the transition state of ATP 
hydrolysis. Cell, 113, 369-381. 
Michalik, A. and Van Broeckhoven, C. (2003) Pathogenesis of polyglutamine disorders: 
aggregation revisited. Hum Mol Genet, 12 Spec No 2, R173-186. 
Miller, V.M., Nelson, R.F., Gouvion, C.M., Williams, A., Rodriguez-Lebron, E., Harper, S.Q., 
Davidson, B.L., Rebagliati, M.R. and Paulson, H.L. (2005) CHIP suppresses 
polyglutamine aggregation and toxicity in vitro and in vivo. Journal of Neuroscience, 25, 
9152-9161. 
References 143                                
 
Minton, A.P. (2001) The influence of macromolecular crowding and macromolecular confinement 
on biochemical reactions in physiological media. Journal of Biological Chemistry, 276, 
10577-10580. 
Modregger, J., DiProspero, N.A., Charles, V., Tagle, D.A. and Plomann, M. (2002) PACSIN 1 
interacts with huntingtin and is absent from synaptic varicosities in presymptomatic 
Huntington's disease brains. Hum Mol Genet, 11, 2547-2558. 
Moechars, D., Dewachter, I., Lorent, K., Reverse, D., Baekelandt, V., Naidu, A., Tesseur, I., 
Spittaels, K., Haute, C.V., Checler, F., Godaux, E., Cordell, B. and Van Leuven, F. (1999) 
Early phenotypic changes in transgenic mice that overexpress different mutants of 
amyloid precursor protein in brain. Journal of Biological Chemistry, 274, 6483-6492. 
Monoi, H., Futaki, S., Kugimiya, S., Minakata, H. and Yoshihara, K. (2000) Poly-L-glutamine 
forms cation channels: relevance to the pathogenesis of the polyglutamine diseases. 
Biophys J, 78, 2892-2899. 
Mooradian, A.D., Morley, J.E. and Korenman, S.G. (1987) Biological actions of androgens. 
Endocrine Reviews, 8, 1-28. 
Muchowski, P.J., Schaffar, G., Sittler, A., Wanker, E.E., Hayer-Hartl, M.K. and Hartl, F.U. (2000) 
Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into 
amyloid-like fibrils. Proc Natl Acad Sci U S A, 97, 7841-7846. 
Muchowski, P.J. and Wacker, J.L. (2005) Modulation of neurodegeneration by molecular 
chaperones. Nat Rev Neurosci, 6, 11-22. 
Mullins, M.C., Hammerschmidt, M., Haffter, P. and Nusslein-Volhard, C. (1994) Large-scale 
mutagenesis in the zebrafish: in search of genes controlling development in a vertebrate. 
Curr Biol, 4, 189-202. 
Mumberg, D., Muller, R. and Funk, M. (1994) Regulatable promoters of Saccharomyces 
cerevisiae: comparison of transcriptional activity and their use for heterologous 
expression. Nucleic Acids Research, 22, 5767-5768. 
Nagai, Y., Fujikake, N., Ohno, K., Higashiyama, H., Popiel, H.A., Rahadian, J., Yamaguchi, M., 
Strittmatter, W.J., Burke, J.R. and Toda, T. (2003) Prevention of polyglutamine 
oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila. 
Hum Mol Genet, 12, 1253-1259. 
Nagai, Y., Inui, T., Popiel, H.A., Fujikake, N., Hasegawa, K., Urade, Y., Goto, Y., Naiki, H. and 
Toda, T. (2007) A toxic monomeric conformer of the polyglutamine protein. Nat Struct 
Mol Biol, 14, 332-340. 
Naiki, H., Gejyo, F. and Nakakuki, K. (1997) Concentration-dependent inhibitory effects of 
apolipoprotein E on Alzheimer's beta-amyloid fibril formation in vitro. Biochemistry, 36, 
6243-6250. 
Nellemann, C., Abell, K., Norremolle, A., Lokkegaard, T., Naver, B., Ropke, C., Rygaard, J., 
Sorensen, S.A. and Hasholt, L. (2000) Inhibition of Huntington synthesis by antisense 
oligodeoxynucleotides. Mol Cell Neurosci, 16, 313-323. 
Nguyen, H.D. and Hall, C.K. (2004) Molecular dynamics simulations of spontaneous fibril 
formation by random-coil peptides. Proceedings of the National Academy of Sciences of 
the United States of America, 101, 16180-16185. 
References 144                                
 
Nucifora, F.C., Jr., Sasaki, M., Peters, M.F., Huang, H., Cooper, J.K., Yamada, M., Takahashi, H., 
Tsuji, S., Troncoso, J., Dawson, V.L., Dawson, T.M. and Ross, C.A. (2001) Interference 
by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. 
Science, 291, 2423-2428. 
Oliveira, J.M.A., Chen, S., Almeida, S., Riley, R., Goncalves, J., Oliveira, C.R., Hayden, M.R., 
Nicholls, D.G., Ellerby, L.M. and Rego, A.C. (2006) Mitochondrial-dependent Ca2+ 
handling in Huntington's disease striatal cells: Effect of histone deacetylase inhibitors. 
Journal of Neuroscience, 26, 11174-11186. 
Oliveira, J.M.A., Jekabsons, M.B., Chen, S., Lin, A., Rego, A.C., Goncalves, J., Ellerby, L.M. and 
Nicholls, D.G. (2007) Mitochondrial dysfunction in Huntington's disease: the 
bioenergetics of isolated and in situ mitochondria from transgenic mice. Journal of 
Neurochemistry, 101, 241-249. 
Orr, H.T. and Zoghbi, H.Y. (2001) SCA1 molecular genetics: a history of a 13 year collaboration 
against glutamines. Human Molecular Genetics, 10, 2307-2311. 
Otzen, D.E., Kristensen, O. and Oliveberg, M. (2000) Designed protein tetramer zipped together 
with a hydrophobic Alzheimer homology: a structural clue to amyloid assembly. 
Proceedings of the National Academy of Sciences of the United States of America, 97, 
9907-9912. 
Pandey, U.B., Nie, Z., Batlevi, Y., McCray, B.A., Ritson, G.P., Nedelsky, N.B., Schwartz, S.L., 
DiProspero, N.A., Knight, M.A., Schuldiner, O., Padmanabhan, R., Hild, M., Berry, D.L., 
Garza, D., Hubbert, C.C., Yao, T.P., Baehrecke, E.H. and Taylor, J.P. (2007) HDAC6 
rescues neurodegeneration and provides an essential link between autophagy and the 
UPS. Nature, 447, 860-864. 
Papalexi, E., Persson, A., Bjorkqvist, M., Petersen, A., Woodman, B., Bates, G.P., Sundler, F., 
Mulder, H., Brundin, P. and Popovic, N. (2005) Reduction of GnRH and infertility in the 
R6/2 mouse model of Huntington's disease. Eur J Neurosci, 22, 1541-1546. 
Pedersen, J.S., Christensen, G. and Otzen, D.E. (2004) Modulation of S6 fibrillation by unfolding 
rates and gatekeeper residues. Journal of Molecular Biology, 341, 575-588. 
Pedersen, J.S., Dikov, D., Flink, J.L., Hjuler, H.A., Christiansen, G. and Otzen, D.E. (2006) The 
changing face of glucagon fibrillation: structural polymorphism and conformational 
imprinting. Journal of Molecular Biology, 355, 501-523. 
Perez, M.K., Paulson, H.L., Pendse, S.J., Saionz, S.J., Bonini, N.M. and Pittman, R.N. (1998) 
Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation. 
Journal of Cell Biology, 143, 1457-1470. 
Perez-Navarro, E., Akerud, P., Marco, S., Canals, J.M., Tolosa, E., Arenas, E. and Alberch, J. 
(2000) Neurturin protects striatal projection neurons but not interneurons in a rat model of 
Huntington's disease. Neuroscience, 98, 89-96. 
Peters, M.F., Nucifora, F.C., Jr., Kushi, J., Seaman, H.C., Cooper, J.K., Herring, W.J., Dawson, 
V.L., Dawson, T.M. and Ross, C.A. (1999) Nuclear targeting of mutant Huntingtin 
increases toxicity. Mol Cell Neurosci, 14, 121-128. 
Petersen, A. and Brundin, P. (1999) Effects of ciliary neurotrophic factor on excitotoxicity and 
calcium-ionophore A23187-induced cell death in cultured embryonic striatal neurons. Exp 
Neurol, 160, 402-412. 
References 145                                
 
Petty, S.A., Adalsteinsson, T. and Decatur, S.M. (2005) Correlations among morphology, beta-
sheet stability, and molecular structure in prion peptide aggregates. Biochemistry, 44, 
4720-4726. 
Picard, D. (2006) Chaperoning steroid hormone action. Trends in Endocrinology & Metabolism, 
17, 229-235. 
Piccioni, F., Pinton, P., Simeoni, S., Pozzi, P., Fascio, U., Vismara, G., Martini, L., Rizzuto, R. 
and Poletti, A. (2002) Androgen receptor with elongated polyglutamine tract forms 
aggregates that alter axonal trafficking and mitochondrial distribution in motor neuronal 
processes. Faseb J, 16, 1418-1420. 
Piccioni, F., Simeoni, S., Andriola, I., Armatura, E., Bassanini, S., Pozzi, P. and Poletti, A. (2001) 
Polyglutamine tract expansion of the androgen receptor in a motoneuronal model of 
spinal and bulbar muscular atrophy. Brain Research Bulletin, 56, 215-220. 
Pickart, C.M. and Cohen, R.E. (2004) Proteasomes and their kin: proteases in the machine age. 
Nature Reviews Molecular Cell Biology, 5, 177-187. 
Pinsky, L., Trifiro, M., Kaufman, M., Beitel, L.K., Mhatre, A., Kazemi-Esfarjani, P., Sabbaghian, 
N., Lumbroso, R., Alvarado, C. and Vasiliou, M. (1992) Androgen resistance due to 
mutation of the androgen receptor. Clinical & Investigative Medicine - Medecine Clinique 
et Experimentale, 15, 456-472. 
Plakoutsi, G., Bemporad, F., Calamai, M., Taddei, N., Dobson, C.M. and Chiti, F. (2005) 
Evidence for a mechanism of amyloid formation involving molecular reorganisation 
within native-like precursor aggregates. Journal of Molecular Biology, 351, 910-922. 
Poirier, M.A., Li, H., Macosko, J., Cai, S., Amzel, M. and Ross, C.A. (2002) Huntingtin spheroids 
and protofibrils as precursors in polyglutamine fibrilization. J Biol Chem, 277, 41032-
41037. 
Pratt, W.B., Galigniana, M.D., Morishima, Y. and Murphy, P.J. (2004) Role of molecular 
chaperones in steroid receptor action. Essays Biochem, 40, 41-58. 
Pratt, W.B. and Toft, D.O. (1997) Steroid receptor interactions with heat shock protein and 
immunophilin chaperones. Endocr Rev, 18, 306-360. 
Preisinger, E., Jordan, B.M., Kazantsev, A. and Housman, D. (1999) Evidence for a recruitment 
and sequestration mechanism in Huntington's disease. Philosophical Transactions of the 
Royal Society of London - Series B: Biological Sciences, 354, 1029-1034. 
Prescott, J. and Coetzee, G.A. (2006) Molecular chaperones throughout the life cycle of the 
androgen receptor. Cancer Letters, 231, 12-19. 
Radford, S.E., Dobson, C.M. and Evans, P.A. (1992) The folding of hen lysozyme involves 
partially structured intermediates and multiple pathways.[see comment]. Nature, 358, 
302-307. 
Raffen, R., Dieckman, L.J., Szpunar, M., Wunschl, C., Pokkuluri, P.R., Dave, P., Wilkins Stevens, 
P., Cai, X., Schiffer, M. and Stevens, F.J. (1999) Physicochemical consequences of amino 
acid variations that contribute to fibril formation by immunoglobulin light chains. Protein 
Science, 8, 509-517. 
References 146                                
 
Rajan, R.S., Illing, M.E., Bence, N.F. and Kopito, R.R. (2001) Specificity in intracellular protein 
aggregation and inclusion body formation. Proceedings of the National Academy of 
Sciences of the United States of America, 98, 13060-13065. 
Rajender, S., Singh, L. and Thangaraj, K. (2007) Phenotypic heterogeneity of mutations in 
androgen receptor gene. Asian J Androl, 9, 147-179. 
Rassow, J., Voos, W. and Pfanner, N. (1995) Partner proteins determine multiple functions of 
Hsp70. Trends Cell Biol, 5, 207-212. 
Ravikumar, B., Duden, R. and Rubinsztein, D.C. (2002) Aggregate-prone proteins with 
polyglutamine and polyalanine expansions are degraded by autophagy. Human Molecular 
Genetics, 11, 1107-1117. 
Ravikumar, B., Vacher, C., Berger, Z., Davies, J.E., Luo, S.Q., Oroz, L.G., Scaravilli, F., Easton, 
D.F., Duden, R., O'Kane, C.J. and Rubinsztein, D.C. (2004) Inhibition of mTOR induces 
autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of 
Huntington disease. Nature Genetics, 36, 585-595. 
Richter, K. and Buchner, J. (2001) Hsp90: chaperoning signal transduction. Journal of Cellular 
Physiology, 188, 281-290. 
Rigamonti, D., Bauer, J.H., De-Fraja, C., Conti, L., Sipione, S., Sciorati, C., Clementi, E., 
Hackam, A., Hayden, M.R., Li, Y., Cooper, J.K., Ross, C.A., Govoni, S., Vincenz, C. and 
Cattaneo, E. (2000) Wild-type huntingtin protects from apoptosis upstream of caspase-3. 
J Neurosci, 20, 3705-3713. 
Riley, B.E. and Orr, H.T. (2006) Polyglutamine neurodegenerative diseases and regulation of 
transcription: assembling the puzzle. Genes & Development, 20, 2183-2192. 
Romisch, K. (2005) Endoplasmic reticulum-associated degradation. Annual Review of Cell & 
Developmental Biology, 21, 435-456. 
Ross, C.A. and Poirier, M.A. (2005) Opinion: What is the role of protein aggregation in 
neurodegeneration? Nat Rev Mol Cell Biol, 6, 891-898. 
Rubinstein, A.L. (2003) Zebrafish: from disease modeling to drug discovery. Curr Opin Drug 
Discov Devel, 6, 218-223. 
Rubinsztein, D.C. (2002) Lessons from animal models of Huntington's disease. Trends Genet, 18, 
202-209. 
Rubinsztein, D.C., Gestwicki, J.E., Murphy, L.O. and Klionsky, D.J. (2007) Potential therapeutic 
applications of autophagy. Nature Reviews, Drug Discovery. 6, 304-312. 
Rudiger, S., Schneider-Mergener, J. and Bukau, B. (2001) Its substrate specificity characterizes the 
DnaJ co-chaperone as a scanning factor for the DnaK chaperone. EMBO Journal, 20, 
1042-1050. 
Saiki, M., Honda, S., Kawasaki, K., Zhou, D., Kaito, A., Konakahara, T. and Morii, H. (2005) 
Higher-order molecular packing in amyloid-like fibrils constructed with linear 
arrangements of hydrophobic and hydrogen-bonding side-chains. Journal of Molecular 
Biology, 348, 983-998. 
References 147                                
 
Sakahira, H., Breuer, P., Hayer-Hartl, M.K. and Hartl, F.U. (2002a) Molecular chaperones as 
modulators of polyglutamine protein aggregation and toxicity. Proc Natl Acad Sci U S A, 
99 Suppl 4, 16412-16418. 
Sakahira, H., Breuer, P., Hayer-Hartl, M.K. and Hartl, F.U. (2002b) Molecular chaperones as 
modulators of polyglutamine protein aggregation and toxicity. Proceedings of the 
National Academy of Sciences of the United States of America, 99 Suppl 4, 16412-16418. 
Sanchez, I., Mahlke, C. and Yuan, J. (2003) Pivotal role of oligomerization in expanded 
polyglutamine neurodegenerative disorders. Nature, 421, 373-379. 
Saric, T., Graef, C.I. and Goldberg, A.L. (2004) Pathway for degradation of peptides generated by 
proteasomes: a key role for thimet oligopeptidase and other metallopeptidases. Journal of 
Biological Chemistry, 279, 46723-46732. 
Sartor, O., Zheng, Q. and Eastham, J.A. (1999) Androgen receptor gene CAG repeat length varies 
in a race-specific fashion in men without prostate cancer. Urology, 53, 378-380. 
Sathasivam, K., Hobbs, C., Mangiarini, L., Mahal, A., Turmaine, M., Doherty, P., Davies, S.W. 
and Bates, G.P. (1999) Transgenic models of Huntington's disease. Philos Trans R Soc 
Lond B Biol Sci, 354, 963-969. 
Satyal, S.H., Schmidt, E., Kitagawa, K., Sondheimer, N., Lindquist, S., Kramer, J.M. and 
Morimoto, R.I. (2000) Polyglutamine aggregates alter protein folding homeostasis in 
Caenorhabditis elegans. Proc Natl Acad Sci U S A, 97, 5750-5755. 
Saudou, F., Finkbeiner, S., Devys, D. and Greenberg, M.E. (1998) Huntingtin acts in the nucleus 
to induce apoptosis but death does not correlate with the formation of intranuclear 
inclusions. Cell, 95, 55-66. 
Schaffar, G., Breuer, P., Boteva, R., Behrends, C., Tzvetkov, N., Strippel, N., Sakahira, H., 
Siegers, K., Hayer-Hartl, M. and Hartl, F.U. (2004) Cellular toxicity of polyglutamine 
expansion proteins:  Mechanism of transcription factor deactivation. Molecular Cell, 15, 
95-105. 
Scherzinger, E., Lurz, R., Turmaine, M., Mangiarini, L., Hollenbach, B., Hasenbank, R., Bates, 
G.P., Davies, S.W., Lehrach, H. and Wanker, E.E. (1997) Huntingtin-encoded 
polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell, 
90, 549-558. 
Schmidt, B.J., Greenberg, C.R., Allingham-Hawkins, D.J. and Spriggs, E.L. (2002) Expression of 
X-linked bulbospinal muscular atrophy (Kennedy disease) in two homozygous women. 
Neurology, 59, 770-772. 
Schmittschmitt, J.P. and Scholtz, J.M. (2003) The role of protein stability, solubility, and net 
charge in amyloid fibril formation. Protein Science, 12, 2374-2378. 
Schroder, M. and Kaufman, R.J. (2005) The mammalian unfolded protein response. Annual 
Review of Biochemistry, 74, 739-789. 
Seo, H., Sonntag, K.C., Kim, W., Cattaneo, E. and Isacson, O. (2007) Proteasome Activator 
Enhances Survival of Huntington's Disease Neuronal Model Cells. PLoS ONE, 2, e238. 
Serio, T.R., Cashikar, A.G., Kowal, A.S., Sawicki, G.J., Moslehi, J.J., Serpell, L., Arnsdorf, M.F. 
and Lindquist, S.L. (2000) Nucleated conformational conversion and the replication of 
conformational information by a prion determinant. Science, 289, 1317-1321. 
References 148                                
 
Serpell, L.C., Sunde, M., Benson, M.D., Tennent, G.A., Pepys, M.B. and Fraser, P.E. (2000) The 
protofilament substructure of amyloid fibrils. Journal of Molecular Biology, 300, 1033-
1039. 
Sha, B., Lee, S. and Cyr, D.M. (2000) The crystal structure of the peptide-binding fragment from 
the yeast Hsp40 protein Sis1.[see comment]. Structure, 8, 799-807. 
Shatkina, L., Mink, S., Rogatsch, H., Klocker, H., Langer, G., Nestl, A. and Cato, A.C. (2003) The 
cochaperone Bag-1L enhances androgen receptor action via interaction with the NH2-
terminal region of the receptor. Mol Cell Biol, 23, 7189-7197. 
Shimohata, M., Shimohata, T., Igarashi, S., Naruse, S. and Tsuji, S. (2005) Interference of CREB-
dependent transcriptional activation by expanded polyglutamine stretches--augmentation 
of transcriptional activation as a potential therapeutic strategy for polyglutamine diseases. 
J Neurochem, 93, 654-663. 
Sikorski, R.S. and Hieter, P. (1989) A system of shuttle vectors and yeast host strains designed for 
efficient manipulation of DNA in Saccharomyces cerevisiae. Genetics, 122, 19-27. 
Simental, J.A., Sar, M., Lane, M.V., French, F.S. and Wilson, E.M. (1991) Transcriptional 
activation and nuclear targeting signals of the human androgen receptor. J Biol Chem, 
266, 510-518. 
Singaraja, R.R., Hadano, S., Metzler, M., Givan, S., Wellington, C.L., Warby, S., Yanai, A., 
Gutekunst, C.A., Leavitt, B.R., Yi, H., Fichter, K., Gan, L., McCutcheon, K., Chopra, V., 
Michel, J., Hersch, S.M., Ikeda, J.E. and Hayden, M.R. (2002) HIP14, a novel ankyrin 
domain-containing protein, links huntingtin to intracellular trafficking and endocytosis. 
Hum Mol Genet, 11, 2815-2828. 
Singh, R., Artaza, J.N., Taylor, W.E., Braga, M., Yuan, X., Gonzalez-Cadavid, N.F. and Bhasin, S. 
(2006) Testosterone inhibits adipogenic differentiation in 3T3-L1 cells: nuclear 
translocation of androgen receptor complex with beta-catenin and T-cell factor 4 may 
bypass canonical Wnt signaling to down-regulate adipogenic transcription factors. 
Endocrinology, 147, 141-154. 
Sipe, J.D. and Cohen, A.S. (2000) Review: history of the amyloid fibril. Journal of Structural 
Biology, 130, 88-98. 
Sirangelo, I., Malmo, C., Iannuzzi, C., Mezzogiorno, A., Bianco, M.R., Papa, M. and Irace, G. 
(2004) Fibrillogenesis and cytotoxic activity of the amyloid-forming apomyoglobin 
mutant W7FW14F. Journal of Biological Chemistry, 279, 13183-13189. 
Slow, E.J., Graham, R.K., Osmand, A.P., Devon, R.S., Lu, G., Deng, Y., Pearson, J., Vaid, K., 
Bissada, N., Wetzel, R., Leavitt, B.R. and Hayden, M.R. (2005) Absence of behavioral 
abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin 
inclusions. Proceedings of the National Academy of Sciences of the United States of 
America, 102, 11402-11407. 
Smith, D.F. (1993) Dynamics of heat shock protein 90-progesterone receptor binding and the 
disactivation loop model for steroid receptor complexes. Mol Endocrinol, 7, 1418-1429. 
Smith, D.F. and Toft, D.O. (1993) Steroid receptors and their associated proteins. Mol Endocrinol, 
7, 4-11. 
References 149                                
 
Sobue, G., Doyu, M., Kachi, T., Yasuda, T., Mukai, E., Kumagai, T. and Mitsuma, T. (1993) 
Subclinical phenotypic expressions in heterozygous females of X-linked recessive 
bulbospinal neuronopathy. Journal of the Neurological Sciences, 117, 74-78. 
Sobue, G., Hashizume, Y., Mukai, E., Hirayama, M., Mitsuma, T. and Takahashi, A. (1989) X-
linked recessive bulbospinal neuronopathy. A clinicopathological study. Brain, 112 ( Pt 
1), 209-232. 
Sopher, B.L., Thomas, P.S., Jr., LaFevre-Bernt, M.A., Holm, I.E., Wilke, S.A., Ware, C.B., Jin, 
L.W., Libby, R.T., Ellerby, L.M. and La Spada, A.R. (2004) Androgen receptor YAC 
transgenic mice recapitulate SBMA motor neuronopathy and implicate VEGF164 in the 
motor neuron degeneration.[see comment]. Neuron, 41, 687-699. 
Stefani, M. (2004) Protein misfolding and aggregation: new examples in medicine and biology of 
the dark side of the protein world. Biochimica et Biophysica Acta, 1739, 5-25. 
Stenoien, D.L., Cummings, C.J., Adams, H.P., Mancini, M.G., Patel, K., DeMartino, G.N., 
Marcelli, M., Weigel, N.L. and Mancini, M.A. (1999) Polyglutamine-expanded androgen 
receptors form aggregates that sequester heat shock proteins, proteasome components and 
SRC-1, and are suppressed by the HDJ-2 chaperone. Human Molecular Genetics, 8, 731-
741. 
Stork, M., Giese, A., Kretzschmar, H.A. and Tavan, P. (2005) Molecular dynamics simulations 
indicate a possible role of parallel beta-helices in seeded aggregation of poly-Gln. Biophys 
J., 88, 2442-2451. 
Strong, T.V., Tagle, D.A., Valdes, J.M., Elmer, L.W., Boehm, K., Swaroop, M., Kaatz, K.W., 
Collins, F.S. and Albin, R.L. (1993) Widespread expression of the human and rat 
Huntington's disease gene in brain and nonneural tissues. Nat Genet, 5, 259-265. 
Sugars, K.L. and Rubinsztein, D.C. (2003) Transcriptional abnormalities in Huntington disease. 
Trends Genet, 19, 233-238. 
Sunde, M. and Blake, C. (1997) The structure of amyloid fibrils by electron microscopy and X-ray 
diffraction. Advances in Protein Chemistry, 50, 123-159. 
Takahashi, Y., Okamoto, Y., Popiel, H.A., Fujikake, N., Toda, T., Kinjo, M. and Nagai, Y. (2007) 
Detection of polyglutamine protein oligomers in cells by fluorescence correlation 
spectroscopy. J Biol Chem, 282, 24039-24048. 
Takeyama, K., Ito, S., Yamamoto, A., Tanimoto, H., Furutani, T., Kanuka, H., Miura, M., Tabata, 
T. and Kato, S. (2002) Androgen-dependent neurodegeneration by polyglutamine-
expanded human androgen receptor in Drosophila. Neuron, 35, 855-864. 
Thomas, P.S., Fraley, G.S., Damien, V., Woodke, L.B., Zapata, F., Sopher, B.L., Plymate, S.R. 
and La Spada, A.R. (2006) Loss of endogenous androgen receptor protein accelerates 
motor neuron degeneration and accentuates androgen insensitivity in a mouse model of 
X-linked spinal and bulbar muscular atrophy. Human Molecular Genetics, 15, 2225-2238. 
Towbin, H., Staehelin, T. and Gordon, J. (1979) Electrophoretic transfer of proteins from 
polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl 
Acad Sci U S A, 76, 4350-4354. 
Trottier, Y., Devys, D., Imbert, G., Saudou, F., An, I., Lutz, Y., Weber, C., Agid, Y., Hirsch, E.C. 
and Mandel, J.L. (1995) Cellular localization of the huntingtons disease protein and 
discrimination of the normal and mutated form. Nature Genetics, 10, 104-110. 
References 150                                
 
Truant, R., Atwal, R.S. and Burtnik, A. (2007) Nucleocytoplasmic trafficking and transcription 
effects of huntingtin in Huntington's disease. Prog Neurobiol, 83, 211-227. 
Trushina, E. and McMurray, C.T. (2007) Oxidative stress and mitochondrial dysfunction in 
neurodegenerative diseases. Neuroscience, 145, 1233-1248. 
Tut, T.G., Ghadessy, F.J., Trifiro, M.A., Pinsky, L. and Yong, E.L. (1997) Long polyglutamine 
tracts in the androgen receptor are associated with reduced trans-activation, impaired 
sperm production, and male infertility. Journal of Clinical Endocrinology & Metabolism, 
82, 3777-3782. 
Tycko, R. (2004) Progress towards a molecular-level structural understanding of amyloid fibrils. 
Current Opinion in Structural Biology, 14, 96-103. 
Uversky, V.N. and Fink, A.L. (2004) Conformational constraints for amyloid fibrillation: the 
importance of being unfolded. Biochimica et Biophysica Acta, 1698, 131-153. 
Uversky, V.N., Li, J., Souillac, P., Millett, I.S., Doniach, S., Jakes, R., Goedert, M. and Fink, A.L. 
(2002) Biophysical properties of the synucleins and their propensities to fibrillate: 
inhibition of alpha-synuclein assembly by beta- and gamma-synucleins. Journal of 
Biological Chemistry, 277, 11970-11978. 
Vainberg, I.E., Lewis, S.A., Rommelaere, H., Ampe, C., Vandekerckhove, J., Klein, H.L. and 
Cowan, N.J. (1998) Prefoldin, a chaperone that delivers unfolded proteins to cytosolic 
chaperonin. Cell, 93, 863-873. 
van Anken, E. and Braakman, I. (2005a) Endoplasmic reticulum stress and the making of a 
professional secretory cell. Critical Reviews in Biochemistry & Molecular Biology, 40, 
269-283. 
van Anken, E. and Braakman, I. (2005b) Versatility of the endoplasmic reticulum protein folding 
factory. Critical Reviews in Biochemistry & Molecular Biology, 40, 191-228. 
van der Sar, A.M., Appelmelk, B.J., Vandenbroucke-Grauls, C.M. and Bitter, W. (2004) A star 
with stripes: zebrafish as an infection model. Trends Microbiol, 12, 451-457. 
Van Raamsdonk, J.M., Gibson, W.T., Pearson, J., Murphy, Z., Lu, G., Leavitt, B.R. and Hayden, 
M.R. (2006) Body weight is modulated by levels of full-length Huntingtin. Human 
Molecular Genetics, 15, 1513-1523. 
Van Raamsdonk, J.M., Murphy, Z., Selva, D.M., Hamidizadeh, R., Pearson, J., Petersen, A., 
Bjorkqvist, M., Muir, C., Mackenzie, I.R., Hammond, G.L., Vogl, A.W., Hayden, M.R. 
and Leavitt, B.R. (2007) Testicular degeneration in Huntington disease. Neurobiol Dis, 
26, 512-520. 
Van Raamsdonk, J.M., Murphy, Z., Slow, E.J., Leavitt, B.R. and Hayden, M.R. (2005) Selective 
degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model 
of Huntington disease. Human Molecular Genetics, 14, 3823-3835. 
Venkatraman, P., Wetzel, R., Tanaka, M., Nukina, N. and Goldberg, A.L. (2004) Eukaryotic 
proteasomes cannot digest polyglutamine sequences and release them during degradation 
of polyglutamine-containing proteins. Molecular Cell, 14, 95-104. 
Ventimiglia, R., Mather, P.E., Jones, B.E. and Lindsay, R.M. (1995) The neurotrophins BDNF, 
NT-3 and NT-4/5 promote survival and morphological and biochemical differentiation of 
striatal neurons in vitro. Eur J Neurosci, 7, 213-222. 
References 151                                
 
Vonsattel, J.P., Myers, R.H., Stevens, T.J., Ferrante, R.J., Bird, E.D. and Richardson, E.P., Jr. 
(1985) Neuropathological classification of Huntington's disease. J Neuropathol Exp 
Neurol, 44, 559-577. 
Walsh, D.M., Hartley, D.M., Kusumoto, Y., Fezoui, Y., Condron, M.M., Lomakin, A., Benedek, 
G.B., Selkoe, D.J. and Teplow, D.B. (1999) Amyloid beta-protein fibrillogenesis. 
Structure and biological activity of protofibrillar intermediates. Journal of Biological 
Chemistry, 274, 25945-25952. 
Walsh, D.M., Klyubin, I., Fadeeva, J.V., Cullen, W.K., Anwyl, R., Wolfe, M.S., Rowan, M.J. and 
Selkoe, D.J. (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit 
hippocampal long-term potentiation in vivo. Nature, 416, 535-539. 
Walsh, D.M., Lomakin, A., Benedek, G.B., Condron, M.M. and Teplow, D.B. (1997) Amyloid 
beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. Journal of 
Biological Chemistry, 272, 22364-22372. 
Wang, W., Duan, W.Z., Igarashi, S., Morita, H., Nakamura, M. and Ross, C.A. (2005) Compounds 
blocking mutant huntingtin toxicity identified using a Huntington's disease neuronal cell 
model. Neurobiology of Disease, 20, 500-508. 
Wanker, E.E., Rovira, C., Scherzinger, E., Hasenbank, R., Walter, S., Tait, D., Colicelli, J. and 
Lehrach, H. (1997) HIP-I: a huntingtin interacting protein isolated by the yeast two-
hybrid system. Hum Mol Genet, 6, 487-495. 
Warner, C.L., Griffin, J.E., Wilson, J.D., Jacobs, L.D., Murray, K.R., Fischbeck, K.H., Dickoff, D. 
and Griggs, R.C. (1992) X-linked spinomuscular atrophy: a kindred with associated 
abnormal androgen receptor binding. Neurology, 42, 2181-2184. 
Warrick, J.M., Chan, H.Y., Gray-Board, G.L., Chai, Y., Paulson, H.L. and Bonini, N.M. (1999) 
Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the 
molecular chaperone HSP70. Nat Genet, 23, 425-428. 
Waza, M., Adachi, H., Katsuno, M., Minamiyama, M., Sang, C., Tanaka, F., Inukai, A., Doyu, M. 
and Sobue, G. (2005) 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated 
motor neuron degeneration. Nature Medicine, 11, 1088-1095. 
Webb, J.L., Ravikumar, B., Atkins, J., Skepper, J.N. and Rubinsztein, D.C. (2003) Alpha-
Synuclein is degraded by both autophagy and the proteasome. Journal of Biological 
Chemistry, 278, 25009-25013. 
Wellington, C.L., Ellerby, L.M., Hackam, A.S., Margolis, R.L., Trifiro, M.A., Singaraja, R., 
McCutcheon, K., Salvesen, G.S., Propp, S.S., Bromm, M., Rowland, K.J., Zhang, T., 
Rasper, D., Roy, S., Thornberry, N., Pinsky, L., Kakizuka, A., Ross, C.A., Nicholson, 
D.W., Bredesen, D.E. and Hayden, M.R. (1998) Caspase cleavage of gene products 
associated with triplet expansion disorders generates truncated fragments containing the 
polyglutamine tract. Journal of Biological Chemistry, 273, 9158-9167. 
Wellington, C.L. and Hayden, M.R. (2000) Caspases and neurodegeneration: on the cutting edge 
of new therapeutic approaches. Clin Genet, 57, 1-10. 
Wellington, C.L., Singaraja, R., Ellerby, L., Savill, J., Roy, S., Leavitt, B., Cattaneo, E., Hackam, 
A., Sharp, A., Thornberry, N., Nicholson, D.W., Bredesen, D.E. and Hayden, M.R. (2000) 
Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in 
neuronal and nonneuronal cells. J Biol Chem, 275, 19831-19838. 
References 152                                
 
Westermark, P., Benson, M.D., Buxbaum, J.N., Cohen, A.S., Frangione, B., Ikeda, S., Masters, 
C.L., Merlini, G., Saraiva, M.J., Sipe, J.D. and Nomenclature Committee of the 
International Society of, A. (2005) Amyloid: toward terminology clarification. Report 
from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid, 
12, 1-4. 
Wolfgang, W.J., Miller, T.W., Webster, J.M., Huston, J.S., Thompson, L.M., Marsh, J.L. and 
Messer, A. (2005) Suppression of Huntington's disease pathology in Drosophila by 
human single-chain Fv antibodies. Proceedings of the National Academy of Sciences of 
the United States of America, 102, 11563-11568. 
Wood, N.I., Pallier, P.N., Wanderer, J. and Morton, A.J. (2007) Systemic administration of Congo 
red does not improve motor or cognitive function in R6/2 mice. Neurobiol Dis, 25, 342-
353. 
Wurth, C., Guimard, N.K. and Hecht, M.H. (2002) Mutations that reduce aggregation of the 
Alzheimer's Abeta42 peptide: an unbiased search for the sequence determinants of Abeta 
amyloidogenesis. Journal of Molecular Biology, 319, 1279-1290. 
Wyttenbach, A. (2004) Role of heat shock proteins during polyglutamine neurodegeneration: 
mechanisms and hypothesis. J Mol Neurosci, 23, 69-96. 
Wyttenbach, A., Carmichael, J., Swartz, J., Furlong, R.A., Narain, Y., Rankin, J. and Rubinsztein, 
D.C. (2000) Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome 
inhibition on protein aggregation in cellular models of Huntington's disease. Proc Natl 
Acad Sci U S A, 97, 2898-2903. 
Yaffe, K., Edwards, E.R., Lui, L.Y., Zmuda, J.M., Ferrell, R.E. and Cauley, J.A. (2003) Androgen 
receptor CAG repeat polymorphism is associated with cognitive function in older men. 
Biological Psychiatry, 54, 943-946. 
Yamamoto, A., Lucas, J.J. and Hen, R. (2000) Reversal of neuropathology and motor dysfunction 
in a conditional model of Huntington's disease.[see comment]. Cell, 101, 57-66. 
Yang, H., Zhong, X., Ballar, P., Luo, S., Shen, Y., Rubinsztein, D.C., Monteiro, M.J. and Fang, S. 
(2007) Ubiquitin ligase Hrd1 enhances the degradation and suppresses the toxicity of 
polyglutamine-expanded huntingtin. Exp Cell Res, 313, 538-550. 
Yen, L., Strittmatter, S.M. and Kalb, R.G. (1999) Sequence-specific cleavage of Huntingtin 
mRNA by catalytic DNA. Ann Neurol, 46, 366-373. 
Young, J.C., Agashe, V.R., Siegers, K. and Hartl, F.U. (2004) Pathways of chaperone-mediated 
protein folding in the cytosol. Nature Reviews Molecular Cell Biology, 5, 781-791. 
Young, J.C. and Hartl, F.U. (2000) Polypeptide release by Hsp90 involves ATP hydrolysis and is 
enhanced by the co-chaperone p23. EMBO Journal, 19, 5930-5940. 
Young, J.C., Moarefi, I. and Hartl, F.U. (2001) Hsp90: a specialized but essential protein-folding 
tool. Journal of Cell Biology, 154, 267-273. 
Zhang, Y., Li, M., Drozda, M., Chen, M., Ren, S., Mejia Sanchez, R.O., Leavitt, B.R., Cattaneo, 
E., Ferrante, R.J., Hayden, M.R. and Friedlander, R.M. (2003) Depletion of wild-type 
huntingtin in mouse models of neurologic diseases. J Neurochem, 87, 101-106. 
References 153                                
 
Zimmerman, S.B. and Trach, S.O. (1991) Estimation of macromolecule concentrations and 
excluded volume effects for the cytoplasm of Escherichia coli. Journal of Molecular 
Biology, 222, 599-620. 
Zoghbi, H.Y. and Orr, H.T. (2000) Glutamine repeats and neurodegeneration. Annual Review of 
Neuroscience, 23, 217-247. 
Zon, L.I. and Peterson, R.T. (2005) In vivo drug discovery in the zebrafish. Nat Rev Drug Discov, 
4, 35-44. 
Zuccato, C., Tartari, M., Crotti, A., Goffredo, D., Valenza, M., Conti, L., Cataudella, T., Leavitt, 
B.R., Hayden, M.R., Timmusk, T., Rigamonti, D. and Cattaneo, E. (2003) Huntingtin 
interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal 
genes. Nat Genet, 35, 76-83. 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 154                                
 
7 Appendix 
7.1 Abbreviations 
Units are expressed according to the international system of units (SI), 
including outside units accepted for use with the SI. Amino acids are abbreviated 
with their one or three letter symbols. Protein and gene names are abbreviated 
according to their SWISSPROT database entries. 
ADP  adenosine 5’-diphosphate 
AF activation function 
AIS androgen insensitivity syndrome 
AO Acridine Orange 
AR androgen receptor 
ARE androgen response elements 
APS  ammonium peroxodisulfate 
ATP  adenosine 5’-triphosphate 
BAG1  BCL2-associated athanogene-1 
bp  base pair 
CAIS complete androgen insensitivity syndrome 
C. elegans  Caenorhabditis elegans 
CHIP carboxyl terminus of HSP70-interacting protein  
CMV  cytomegalovirus immediate-early promoter 
CIP calf intestine alkaline phosphatase 
Da  Dalton 
DBD DNA-binding domain 
ddH2O  double distilled water 
DAPI  4,6-diamidin-2-phenylindol 
DNA  deoxyribonucleic acid 
dNTP  didesoxy-nucleoside triphosphate 
DHT dihydrotestosterone 
DMSO  dimethylsulfoxid 
D. rerio Danio rerio 
DTT  dithiothreitol 
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DMEM  Dulbecco’s Modified Eagle’s Medium 
Dox doxycycline 
DRPLA Dentatorubral-pallidoluysian atrophy 
ECL  enhance chemiluminescence 
E.coli  Escherichia coli 
EDTA  ethylenediaminetetraacetic acid 
ER endoplasmic reticulum 
ERAD ER-associated degradation 
FCS  fetal calf serum 
FITC  fluorescein-isothiocyanate 
FPLC  fast performance liquid chromatography 
g  acceleration of gravity, 9.81 m/s2 
Gal galactose 
GFP green fluorescent protein 
Glu glucose 
GuHCL guanidinium hydrochloride 
HD Huntington’s disease 
Hip hsc70 interacting protein 
Hop Hsp-organizing protein 
hr  hours 
Hsp heat shock protein 
htt huntingtin 
IB inclusion body 
LB  Luria-Bertani 
LBD C-terminal ligand-binding domain 
Luc luciferase 
min  minutes 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NAC nascent chain-associated complex 
NBB N’-benzylidene-benzohydrazide 
NLS nuclear localization signal 
OD  optical density 
Pi  inorganic Phosphate 
PBS  phosphate-buffered saline 
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PEG  polyethylene glycol 
PMSF  phenylmethylsulfonyl fluoride 
pH reverse logarithm of relative hydrogen proton (H+)  concentration 
RAC ribosome-associated complex 
RT  room temperature 
SBMA Spinal bulbar muscular atrophy, Kennedy’s disease 
S. cerevisiae  Saccharomyces cerevisiae 
S.D. standard deviation 
SDS  sodium dodecylsulfate 
TAD N-terminal transactivation domain 
TCA  trichloroacetic acid 
TEM transmission electron microscopy 
TEMED  N,N,N’,N’-tetramethylethylendiamine 
tPSA total polar surface area 
Tris  Tris(hydroxymethyl)aminomethane 
Triton X-100  octyl phenol ethoxylate 
TRP tetratricopeptide repeat 
U unit 
Ub ubiquitin polypeptide 
UPR unfolded protein response 
UPS ubiquitin-proteasome system 
U.S. United States of America 
Tween 20  polyoxyethylen-sorbitan-monolaurate 
w/o without 
YFP yellow fluorescent protein 
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